<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005064.pub2" GROUP_ID="ADDICTN" ID="869004031711303335" MERGED_FROM="" MODIFIED="2010-02-15 16:09:48 +0100" MODIFIED_BY="Laura Amato" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Exported from Review Manager 4.2.3&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 16:06:07 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="27" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2010-02-15 16:04:42 +0100" MODIFIED_BY="Laura Amato">
<TITLE>Anticonvulsants for alcohol withdrawal</TITLE>
<CONTACT>
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-02-15 16:04:42 +0100" MODIFIED_BY="Laura Amato">
<PERSON ID="6297" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Silvia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Minozzi</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>minozzi.silvia@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11445" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Laura</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Amato</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinator</POSITION>
<EMAIL_1>amato@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+390683060479</PHONE_1>
<PHONE_2/>
<FAX_1>+390683060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11551" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simona</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vecchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research worker</POSITION>
<EMAIL_1>vecchi@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>39 0683060421</PHONE_1>
<PHONE_2/>
<FAX_1>39 0683060374</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6213" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Davoli</LAST_NAME>
<SUFFIX/>
<POSITION>Coordinating Editor</POSITION>
<EMAIL_1>davoli@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00199</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>+39 06 83060 483</PHONE_1>
<PHONE_2/>
<FAX_1>+39 06 83060463</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-01-08 09:28:37 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 07/05/05&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 09:28:37 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="12" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="12" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="12" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-01-08 09:33:42 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-01-07 15:47:54 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>new studies founded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-08 09:33:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>substantially updated; authors changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-01-07 15:48:25 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-07 15:48:25 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="3" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="13" MONTH="4" YEAR="2005"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>EDAP Project (Evidence for Drugs and Alcohol Policy) sponsored by the European Community- Directorate Public Health (Grant Agreement SPC.2002454)</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-02-15 16:06:07 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-02-15 16:06:07 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-12-07 10:14:34 +0100" MODIFIED_BY="[Empty name]">Anticonvulsants for alcohol withdrawal syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2010-02-15 16:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>There are limited data on anticonvulsants versus placebo for alcohol withdrawal syndrome, while comparisons with other drugs show no clear differences.</P>
<P>This Cochrane review summarizes evidence from forty-eight randomised controlled trials evaluating the effectiveness and safety of anticonvulsants in the treatment of alcohol withdrawal symptoms. There are limited data comparing anticonvulsants versus placebo and no clear differences between anticonvulsants and other drugs in the rates of therapeutic success. Data on safety outcomes are sparse and fragmented. There is a need for larger, well-designed studies in this field.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-07 16:25:45 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-01-07 15:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Besides benzodiazepines, anticonvulsants are often used for the treatment of alcohol withdrawal symptoms. Anticonvulsants drugs are indicated for the treatment of alcohol withdrawal syndrome, alone or in combination with benzodiazepine treatments. In spite of the wide use, the exact role of the anticonvulsants for the treatment of alcohol withdrawal has not yet bee adequately assessed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-12-07 10:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the effectiveness and safety of anticonvulsants in the treatment of alcohol withdrawal.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-01-07 16:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>We searched Cochrane Drugs and Alcohol Group' Register of Trials (December 2009), PubMed,  EMBASE,  CINAHL (1966 to December 2009), EconLIT (1969 to December 2009). Parallel searches on web sites of health technology assessment and related agencies, and their databases.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-12-07 10:12:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) examining the effectiveness, safety and overall risk-benefit of anticonvulsants in comparison with a placebo or other pharmacological treatment. All patients were included regardless of age, gender, nationality, and outpatient or inpatient therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-12-07 10:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened and extracted data from studies.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-07 16:25:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-six studies, with a total of 4076 participants, met the inclusion criteria. Comparing anticonvulsants with placebo, no statistically significant differences for the six outcomes considered. </P>
<P>Comparing anticonvulsant versus other drug, 19 outcomes considered, results favour anticonvulsants only in the comparison carbamazepine versus benzodiazepine (oxazepam and lorazepam) for  alcohol withdrawal symptoms (CIWA-Ar score): 3 studies, 262 participants, MD -1.04 (-1.89 to -0.20),  none of the other comparisons reached statistical significance. </P>
<P>Comparing different anticonvulsants no statistically significant differences in the two outcomes considered. </P>
<P>Comparing anticonvulsants plus other drugs versus other drugs (3 outcomes considered), results from one study, 72 participants, favour paraldehyde plus chloral hydrate versus chlordiazepoxide, for the severe-life threatening side effects, RR 0.12 (0.03 to 0.44).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-12-07 10:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>Results of this review do not provide sufficient evidence in favour of anticonvulsants for the treatment of AWS. There are some suggestions that carbamazepine may actually be more effective in treating some aspects of alcohol withdrawal when compared to benzodiazepines, the current first-line regimen for alcohol withdrawal syndrome. Anticonvulsants seem to have limited side effects, although adverse effects are not rigorously reported in the analysed trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2009-12-07 10:29:20 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Dependence on alcohol is associated with both physiological symptoms such as tolerance and withdrawal, and behavioural symptoms such as impaired control over drinking (<LINK REF="REF-Hasin-1990" TYPE="REFERENCE">Hasin 1990</LINK>). Alcohol withdrawal syndrome is a cluster of symptoms that occurs in alcohol-dependent people after cessation or reduction in alcohol use that has been heavy or prolonged. The clinical presentation varies from mild to serious and the onset of symptoms typically occurs a few hours after the last alcohol intake. The most common manifestations are tremor, restlessness, insomnia, nightmares, paroxysmal sweats, tachycardia, fever, nausea, vomiting, seizures, hallucinations (auditory, visual, tactile), increased agitation, tremulousness and delirium. These symptoms involve a wide range of neurotransmitter circuits that are implicated in alcohol tolerance and reflect a homeostatic readjustment of the central nervous system (<LINK REF="REF-De-Witte-2003" TYPE="REFERENCE">De Witte 2003</LINK>; <LINK REF="REF-Koob-1997" TYPE="REFERENCE">Koob 1997</LINK>; <LINK REF="REF-Nutt-1999" TYPE="REFERENCE">Nutt 1999</LINK>; <LINK REF="REF-Slawecki-1999" TYPE="REFERENCE">Slawecki 1999</LINK>). Long-term alcohol consumption affects brain receptors that undergo adaptive changes in an attempt to maintain normal function. Some of the key changes involve reduced brain gamma-amino butyric acid (GABA) levels and GABA- receptor sensitivity (<LINK REF="REF-Dodd-2000" TYPE="REFERENCE">Dodd 2000</LINK>; <LINK REF="REF-Gilman-1996" TYPE="REFERENCE">Gilman 1996</LINK>; <LINK REF="REF-Kohl-1998" TYPE="REFERENCE">Kohl 1998</LINK>; <LINK REF="REF-Petty-1993" TYPE="REFERENCE">Petty 1993</LINK>) and activation of glutamate systems (<LINK REF="REF-Tsai-1995" TYPE="REFERENCE">Tsai 1995</LINK>), which lead to nervous system hyperactivity in the absence of alcohol. The advances in knowledge of neurobiology and neurochemistry have prompted the use of drugs in the treatment of alcohol dependence and withdrawal that act through these GABA pathways.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-12-07 10:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Besides benzodiazepines, anticonvulsants are often used for the treatment of alcohol withdrawal symptoms. A meta-analysis of studies concerning pharmacological therapies of alcohol withdrawal (<LINK REF="REF-Mayo_x002d_Smith-1997" TYPE="REFERENCE">Mayo-Smith 1997</LINK>) has suggested that carbamazepine, an anticonvulsant agent that is widely used in particular in Europe, may have modest beneficial effects on selected signs and symptoms of withdrawal. Carbamazepine may also be considered as adjunctive therapy to benzodiazepines, the classic treatment for alcohol withdrawal.</P>
</INTERVENTION>
<THEORY MODIFIED="2010-01-01 17:16:28 +0100" MODIFIED_BY="[Empty name]">
<P>Anticonvulsants drugs are indicated for the treatment of alcohol withdrawal syndrome, alone or in combination with benzodiazepine treatments. In spite of the wide use, the exact role of the anticonvulsants for the treatment of alcohol withdrawal has not yet been adequately assessed. Moreover not all patients may need pharmacological treatment and it is unknown whether different anticonvulsants and different regimens of administration (e.g. symptom-triggered versus fixed schedule) may have the same merits.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]">
<P>The need to research non-benzodiazepines effective in Alcohol Withdrawal is related to the risks of side-effects and the potential of abuse of benzodiazepine (<LINK REF="REF-Leggio-2008" TYPE="REFERENCE">Leggio 2008</LINK>).</P>
<P>Since there are several anticonvulsant agents and a large amount of evidence of their use in the management of alcohol withdrawal has been published during the last years, an updated systematic is needed in order to clarify the exact role of anticonvulsants in the management of alcohol withdrawal.</P>
<P>The purpose of this systematic review is to examine the evidence in the effectiveness and safety of anticonvulsants in the treatment of alcohol withdrawal symptoms. Results of a previous version of a Cochrane Systematic review (<LINK REF="REF-Polycarpou-2005" TYPE="REFERENCE">Polycarpou 2005</LINK>) on anticonvulsants efficacy and safety are not conclusive. New trials have been published and the review needs update.</P>
<P>This review has a parallel one on benzodiazepines for alcohol withdrawal (<LINK REF="REF-Amato-2010" TYPE="REFERENCE">Amato 2010</LINK>) and together they are part of a series of reviews and protocols on the efficacy of pharmacological treatment (Acamprosate GHB, nitrous oxide, magnesium) for alcohol withdrawal (<LINK REF="REF-Gillman-2007" TYPE="REFERENCE">Gillman 2007</LINK>; <LINK REF="REF-Leone-2010" TYPE="REFERENCE">Leone 2010</LINK>; <LINK REF="REF-Fox-2003" TYPE="REFERENCE">Fox 2003</LINK>; <LINK REF="REF-Tejani-2010" TYPE="REFERENCE">Tejani 2010</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-01-01 17:17:57 +0100" MODIFIED_BY="[Empty name]">
<P>The objectives of this systematic review are:</P>
<OL>
<LI>To evaluate the effectiveness of anticonvulsants in the treatment of alcohol withdrawal.</LI>
<LI>To evaluate the safety of anticonvulsants in the treatment of the alcohol withdrawal symptoms (AWS).</LI>
</OL>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-15 11:06:16 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2010-01-15 11:06:16 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-01-01 17:18:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized Controlled Trials (RCT) and Controlled Clinical Trials (CCT) evaluating the efficacy, safety and overall risk-benefit of anticonvulsants for the treatment of alcohol withdrawal. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-01-15 11:06:16 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients diagnosed in accordance with appropriate standardized criteria (e.g., criteria of Diagnostic and Statistical Manual of Mental Disorders (<LINK REF="REF-DSM_x002d_IV_x002d_R" TYPE="REFERENCE">DSM-IV-R</LINK>) or ICD) who experienced alcohol withdrawal symptoms regardless of the severity of the withdrawal manifestations.  All patients were included regardless of age, gender, nationality, and outpatient or inpatient therapy. The history of previous treatments was considered, but it was not an eligibility criterion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-01-07 15:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>- <I>
<B>Experimental intervention</B>
</I>
</P>
<P>Anticonvulsants drugs alone or in combination with other drugs</P>
<P>
<I>
<B>- Control Intervention</B>
</I>
</P>
<P>Placebo; Other pharmacological interventions</P>
<P>
<B>Types of comparisons</B>
</P>
<OL>
<LI>anticonvulsant versus placebo;</LI>
<LI>anticonvulsant versus other drugs;</LI>
<LI>different anticonvulsants between themselves;</LI>
<LI>anticonvulsant combined with other drugs versus other drugs.</LI>
<LI>anticonvulsant 1 combined with other drugs versus anticonvulsant 2</LI>
</OL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-12-14 11:11:26 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-12-14 11:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy outcomes</B>
</P>
<OL>
<LI>Alcohol withdrawal seizures as number of subjects experiencing seizures</LI>
<LI>Alcohol withdrawal delirium as number of subjects experiencing delirium</LI>
<LI>Alcohol withdrawal symptoms as measured by prespecified scales(as the CIWA-Ar score)</LI>
<LI>Global improvement of overall alcohol withdrawal syndrome as measured in pre-specified scales ( as number of patients with global improvement, global doctors assessment of efficacy, Patients assessment of efficacy)</LI>
<LI>Craving as measured by prespecified scales</LI>
</OL>
<P>
<B>Safety outcomes </B>
</P>
<OL>
<LI>Adverse events as number of subjects experiencing at least one adverse event</LI>
<LI>Severe, life-threatening adverse events as measured by number of subjects experiencing severe, life threatening adverse events</LI>
</OL>
<P>
<B>Acceptability outcomes</B>
</P>
<OL>
<LI>Dropout</LI>
<LI>Dropout due to adverse events</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-12-08 14:55:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Additional medication needed</LI>
<LI>Length of stay in intensive therapy</LI>
<LI>Mortality</LI>
<LI>Quality of life</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-01-01 17:20:54 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2010-01-01 17:20:54 +0100" MODIFIED_BY="[Empty name]">
<P>Relevant trials were obtained from the following sources:</P>
<OL>
<LI>Cochrane Drugs and Alcohol Group' Register of Trials (December 2009)</LI>
<LI>PubMed (January 1966&#8211; December 2009)<B> </B>
</LI>
<LI>EMBASE (January 1988&#8211; December 2009)</LI>
<LI>CINAHL (January 1982&#8211; December 2009)</LI>
<LI>EconLIT (1969 to December 2009)</LI>
</OL>
<P>We compiled detailed search strategies for each database searched, for detail see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-12-08 14:58:36 +0100" MODIFIED_BY="[Empty name]">
<P>We also searched:</P>
<OL>
<LI>the reference lists of all relevant papers to identify further studies.</LI>
<LI>conference proceedings likely to contain trials relevant to the review.</LI>
</OL>
<P>We contacted investigators seeking information about unpublished or incomplete trials.All searches included non-English language literature and studies with English abstracts were assessed for inclusion. When considered likely to meet inclusion criteria, studies were translated.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-01-07 15:23:11 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2009-12-08 14:59:41 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently screened the titles and abstracts of all publications, obtained through the search strategy. All potentially eligible studies were obtained as full articles and two authors independently assessed these for inclusion. In doubtful or controversial cases, all identified discrepancies were discussed and reached consensus on all items.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-12-08 14:59:49 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted data from published sources, where differences in data extracted occurred this was resolved through discussion. Where required additional information was obtained through collaboration with the original authors.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-12-14 11:14:38 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias assessment  for RCTs and CCTs in this review was performed using four out of the six criteria recommended by the Cochrane Handbbok (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). The recommended approach for assessing risk of bias in studies included in Cochrane Review is a two-part tool, addressing four specific domains (namely sequence generation, allocation concealment, blinding, incomplete outcome data). The first part of the tool involves describing what was reported to have happened in the study. The second part of the tool involves assigning a judgement relating to the risk of bias for that entry. This is achieved by answering a pre-specified question about the adequacy of the study in relation to the entry, such that a judgement of "Yes" indicates low risk of bias, "No" indicates high risk of bias, and "Unclear" indicates unclear or unknown risk of bias. To make these judgments we will use the criteria indicated by the handbook adapted to  the addiction field. See <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK> for details.</P>
<P>The domains of sequence generation and  allocation concealment (avoidance of selection bias) will be addressed in the tool by a single entry for each study.</P>
<P>Blinding of participants, personnel and outcome assessor (avoidance of performance bias and detection bias) was considered separately for objective outcomes (e.g. drop out, drop out due to adverse events, seizures, delirium, adverse events) and subjective outcomes (e.g. duration and severity of signs and symptoms of withdrawal, craving, psychiatric symptoms; improvements assessed by doctors and patients).</P>
<P>Incomplete outcome data (avoidance of attrition bias) was considered for all outcomes except for the drop out from the treatment, which is very often the primary outcome measure in trials on addiction.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-12-14 11:16:33 +0100" MODIFIED_BY="[Empty name]">
<P>Dichotomous outcomes were analysed calculating the Relative risk (RR) for each trial with the uncertainty in each result being expressed by their confidence intervals. Continuous outcomes were analysed calculating the MD or the SMD with 95%CI. In case of missing standard deviation of the differences from baseline to the end of treatment, the standard deviation were imputed using the standard deviation of the mean at the end of treatment for each group.</P>
</EFFECT_MEASURES>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-12-14 11:18:10 +0100" MODIFIED_BY="[Empty name]">
<P>Statistically significant heterogeneity among primary outcome studies will be assessed with Chi-squared (Q) test and I-squared (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). A significant Q ( P&lt;.05) and I-squared of at least 50% will be considered as statistical heterogeneity</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-12-08 15:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Funnel plot (plot of the effect estimate from each study against the sample size or effect standard error) was not used to assess the potential for bias related to the size of the trials, because all the included studies had small sample size and not statistically significant results.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-12-08 15:21:31 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes from the individual trials have been combined through meta-analysis where possible (comparability of intervention and outcomes between trials) using a fixed effect model unless there was significant heterogeneity, in which case a random effect model have been used.</P>
<P>If all arms in a multi-arm trial are to be included in the meta-analysis and one treatment arm is to be included in more than one of the treatment comparisons, then we divided the number of events and the number of participants in that arm by the number of treatment comparisons made. This method avoid the multiple use of participants in the pooled estimate of treatment effect while retaining information from each arm of the trial. It compromise the precision of the pooled estimate slightly.</P>
</DATA_SYNTHESIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-01-07 15:23:11 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effect of methodological quality on the results, we first performed a graphical inspection of any effect sorting the results on the forest plots according to risk of bias for sequence generation, allocation concealment, blinding (subjective outcomes) ; if we found a difference in the results between studies at low, unclear, high risk of bias, we performed a sensitivity analysis excluding studies at high risk of bias</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-08 13:09:08 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2010-01-08 11:48:26 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2010-01-08 09:35:42 +0100" MODIFIED_BY="[Empty name]">
<P>We identified 993 reports from all electronic databases searched excluding duplicate, 899 were excluded on basis of title and abstract; 91 articles were retrieved in full text for more detailed evaluation, 35 of which were excluded, 56 satisfied all the criteria to be included in the review. Three studies are awaiting assessment because we are trying to find the full text. <I>See<B> </B>
</I>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> to see the Flow chart showing the identification of included trials.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-01-08 11:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>56 studies met the inclusion criteria, with a total of 4076 participants. For a description of the characteristics of the included studies, see<I>
<B> </B>
</I>
<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table</P>
<P>
<I>
<B>Country of origin of the included studies</B>
</I>
</P>
<P>33 studies were conducted in Europe, 18 in North America, 4 in Australia/New Zealand, and one in Asia. </P>
<P>
<I>
<B>Number of studies per type of comparison</B>
</I>
</P>
<OL>
<LI>Anticonvulsant versus placebo (No. = 17 studies, 17 comparisons) (<LINK REF="STD-Alldredge-1989" TYPE="STUDY">Alldredge 1989</LINK>; <LINK REF="STD-Bjorkqvist-1976" TYPE="STUDY">Bjorkqvist 1976</LINK>; <LINK REF="STD-Blanchard-1985" TYPE="STUDY">Blanchard 1985</LINK>; <LINK REF="STD-Bonnet-2003" TYPE="STUDY">Bonnet 2003</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Chance-1991" TYPE="STUDY">Chance 1991</LINK>; <LINK REF="STD-Gann-2004" TYPE="STUDY">Gann 2004</LINK>; <LINK REF="STD-Glatt-1966" TYPE="STUDY">Glatt 1966</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Koethe-2007" TYPE="STUDY">Koethe 2007</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lambie-1980" TYPE="STUDY">Lambie 1980</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Rathlev-1994" TYPE="STUDY">Rathlev 1994</LINK>; <LINK REF="STD-Reoux-2001" TYPE="STUDY">Reoux 2001</LINK>; <LINK REF="STD-Sampliner-1974" TYPE="STUDY">Sampliner 1974</LINK>; <LINK REF="STD-Stanhope-1989" TYPE="STUDY">Stanhope 1989</LINK>)</LI>
<LI>Anticonvulsant versus other drug (No. = 32 studies, 36 comparisons) (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Choi-2005" TYPE="STUDY">Choi 2005</LINK>; <LINK REF="STD-Dencker-1978" TYPE="STUDY">Dencker 1978</LINK>; <LINK REF="STD-Elsing-1996" TYPE="STUDY">Elsing 1996</LINK>; <LINK REF="STD-Elsing-2009" TYPE="STUDY">Elsing 2009</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Koppi-1987" TYPE="STUDY">Koppi 1987</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Madden-1969" TYPE="STUDY">Madden 1969</LINK>; <LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Malcolm-2007" TYPE="STUDY">Malcolm 2007</LINK>; <LINK REF="STD-Manhem-1985" TYPE="STUDY">Manhem 1985</LINK>; <LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Robinson-1989" TYPE="STUDY">Robinson 1989</LINK>; <LINK REF="STD-Santo-1985" TYPE="STUDY">Santo 1985</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Stuppaeck-1998" TYPE="STUDY">Stuppaeck 1998</LINK>; <LINK REF="STD-Thompson-1975" TYPE="STUDY">Thompson 1975</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>)</LI>
<LI>Different anticonvulsants between themselves (No.= 10 studies, 11 comparisons) (<LINK REF="STD-Flygering-1984" TYPE="STUDY">Flygering 1984</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Mariani-2006" TYPE="STUDY">Mariani 2006</LINK>; <LINK REF="STD-Ritola-1981" TYPE="STUDY">Ritola 1981</LINK>; <LINK REF="STD-Rosenthal-1998" TYPE="STUDY">Rosenthal 1998</LINK>; <LINK REF="STD-Schik-2005" TYPE="STUDY">Schik 2005</LINK>; <LINK REF="STD-Seifert-2004" TYPE="STUDY">Seifert 2004</LINK>; <LINK REF="STD-Teijeiro-1975" TYPE="STUDY">Teijeiro 1975</LINK>)</LI>
<LI>Anticonvulsant combined with other drug versus other drug (No. = 6 studies, 7 comparisons) (<LINK REF="STD-Balldin-1986" TYPE="STUDY">Balldin 1986</LINK>; <LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Myrick-2000" TYPE="STUDY">Myrick 2000</LINK>; <LINK REF="STD-Spies-1996" TYPE="STUDY">Spies 1996</LINK>; <LINK REF="STD-Spies-1996" TYPE="STUDY">Spies 1996</LINK>; <LINK REF="STD-Rothstein-1973" TYPE="STUDY">Rothstein 1973</LINK>)</LI>
<LI>Anticonvulanst combined with other drug vs different anticonvulsant (No=1 study) (<LINK REF="STD-Croissant-2009" TYPE="STUDY">Croissant 2009</LINK>)</LI>
</OL>
<P>For a more detailed information about the comparisons considered in the studies, <I>see</I> Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>; <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>; <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>; <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> </P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-01-08 11:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>35 studies did not meet the criteria for inclusion in this review. The grounds for exclusion were: type of intervention not in the inclusion criteria: 13 studies; study design not in the inclusion criteria: 12 studies; type of outcomes measures not in the inclusion criteria: 6 studies; duplicate publication: 2 studies, outcome measures presented in a way not suitable for meta-analysis: 2 studies. <I>See</I> <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies</LINK> Table</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-01-08 11:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>All the studies were randomised controlled trials.</P>
<ALLOCATION MODIFIED="2010-01-08 11:49:04 +0100" MODIFIED_BY="[Empty name]">
<P>The sequence generation was adequate in 17  studies, unclear in 34 and inadequate in 5 studies; the allocation concealment was adequate in 9 studies, unclear in 42 and  inadequate in 5 studies</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-01-08 11:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding for subjective outcomes was adequate in 33 studies, it was unclear in 10 and inadequate in 13</P>
<P>Blinding for objective outcomes was adequate in 52 studies and unclear in 4 studies</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-01-08 11:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>Incomplete outcome data were addressed in 48 studies, it was unclear in 6 studies and were not addressed in 2 studies.</P>
<P>See <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK> Table and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> for a more detailed description of risk of bias across the studies.</P>
<P>With a graphical inspection of the forest plots sorting studies according to the risk of bias, we didn't find any systematic difference in the results between studies at high risk of bias and studies at low or unclear risk of bias. So sensitivity analysis excluding studies at high risk of bias was not performed</P>
</EXCLUSIONS>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-08 13:09:08 +0100" MODIFIED_BY="[Empty name]">
<P>We only performed meta-analysis for the studies that had directly comparable interventions and used exactly the same rating scales for continuous outcome measures or had the same binary outcomes. The rest of the data retrieved from the studies (single comparison data) were not synthesized quantitatively. The following results refer to the cases where quantitative synthesis was performed.</P>
<P>The Results are split into four sections referring to the four main comparisons:</P>
<OL>
<LI>Anticonvulsant versus Placebo,</LI>
<LI>Anticonvulsant versus Other Drug,</LI>
<LI>Anticonvulsant 1 versus Anticonvulsant 2,</LI>
<LI>(Anticonvulsant + Other drug) versus Other Drug.</LI>
<LI>(Anticonvlusant 1 + other drug) versus Anticonvulsant 2</LI>
</OL>
<P>The outcomes are categorized as primary efficacy outcomes and secondary efficacy outcomes, according to the protocol. We dived them according to efficacy, safety and acceptability.</P>
<P>We decided to not consider separately the comparison between anticonvulsants and benzodiazepines because this is due in the parallel review (<LINK REF="REF-Amato-2010" TYPE="REFERENCE">Amato 2010</LINK>) on benzodiazepines for alcohol withdrawal</P>
<P>For a summary of results of some important outcomes see Summary of findings table 1 and Summary of findings table 2</P>
<P>
<B>Comparison 1 Anticonvulsant versus placebo:</B>
</P>
<P>
<B>Efficacy</B>
</P>
<P>
<I>
<B>1.1 Alcohol withdrawal seizures </B>
</I>
</P>
<P>
<I>
<U>1.1.1 Any Anticonvulsants versus placebo,</U>
</I> 9 studies (<LINK REF="STD-Alldredge-1989" TYPE="STUDY">Alldredge 1989</LINK>; <LINK REF="STD-Bonnet-2003" TYPE="STUDY">Bonnet 2003</LINK>; <LINK REF="STD-Chance-1991" TYPE="STUDY">Chance 1991</LINK>; <LINK REF="STD-Koethe-2007" TYPE="STUDY">Koethe 2007</LINK>; <LINK REF="STD-Lambie-1980" TYPE="STUDY">Lambie 1980</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Rathlev-1994" TYPE="STUDY">Rathlev 1994</LINK>; <LINK REF="STD-Sampliner-1974" TYPE="STUDY">Sampliner 1974</LINK>; <LINK REF="STD-Stanhope-1989" TYPE="STUDY">Stanhope 1989</LINK>), 883 participants, RR 0.61 (0.31 to 1.20), the result is not statistically significant, see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> or <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>
<I>
<U>1.1.2 Phenytoin versus placebo</U>
<B>,</B>
</I> 4 studies, (<LINK REF="STD-Alldredge-1989" TYPE="STUDY">Alldredge 1989</LINK>; <LINK REF="STD-Chance-1991" TYPE="STUDY">Chance 1991</LINK>; <LINK REF="STD-Rathlev-1994" TYPE="STUDY">Rathlev 1994</LINK>; <LINK REF="STD-Sampliner-1974" TYPE="STUDY">Sampliner 1974</LINK>), 381 participants, RR 0.78 (0.35 to 1.77), the result is not statistically significant, see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> or <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>
</P>
<P>
<B>Safety </B>
</P>
<P>
<I>
<B>1.2 Adverse events </B>
</I>as number of participants with at least one adverse event</P>
<P>7 studies (<LINK REF="STD-Bjorkqvist-1976" TYPE="STUDY">Bjorkqvist 1976</LINK>; <LINK REF="STD-Bonnet-2003" TYPE="STUDY">Bonnet 2003</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Chance-1991" TYPE="STUDY">Chance 1991</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lambie-1980" TYPE="STUDY">Lambie 1980</LINK>; <LINK REF="STD-Stanhope-1989" TYPE="STUDY">Stanhope 1989</LINK>), 516 participants, RR 1.56 (0.74, 3.31), the result is not statistically significant, see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> or <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>
</P>
<P>
<B>Acceptability </B>
</P>
<P>
<I>
<B>1.3 Dropout</B>
</I>
</P>
<P>
<I>
<U>1.5.1 Any Anticonvulsants versus placebo</U>
</I>, 7 studies (<LINK REF="STD-Bjorkqvist-1976" TYPE="STUDY">Bjorkqvist 1976</LINK>; <LINK REF="STD-Blanchard-1985" TYPE="STUDY">Blanchard 1985</LINK>; <LINK REF="STD-Bonnet-2003" TYPE="STUDY">Bonnet 2003</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Gann-2004" TYPE="STUDY">Gann 2004</LINK>; <LINK REF="STD-Glatt-1966" TYPE="STUDY">Glatt 1966</LINK>; <LINK REF="STD-Reoux-2001" TYPE="STUDY">Reoux 2001</LINK>), 344 participants, RR 0.82 (0.50 to 1.34), the result is not statistically significant, see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> or <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>
</P>
<P>
<I>
<U>1.1.2 Chlormethiazole versus placebo</U>
</I>, 3 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Gann-2004" TYPE="STUDY">Gann 2004</LINK>; <LINK REF="STD-Glatt-1966" TYPE="STUDY">Glatt 1966</LINK>), 140 participants, RR 1.05 (0.22 to 5.11), the result is not statistically significant, see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> or <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>
</P>
<P>
<I>
<B>1.4 Dropout due to adverse events</B>
</I>
</P>
<P>8 studies (<LINK REF="STD-Bjorkqvist-1976" TYPE="STUDY">Bjorkqvist 1976</LINK>; <LINK REF="STD-Blanchard-1985" TYPE="STUDY">Blanchard 1985</LINK>; <LINK REF="STD-Bonnet-2003" TYPE="STUDY">Bonnet 2003</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Chance-1991" TYPE="STUDY">Chance 1991</LINK>; <LINK REF="STD-Koethe-2007" TYPE="STUDY">Koethe 2007</LINK>; <LINK REF="STD-Lambie-1980" TYPE="STUDY">Lambie 1980</LINK>; <LINK REF="STD-Stanhope-1989" TYPE="STUDY">Stanhope 1989</LINK>), 623 participants, 0.67 (0.13, 3.36), the result is not statistically significant, see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> or <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>
</P>
<P>
<B>Comparison 2 Anticonvulsant versus Other:</B>
</P>
<P>
<B>Efficacy</B>
</P>
<P>
<I>
<B>2.1 Alcohol withdrawal seizures </B>
</I>
</P>
<P>
<I>
<U>2.1.1 Any Anticonvulsants versus any Other</U>
</I>, 12 studies (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Koppi-1987" TYPE="STUDY">Koppi 1987</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>;<LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK> ;<LINK REF="STD-Robinson-1989" TYPE="STUDY">Robinson 1989</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 880 participants, RR 0.58 (0.22 to 1.58), the result is not statistically significant, see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>
</P>
<P>
<I>
<U>2.1.2 Chlormethiazole versus Benzodiazepine</U>
</I>
<U>,</U> 2 studies (<LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 155 participants, RR 0.35 (0.01 to 8.33), the result is not statistically significant, see or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>
</P>
<P>
<I>
<B>2.2</B>
</I> <I>
<B>Alcohol withdrawal delirium </B>
</I>
</P>
<P>
<I>
<U>2.2.1 Any Anticonvulsants versus any Other</U>
</I>, 6 studies (<LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Manhem-1985" TYPE="STUDY">Manhem 1985</LINK>;<LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; ), 394 participants, RR 0.88 (0.23, 3.42), the result is not statistically significant, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> or <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>
</P>
<P>
<I>
<U>2.2.2 Carbamazepine versus Benzodiazepine, </U>
</I>2 studies (<LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 125 participants, RR 1.01 (0.04 to 24.43), the result is not statistically significant, see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> or <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>
</P>
<P>
<I>
<B>2.3 CIWA-Ar score at 48 hours</B>
</I>
</P>
<P>
<I>
<U>2.3.1 Any Anticonvulsants versus any Other</U>
</I>, 4 studies (<LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 358 participants, MD -0.21 (-0.95 to 0.53), the result is not statistically significant, see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>
</P>
<P>
<I>
<U>2.3.2 Carbamazepine versus Benzodiazepine</U>
</I>
<U>, </U>3 studies (<LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 260 participants MD -0.60 (-1.88 to 0.67), the result is not statistically significant, see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>
</P>
<P>
<I>
<B>2.4 CIWA-Ar score at the end of treatment</B>
</I>
</P>
<P>
<I>
<U>2.4.1 Any Anticonvulsants versus any Other</U>
</I>, 4 studies (<LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 358 participants, MD -0.73 (-1.76 to 0.31), the result is not statistically significant, see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>
</P>
<P>
<I>
<U>2.4.2 Carbamazepine versus Benzodiazepine</U>
</I>, 3 studies (<LINK REF="STD-Malcolm-1989" TYPE="STUDY">Malcolm 1989</LINK>; <LINK REF="STD-Malcolm-2002" TYPE="STUDY">Malcolm 2002</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>), 260 participants MD -1.04 (-1.89 to -0.20), the result is statistically significant in favour of carbamazepine, see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>
</P>
<P>
<I>
<B>2.5 Global Doctor&#8217;s Assessment of Efficacy</B>
</I>
</P>
<P>2 studies (<LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 181 participants, RR 0.97 (0.88 to 1.08), the result is not statistically significant, see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>
</P>
<P>
<B>Safety </B>
</P>
<P>
<I>
<B>2.6</B>
</I> Adverse events as number of participants with at least one adverse event</P>
<P>
<I>
<U>2.6.1 Any Anticonvulsants versus any Other</U>
</I> (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>;<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>;<LINK REF="STD-Elsing-2009" TYPE="STUDY">Elsing 2009</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Longo-2002" TYPE="STUDY">Longo 2002</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK> ;<LINK REF="STD-Robinson-1989" TYPE="STUDY">Robinson 1989</LINK>; <LINK REF="STD-Santo-1985" TYPE="STUDY">Santo 1985</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 14 studies, 726 participants, RR 0.71(0.45 to 1.12), the result is not statistically significant, see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> or <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>
</P>
<P>
<I>
<U>2.6.2 Chlormethiazole versus Benzodiazepine</U>
</I>, (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 5 studies, 235 participants, RR 0.75 (0.35 to 1.59), the result is not statistically significant, see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK> or <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>
</P>
<P>
<I>
<B>2.7 Severe, life-treating adverse events</B>
</I>
</P>
<P>
<I>
<U>2.17.1 Any Anticonvulsants versus any Other</U>
</I>, 12 studies (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Dencker-1978" TYPE="STUDY">Dencker 1978</LINK>;<LINK REF="STD-Elsing-2009" TYPE="STUDY">Elsing 2009</LINK>; <LINK REF="STD-Koppi-1987" TYPE="STUDY">Koppi 1987</LINK>; <LINK REF="STD-Krupitsky-2007" TYPE="STUDY">Krupitsky 2007</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK>; <LINK REF="STD-Santo-1985" TYPE="STUDY">Santo 1985</LINK>; <LINK REF="STD-Thompson-1975" TYPE="STUDY">Thompson 1975</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 578 participants, RR 2.38 (0.33 to 17.24), the result is not statistically significant, see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> or <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<I>
<U>2.7.2 Chlormethiazole versus Benzodiazepine</U>
</I>, (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 4 studies, 170 participants, RR 0.69 (95% CI, 0.09 to 5.33), the result is not statistically significant, see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK> or <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<B>Acceptability </B>
</P>
<P>
<I>
<B>2.8 Dropout</B>
</I>
</P>
<P>
<I>
<U>2.8.1 Any Anticonvulsants versus any Other</U>
</I>, 20 studies (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>; <LINK REF="STD-Borg-1986" TYPE="STUDY">Borg 1986</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Dencker-1978" TYPE="STUDY">Dencker 1978</LINK>; <LINK REF="STD-Elsing-2009" TYPE="STUDY">Elsing 2009</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Kalyoncu-1996" TYPE="STUDY">Kalyoncu 1996</LINK>; <LINK REF="STD-Koppi-1987" TYPE="STUDY">Koppi 1987</LINK>; <LINK REF="STD-Kramp-1978" TYPE="STUDY">Kramp 1978</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Manhem-1985" TYPE="STUDY">Manhem 1985</LINK>;<LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Murphy-1983" TYPE="STUDY">Murphy 1983</LINK>; <LINK REF="STD-Nimmerichter-2002" TYPE="STUDY">Nimmerichter 2002</LINK>; <LINK REF="STD-Radouco_x002d_Thomas-1989" TYPE="STUDY">Radouco-Thomas 1989</LINK> ;<LINK REF="STD-Robinson-1989" TYPE="STUDY">Robinson 1989</LINK>; <LINK REF="STD-Santo-1985" TYPE="STUDY">Santo 1985</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 1359 participants, RR 0.92 (0.67, 1.26), the result is not statistically significant, see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> or <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>
</P>
<P>
<I>
<U>2.8.2 Chlormethiazole versus Benzodiazepine,</U>
</I> 5 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>;<LINK REF="STD-McGrath-1975" TYPE="STUDY">McGrath 1975</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 311 participants, RR 0.68 (0.37, 1.24), the result is not statistically significant, see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> or <LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>
</P>
<P>
<I>
<B>2.9 Dropout due to adverse events</B>
</I>
</P>
<P>
<I>
<U>2.9.1 Any Anticonvulsants versus any Other</U>
</I>, 10 studies (<LINK REF="STD-Agricola-1982" TYPE="STUDY">Agricola 1982</LINK>; <LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Dencker-1978" TYPE="STUDY">Dencker 1978</LINK>; <LINK REF="STD-Elsing-2009" TYPE="STUDY">Elsing 2009</LINK>; <LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>; <LINK REF="STD-Koppi-1987" TYPE="STUDY">Koppi 1987</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Stuppaeck-1992" TYPE="STUDY">Stuppaeck 1992</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 596 participants, RR 2.28 (0.67 to 7.70), the result is not statistically significant, see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK> or <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>
</P>
<P>
<I>
<U>2.9.2 Chlormethiazole versus Benzodiazepine</U>
</I>
<U>,</U> 4 studies (<LINK REF="STD-Burroughs-1985a" TYPE="STUDY">Burroughs 1985a</LINK>; <LINK REF="STD-Burroughs-1985b" TYPE="STUDY">Burroughs 1985b</LINK>; <LINK REF="STD-Lapierre-1983" TYPE="STUDY">Lapierre 1983</LINK>; <LINK REF="STD-Tubridy-1988" TYPE="STUDY">Tubridy 1988</LINK>), 170 participants, RR 1.09 (0.12 to 9.97), the result is not statistically significant, see <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK> or <LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>
</P>
<P>
<B>Comparison 3 Anticonvulsant 1 versus Anticonvulsant 2:</B>
</P>
<P>
<B>Safety</B>
</P>
<P>
<I>
<B>3.1</B>
</I> Adverse events as number of participants with at least one adverse event</P>
<P>
<I>
<U>3.1.1 Carbamazepine versus Chlormethiazole</U>
</I>, 2 studies (<LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Ritola-1981" TYPE="STUDY">Ritola 1981</LINK>), 121 participants, RR 3.12 (0.50 to 19.27), the result is not statistically significant</P>
<P>
<I>
<U>3.1.2 Carbamazepine versus Barbital</U>
</I>, 1 study (<LINK REF="STD-Flygering-1984" TYPE="STUDY">Flygering 1984</LINK>), 61 participants, RR 1.81 (0.70 to 4.68), the result is not statistically significant</P>
<P>
<I>
<U>3.1.3 Carbamazepine versus Oxcarbazepine</U>
</I>, 1 study (<LINK REF="STD-Schik-2005" TYPE="STUDY">Schik 2005</LINK>), 29 participants, the result is not estimable because there were no side effects in both groups</P>
<P>
<I>
<U>3.1.4 Chlormethiazole versus Pentobarbital</U>
</I>, 1 study (<LINK REF="STD-Mariani-2006" TYPE="STUDY">Mariani 2006</LINK>), 27 participants, RR 2.80 (0.12 to 63.20), the result is not statistically significant</P>
<P>See <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> or <LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>
</P>
<P>
<B>Acceptability</B>
</P>
<P>
<I>
<B>3.2 Dropout</B>
</I>
</P>
<P>
<I>
<U>3.2.1 Carbamazepine versus Chlormethiazole</U>
</I>, 2 studies (<LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Ritola-1981" TYPE="STUDY">Ritola 1981</LINK>), 121 participants, RR 0.51 (0.08 to 3.11), the result is not statistically significant</P>
<P>
<I>
<U>3.2.2 Carbamazepine versus Barbital</U>
</I>, 1 study (<LINK REF="STD-Flygering-1984" TYPE="STUDY">Flygering 1984</LINK>), 60 participants, RR 0.94 (0.34 to 2.57), the result is not statistically significant</P>
<P>
<I>
<U>3.2.3 Carbamazepine versus Oxcarbazepine</U>
</I>, 1 study (<LINK REF="STD-Schik-2005" TYPE="STUDY">Schik 2005</LINK>), 29 participants, RR 3.20 (0.14 to 72.62), the result is not statistically significant</P>
<P>
<I>
<U>3.2.4 Pentobarbital  versus Paraldehyde</U>
</I>, 1 study (<LINK REF="STD-Kaim-1972" TYPE="STUDY">Kaim 1972</LINK>), 96 participants, RR 0.37 (0.03 to 3.97), the result is not statistically significant</P>
<P>
<I>
<U>3.1.4 Chlormethiazole versus Pentobarbital</U>
</I>, 1 study (<LINK REF="STD-Mariani-2006" TYPE="STUDY">Mariani 2006</LINK>), 27 participants, RR 1.39 (0.28 to 7.05), the result is not statistically significant</P>
<P>See <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> or <LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>
</P>
<P>
<B>Comparison 4 (Anticonvulsant + Other drug) versus Other Drug:</B>
</P>
<P>
<B>Efficacy</B>
</P>
<P>
<I>
<B>4.1</B>
</I>
<B> <I>Alcohol withdrawal delirium </I>
</B>
</P>
<P>3 studies (<LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Rothstein-1973" TYPE="STUDY">Rothstein 1973</LINK>), 311 participants, RR 0.79 (0.18 to 3.52), the result is not statistically significant, see <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK> or <LINK REF="FIG-16" TYPE="FIGURE">Figure 16</LINK>
</P>
<P>
<B>Safety</B>
</P>
<P>
<I>
<B>4.2 Severe, life-threatening adverse events</B>
</I>
</P>
<P>1 study, (<LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; ), 49 participants, RR 0.13 (0.02 to 0.89), the result is statistically significant in favour of the association Paraldehyde+ chloral hydrate  in respect of chlordiazepoxide, see <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>
</P>
<P>
<B>Acceptability</B>
</P>
<P>
<I>
<B>4.3 Dropout</B>
</I>
</P>
<P>Three studies (<LINK REF="STD-Golbert-1967" TYPE="STUDY">Golbert 1967</LINK>; <LINK REF="STD-Lucht-2003" TYPE="STUDY">Lucht 2003</LINK>; <LINK REF="STD-Spies-1996" TYPE="STUDY">Spies 1996</LINK>), 267 participants, RR 0.56 (0.18 to 1.72), the result is not statistically significant, see <LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK> or <LINK REF="FIG-17" TYPE="FIGURE">Figure 17</LINK>
</P>
<P>
<B>Comparison 5 (Anticonvulsant 1 + Other drug) versus Anticonvulsant 2</B>
</P>
<P>
<B>Efficacy</B>
</P>
<P>1 study( <LINK REF="STD-Croissant-2009" TYPE="STUDY">Croissant 2009</LINK>), 56 participants, compared Oxcarbaxepine plus Tiapride versus Chlormethiazole. No alcohol withdrawal seizures or delirium happened in both groups. See <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK> and <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>
</P>
<P>
<B>Safety</B>
</P>
<P>
<B>5.3. Adverse events</B>
</P>
<P>1 study (<LINK REF="STD-Croissant-2009" TYPE="STUDY">Croissant 2009</LINK>) 56 participants, compared Oxcarbaxepine plus Tiapride versus Chlormethiazole, RR 0.68 (0.45 to 1.04) , the result is not statistically significant, see <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>
</P>
<P>
<B>5.4</B> <I>
<B>Severe, life-threatening adverse events</B>
</I>
</P>
<P>1 study ( <LINK REF="STD-Croissant-2009" TYPE="STUDY">Croissant 2009</LINK>), 56 participants, compared Oxcarbaxepine plus Tiapride versus Chlormethiazole. No severe adverse events happened in both groups.<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>
</P>
<P>
<B>Acceptability</B>
</P>
<P>
<B>5.5 Drop out</B>
</P>
<P>1 study (<LINK REF="STD-Croissant-2009" TYPE="STUDY">Croissant 2009</LINK>) 56 participants, compared Oxcarbaxepine plus Tiapride versus Chlormethiazole, RR 5.36 (0.27 to 106.78) the result is not statistically significant. See <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>
</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-01-08 12:07:21 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2010-01-08 12:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-six studies, with a total of 4076 participants, met the inclusion criteria for this review. However, despite the considerable number of randomised controlled trials, the large variety of outcomes and rating scales considerably limited a quantitative synthesis of data. A large chunk of information could not be synthesized.</P>
<P>- No statistically significant differences were found in the four outcomes considered in the comparisons of anticonvulsants versus placebo. Anticonvulsant showed a potentially protective benefit against seizures. The adverse events were non-significantly more common among the anticonvulsant-treated patients, but the discontinuations due to adverse events tended to be more common in the placebo-group. None of these trends, however, reached statistical significance.</P>
<P>- For the anticonvulsant versus other drug, results favour anticonvulsants only in one of the nine outcomes considered: comparing carbamazepine with benzodiazepine (oxazepam and lorazepam), results favour carbamazepine for alcohol withdrawal symptoms rated with CIWA-Ar score.  None of the other comparisons reached statistical significance. This can suggests that anticonvulsants and specifically carbamazepine may actually be more effective in treating some aspects of alcohol withdrawal when compared to benzodiazepines, the current first-line regimen for alcohol withdrawal syndrome. The incidence of seizures tended to be more common among the participants that were treated with other drugs (e.g. benzodiazepines) than anticonvulsants, but delirium tremens favoured the other-treatment participants. Adverse events showed a potentially better profile for the anticonvulsants.</P>
<P>- Comparing different anticonvulsants (2 outcomes considered), when carbamazepine was compared to Chlormethiazole the incidence of adverse events tended to be more common among the carbamazepine-treated participants, whereas withdrawals tended to be more common among the Chlormethiazole participants. When carbamazepine was compared to barbital, the side effects were not statistically significant but more common among the carbamazepine patients, and no difference was found regarding the withdrawals between the compared drugs. Out of eleven studies comparing different anticonvulsant agents, no participant died during the treatment period.</P>
<P>- Comparing anticonvulsants plus other drugs versus other drugs (3 outcomes considered), results favour paraldehyde plus chloral hydrate versus chlordiazepoxide, for the severe-life threatening side effects, but only one study, with four arms, and 72 participants was included in this comparison.</P>
<P>- Comparing anticonvulsant plus other drug versus another anticonvulsant, no significant difference were found in all the outcome considered (seizures, delirium, adverse events and drop out). But only one study with 56 participants, which compared oxcarbazepine plus Tiapride versus Chlormethiazolewas included in this comparison.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-12-14 15:59:03 +0100" MODIFIED_BY="[Empty name]">
<P>Our review has some important limitations. First, most studies involve a very small sample size and have been conducted in different years, and in diverse patient populations.</P>
<P>Another potential limitation is the unavoidable grouping of drugs. All anticonvulsants were analysed together compared to the other drugs. Differences between specific anticonvulsant agents could not be seen, because of the limited number of studies comparing different anticonvulsants between themselves. Other drugs included a large variety of medicines such as benzodiazepines, neuroleptics, hypnotics, etc.  These drugs do not belong to the same class and do not share the same mechanism of action. The grouping of all these drugs together, could have led to the loss of possibly important between-drugs differences concerning effectiveness or safety. While we made an effort to address drug-specific comparisons as well, these data are definitely more limited and even more inconclusive. It was also not possible to examine dose-response effects, since participants were not treated with even similar doses of various anticonvulsants across RCTs. Moreover, data on side effects should be interpreted cautiously, as they were derived from participants with different co-morbidity. Many trials tended to exclude participants in severe, medical conditions such as hepatic, heart or lung disease. However, these participants may be more sensitive to various adverse events of anticonvulsants or comparator drugs.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-12-14 15:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Although randomisation was an inclusion criterion, indicating a degree of methodological quality for these studies, many of them are quite old, the mode of randomisation is not described, allocation of concealment is often unclear and information on follow-up is frequently missing. On the other hand, this makes the meta-analysis potentially more useful, since small trends that could not reach statistical significance due to the small number of participants in these trials, could now be revealed after the data synthesis. Also highlighting reporting deficits is important for improving future research.</P>
</QUALITY_OF_EVIDENCE>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-12-14 16:00:11 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-12-14 15:59:55 +0100" MODIFIED_BY="[Empty name]">
<P>Results of this review do not provide sufficient evidence in favour of anticonvulsants for the treatment of AWS. Anticonvulsants seem to have limited side effects, although adverse effects are not rigorously reported in the analysed trials.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-12-14 16:00:11 +0100" MODIFIED_BY="[Empty name]">
<P>Although a significant number of trends has emerged, most of these were small and the data for most outcomes did not reach statistical significance; the need for  further studies should be carefully evaluated on the basis of these findings.  If these studies are going to be carried out, they should be limited to few important efficacy and safety measures such as the severity of the alcohol withdrawal syndrome, the incidence of seizures and delirium tremens, side effects, withdrawals and mortality. In the case of continuous outcomes the same rating scale (e.g. CIWA-Ar) should preferably be used, in order to have more comparable information across studies and to be able to estimate the real effect of all these agents.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-12-07 09:14:31 +0100" MODIFIED_BY="[Empty name]">
<P>We thank the author of the first version of the review that did an excellent work that was very helpful for this update and Zuzana Mitrova for providing helpful assistance during all the process</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-06 11:35:19 +0100" MODIFIED_BY="[Empty name]">
<P>Vecchi performed the literature searches; Mitrova organised papers collection; Minozzi and Amato reviewed the papers, abstracted data from the papers for meta-analysis. Amato and Minozzi wrote abstract, introduction, discussion and conclusions sections. Minozzi wrote methods , assessed methodological quality of included studies and wrote results sections. Davoli supervised to all the process and all authors provided comments to the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES MODIFIED="2009-12-14 16:00:51 +0100" MODIFIED_BY="[Empty name]">
<P>This review is a substantial update of a previous version (<LINK REF="REF-Polycarpou-2005" TYPE="REFERENCE">Polycarpou 2005</LINK>). The authors of the first version are not yet interested in updating this review that for that change the authorship.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-02-15 14:52:19 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-02-15 14:52:19 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-02-15 13:39:42 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Agricola-1982" NAME="Agricola 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;0300-0605&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agricola R, Mazzarino M, Urani R, Gallo V, Grossi E</AU>
<TI>Treatment of acute alcohol withdrawal syndrome with carbamazepine: a double-blind comparison with tiapride</TI>
<SO>Journal of Internal Medical Research</SO>
<YR>1982</YR>
<VL>10</VL>
<NO>3</NO>
<PG>160-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alldredge-1989" NAME="Alldredge 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0002-9343&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alldredge BK, Lowenstein DH, Simon RP</AU>
<TI>Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures</TI>
<SO>American Journal of Medicine</SO>
<YR>1989</YR>
<VL>87</VL>
<NO>6</NO>
<PG>645-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balldin-1986" NAME="Balldin 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;0065-1591&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balldin J, Bokstrom K</AU>
<TI>Treatment of alcohol abstinence symptoms with the alpha 2-agonist clonidine</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1986</YR>
<VL>327</VL>
<PG>131-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bjorkqvist-1976" MODIFIED="2008-03-21 11:26:55 +0100" MODIFIED_BY="[Empty name]" NAME="Bjorkqvist 1976" YEAR="1976">
<REFERENCE MODIFIED="2008-03-21 11:26:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:26:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bjorkqvist SE, Isohanni M, Makela R, Malinen L</AU>
<TI>Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal Multicentre double-blind comparison with placebo</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1976</YR>
<VL>53</VL>
<NO>5</NO>
<PG>333-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blanchard-1985" MODIFIED="2010-01-08 12:28:54 +0100" MODIFIED_BY="[Empty name]" NAME="Blanchard 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-01-08 12:28:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blanchard C</AU>
<TI>Atrium 300 and Alcohol Withdrawal: Double-Blind Placebo-Controlled Study in 38 hospitalised patients</TI>
<TO>Atrium 300 et Sevrage Alcoolique. Etude en Double Aveugle Versus Placebo chez 38 malades hospitalises</TO>
<SO>Psychological Medicine (Paris)</SO>
<YR>1985</YR>
<VL>17</VL>
<NO>1</NO>
<PG>159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnet-2003" MODIFIED="2010-01-08 12:29:11 +0100" MODIFIED_BY="[Empty name]" NAME="Bonnet 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-12-14 11:55:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0271-0749&lt;/p&gt;" NOTES_MODIFIED="2009-12-14 11:55:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet U, Banger M, Leweke FM, Specka M, Muller BW, Hashemi T et al</AU>
<TI>Treatment of acute alcohol withdrawal with gabapentin: results from a controlled two-centre trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>5</NO>
<PG>514-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-01-08 12:29:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet U, Speeka M, Leweke FM, Nyhuis P, Banger M</AU>
<TI>Gabapentin's acute effect on mood profile - a controlled study on patients with alcohol withdrawal</TI>
<SO>Progress in Neuro-Pharmacology &amp; Biological Psychiatry</SO>
<YR>2007</YR>
<VL>31</VL>
<PG>434-438</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borg-1986" NAME="Borg 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borg S, Kvande H, Valverius P</AU>
<TI>Clinical conditions and central dopamine metabolism in alcoholics during acute withdrawal under treatment with different pharmacological agents</TI>
<SO>Psychopharmacology (Berlin)</SO>
<YR>1986</YR>
<VL>88</VL>
<NO>1</NO>
<PG>12-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1985a" MODIFIED="2010-01-08 12:29:23 +0100" MODIFIED_BY="[Empty name]" NAME="Burroughs 1985a" YEAR="">
<REFERENCE MODIFIED="2010-01-08 12:29:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, Morgan MY, Sherlock S</AU>
<TI>Double-blind controlled trial of bromocriptine, chlordiazepoxide and Chlormethiazole for alcohol withdrawal symptoms</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>3</NO>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burroughs-1985b" MODIFIED="2010-01-08 12:29:41 +0100" MODIFIED_BY="[Empty name]" NAME="Burroughs 1985b" YEAR="1985">
<REFERENCE MODIFIED="2010-01-08 12:29:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burroughs AK, Morgan MY, Sherlock S</AU>
<TI>Double-blind controlled trial of bromocriptine, chlordiazepoxide and Chlormethiazole for alcohol withdrawal symptoms</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1985</YR>
<VL>20</VL>
<NO>3</NO>
<PG>263-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chance-1991" NAME="Chance 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;0196-0644&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chance JF</AU>
<TI>Emergency department treatment of alcohol withdrawal seizures with phenytoin</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1991</YR>
<VL>20</VL>
<NO>5</NO>
<PG>520-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choi-2005" MODIFIED="2010-02-15 13:20:46 +0100" MODIFIED_BY="[Empty name]" NAME="Choi 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-02-15 13:20:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choi EA, Ki SW, Kim SE, Kim JW, Park JK</AU>
<TI>The efficacy and safety of topiramate in the treatment of alcohol withdrawal</TI>
<SO>Journal of Korean Neuropsychiatric Association</SO>
<YR>2005</YR>
<VL>44</VL>
<PG>328-33</PG>
<IDENTIFIERS MODIFIED="2009-08-18 17:41:26 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croissant-2009" MODIFIED="2010-02-15 11:37:30 +0100" MODIFIED_BY="[Empty name]" NAME="Croissant 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-02-15 11:37:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croissant B, Loeber S, Diehl A, Nakovics H, Wagner F, Kiefer F et al</AU>
<TI>Oxcarbazepine in combination with Tiaprid in inpatient alcohol-withdrawal--a RCT</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2009</YR>
<VL>42</VL>
<PG>175 &#8211; 81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dencker-1978" MODIFIED="2010-01-08 12:29:52 +0100" MODIFIED_BY="[Empty name]" NAME="Dencker 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-01-08 12:29:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0300-0605&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:29:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dencker SJ, Wilhelmson G, Carlsson E, Bereen FJ</AU>
<TI>Piracetam and Chlormethiazole in acute alcohol withdrawal: a controlled clinical trial</TI>
<SO>Journal of Internal Medical Research</SO>
<YR>1978</YR>
<VL>6</VL>
<NO>5</NO>
<PG>395-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elsing-1996" MODIFIED="2010-01-08 12:30:15 +0100" MODIFIED_BY="[Empty name]" NAME="Elsing 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-08 12:30:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elsing C, Schimanski U, Stremmel W</AU>
<TI>Randomized controlled trial for the treatment of alcohol withdrawal syndrome: gamma-hydroxybutyric acid abstract</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1996</YR>
<VL>26 S</VL>
<PG>A17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elsing-2009" MODIFIED="2010-02-15 13:22:27 +0100" MODIFIED_BY="[Empty name]" NAME="Elsing 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-02-15 13:22:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elsing C, Stremmel W, Grenda U, Herrmann T</AU>
<TI>Gamma-hydroxybutyric acid versus clomethiazole for the treatment of alcohol withdrawal syndrome in a medical intensive care unit: an open, single-center randomized study</TI>
<SO>The American Journal of Drug and Alcohol Abuse</SO>
<YR>2009</YR>
<VL>35</VL>
<PG>189-192</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flygering-1984" MODIFIED="2010-01-08 12:30:28 +0100" MODIFIED_BY="[Empty name]" NAME="Flygering 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-01-08 12:30:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:30:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flygenring J, Hansen J, Holst B, Petersen E, Sorensen A</AU>
<TI>Treatment of alcohol withdrawal symptoms in hospitalised patients. A randomised, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal)</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1984</YR>
<VL>69</VL>
<NO>5</NO>
<PG>398-408</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gann-2004" MODIFIED="2010-01-08 12:30:56 +0100" MODIFIED_BY="[Empty name]" NAME="Gann 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-08 12:30:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gann H, Feige B, Cloot O, Van Wasen H, Zinzgraf D, Hohagen F et al</AU>
<TI>Polysomnography during withdrawal with Chlormethiazole or placebo in alcohol dependent patients--a double-blind and randomised study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>2004</YR>
<VL>37</VL>
<PG>228-35</PG>
<IDENTIFIERS MODIFIED="2009-08-18 17:43:24 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-18 17:43:24 +0200" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15359376"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glatt-1966" MODIFIED="2010-01-08 12:32:22 +0100" MODIFIED_BY="[Empty name]" NAME="Glatt 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-01-08 12:32:22 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0065-1591&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:32:22 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glatt MM, George HR, Frisch EP</AU>
<TI>Evaluation of Chlormethiazole in treatment for alcohol withdrawal syndrome. Results of a controlled trial</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1966</YR>
<VL>192</VL>
<PG>121-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Golbert-1967" MODIFIED="2010-01-05 14:58:21 +0100" MODIFIED_BY="[Empty name]" NAME="Golbert 1967" YEAR="1967">
<REFERENCE MODIFIED="2009-12-14 15:41:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Golbert TM, Sanz CJ, Rose HD, Leitschuh TH</AU>
<TI>Comparative evaluation of treatments of alcohol withdrawal syndromes</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1967</YR>
<VL>201</VL>
<NO>2</NO>
<PG>99-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaim-1972" MODIFIED="2010-02-15 13:23:07 +0100" MODIFIED_BY="[Empty name]" NAME="Kaim 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-02-15 13:23:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaim SC, Klett CJ</AU>
<TI>Treatment of delirium tremens: a comparative evaluation of four drugs</TI>
<SO>Quarterly Journal of Studies on Alcohol</SO>
<YR>1972</YR>
<VL>33</VL>
<PG>1065-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalyoncu-1996" MODIFIED="2010-02-15 13:24:33 +0100" MODIFIED_BY="[Empty name]" NAME="Kalyoncu 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-02-15 13:24:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalyoncu O, Beyazyurek M, Kuru L, Solukcu R, Yazman U</AU>
<TI>Double-blind comparative trial with carbamazepine vs diazepam treatment of alcohol withdrawal</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6 Suppl 3</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koethe-2007" MODIFIED="2010-02-15 11:39:41 +0100" MODIFIED_BY="[Empty name]" NAME="Koethe 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-15 11:39:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Koethe D, Juelicher A, Nolden BM,  Braunwarth WD, Klosterkotter J, Niklewski G et al</AU>
<TI>Oxcarbazepine--efficacy and tolerability during treatment of alcohol withdrawal: a double-blind, randomised, placebo-controlled multicenter pilot study</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>7</NO>
<PG>1188-94</PG>
<IDENTIFIERS MODIFIED="2010-02-15 11:39:41 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koppi-1987" MODIFIED="2010-01-08 12:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Koppi 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-01-08 12:31:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0302-282x&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:31:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koppi S, Eberhardt G, Haller R, Konig P</AU>
<TI>Calcium-channel-blocking agent in the treatment of acute alcohol withdrawal--Caroverine versus meprobamate in a randomised double-blind study</TI>
<SO>Neuropsychobiology</SO>
<YR>1987</YR>
<VL>17</VL>
<NO>1-2</NO>
<PG>49-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramp-1978" NAME="Kramp 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramp P, Rafaelsen OJ</AU>
<TI>Delirium tremens: a double-blind comparison of diazepam and barbital treatment</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1978</YR>
<VL>58</VL>
<NO>2</NO>
<PG>174-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krupitsky-2007" MODIFIED="2010-02-15 11:40:18 +0100" MODIFIED_BY="[Empty name]" NAME="Krupitsky 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-15 11:40:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krupitsky EM, Rudenko AA, Burakov AA,  Slavina TY, Grinenko AA,  Pittman B et al</AU>
<TI>Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>604-11</PG>
<IDENTIFIERS MODIFIED="2010-02-15 11:40:18 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lambie-1980" NAME="Lambie 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;0004-8674&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lambie DG, Johnson RH, Vijayasenan ME, Whiteside EA</AU>
<TI>Sodium valproate in the treatment of the alcohol withdrawal syndrome</TI>
<SO>Australian and New Zeland Journal of Psychiatry</SO>
<YR>1980</YR>
<VL>14</VL>
<NO>3</NO>
<PG>213-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lapierre-1983" MODIFIED="2010-02-15 13:27:52 +0100" MODIFIED_BY="[Empty name]" NAME="Lapierre 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-02-15 13:27:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0302-282x&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:27:52 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lapierre YD, Bulmer DR, Oyewumi LK, Mauguin ML, Knott VJ</AU>
<TI>Comparison of chlormethiazole (Heminevrin) and chlordiazepoxide (Librium) in the treatment of acute alcohol withdrawal</TI>
<SO>Neuropsychobiology</SO>
<YR>1983</YR>
<VL>10</VL>
<NO>2-3</NO>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Longo-2002" NAME="Longo 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;1055-0887&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Longo LP, Campbell T, Hubatch S</AU>
<TI>Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention</TI>
<SO>Journal of Addictive Diseases</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>2</NO>
<PG>55-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucht-2003" MODIFIED="2010-02-15 13:35:20 +0100" MODIFIED_BY="[Empty name]" NAME="Lucht 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-02-15 13:35:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:35:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucht M, Kuehn KU, Armbruster J, Abraham G, Gaensicke M, Barnow S et al</AU>
<TI>Alcohol withdrawal treatment in intoxicated vs non-intoxicated patients: a controlled open-label study with tiapride/carbamazepine, chlormethiazole and diazepam</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>2</NO>
<PG>168-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Madden-1969" NAME="Madden 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;0007-1250&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Madden JS, Jones D, Frisch EP</AU>
<TI>Chlormethiazole and trifluoperazine in alcohol withdrawal</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1969</YR>
<VL>115</VL>
<NO>527</NO>
<PG>1191-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1989" NAME="Malcolm 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0002-953x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Ballenger JC, Sturgis ET, Anton R</AU>
<TI>Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<NO>5</NO>
<PG>617-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2002" MODIFIED="2009-12-08 15:44:47 +0100" MODIFIED_BY="[Empty name]" NAME="Malcolm 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-03-21 11:27:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0884-8734&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:27:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC</AU>
<TI>The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomised trial</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>349-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-2007" MODIFIED="2010-02-15 11:40:56 +0100" MODIFIED_BY="[Empty name]" NAME="Malcolm 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-15 11:40:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Myrick LH, Veatch LM, Boyle E and Randall PK</AU>
<TI>Self-reported sleep, sleepiness, and repeated alcohol withdrawals: a randomised,  double blind, controlled comparison of lorazepam vs gabapentin</TI>
<SO>Journal of Clinical Sleep Medicine</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>1</NO>
<PG>24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manhem-1985" NAME="Manhem 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manhem P, Nilsson LH, Moberg AL, Wadstein J, Hokfelt B</AU>
<TI>Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin-aldosterone system, and clinical symptoms</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1985</YR>
<VL>9</VL>
<NO>3</NO>
<PG>238-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mariani-2006" MODIFIED="2010-01-08 12:32:01 +0100" MODIFIED_BY="[Empty name]" NAME="Mariani 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-01-08 12:32:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP</AU>
<TI>A randomised, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal</TI>
<SO>American Journal on Addictions</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>1</NO>
<PG>76-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGrath-1975" MODIFIED="2010-01-08 12:32:35 +0100" MODIFIED_BY="[Empty name]" NAME="McGrath 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-01-08 12:32:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0007-0890&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:32:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGrath SD</AU>
<TI>A controlled trial of Chlormethiazole and chlordiazepoxide in the treatment of the acute withdrawal phase of alcoholism</TI>
<SO>British Journal of Addiction to Alcohol and Other Drugs</SO>
<YR>1975</YR>
<VL>70 Suppl 1</VL>
<PG>81-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1983" MODIFIED="2010-02-15 13:36:11 +0100" MODIFIED_BY="[Empty name]" NAME="Murphy 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-02-15 13:36:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy DJ, Shaw GK, Clarke I</AU>
<TI>Tiapride and chlormethiazole in alcohol withdrawal: a double-blind trial</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1983</YR>
<VL>18</VL>
<NO>3</NO>
<PG>227-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrick-2000" NAME="Myrick 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0095-2990&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrick H, Brady KT, Malcolm R</AU>
<TI>Divalproex in the treatment of alcohol withdrawal</TI>
<SO>American Journal of Drug and Alcohol Abuse</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>1</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nimmerichter-2002" MODIFIED="2010-01-08 12:33:12 +0100" MODIFIED_BY="[Empty name]" NAME="Nimmerichter 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-08 12:33:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:33:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nimmerrichter AA, Walter H, Gutierrez-Lobos KE, Lesch OM</AU>
<TI>Double-blind controlled trial of gamma-hydroxybutyrate and Chlormethiazole in the treatment of alcohol withdrawal</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>1</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Radouco_x002d_Thomas-1989" MODIFIED="2010-01-08 12:33:24 +0100" MODIFIED_BY="[Empty name]" NAME="Radouco-Thomas 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-01-08 12:33:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0278-5846&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:33:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Radouco-Thomas S, Garcin F, Guay D, Marquis PA, Chabot F, Huot J et al</AU>
<TI>Double blind study on the efficacy and safety of Tetrabamate and chlordiazepoxide in the treatment of the acute alcohol withdrawal syndrome</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1-2</NO>
<PG>55-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rathlev-1994" NAME="Rathlev 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;0196-0644&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rathlev NK, D'Onofrio G, Fish SS, Harrison PM, Bernstein E, Hossack RW et al</AU>
<TI>The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures</TI>
<SO>Annals of Emergency Medicine</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>3</NO>
<PG>513-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reoux-2001" MODIFIED="2008-03-21 11:27:46 +0100" MODIFIED_BY="[Empty name]" NAME="Reoux 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-03-21 11:27:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:27:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL</AU>
<TI>Divalproex sodium in alcohol withdrawal: a randomised double-blind placebo-controlled clinical trial</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>9</NO>
<PG>1324-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ritola-1981" MODIFIED="2010-02-15 13:36:57 +0100" MODIFIED_BY="[Empty name]" NAME="Ritola 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-02-15 13:36:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:36:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ritola E, Malinen L</AU>
<TI>A double-blind comparison of carbamazepine and chlormethiazole in the treatment of alcohol withdrawal syndrome</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1981</YR>
<VL>64</VL>
<NO>3</NO>
<PG>254-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1989" NAME="Robinson 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson BJ, Robinson GM, Maling TJ, Johnson RH</AU>
<TI>Is clonidine useful in the treatment of alcohol withdrawal?</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>1</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rosenthal-1998" MODIFIED="2008-03-21 11:27:59 +0100" MODIFIED_BY="[Empty name]" NAME="Rosenthal 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-03-21 11:27:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1055-0496&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:27:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR</AU>
<TI>A pilot open randomised trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal</TI>
<SO>American Journal on Addictions</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rothstein-1973" NAME="Rothstein 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;0002-953x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rothstein E</AU>
<TI>Prevention of alcohol withdrawal seizures: the roles of diphenylhydantoin and chlordiazepoxide</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1973</YR>
<VL>130</VL>
<NO>12</NO>
<PG>1381-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sampliner-1974" NAME="Sampliner 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;0098-7484&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sampliner R, Iber FL</AU>
<TI>Diphenylhydantoin control of alcohol withdrawal seizures. Results of a controlled study</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1974</YR>
<VL>230</VL>
<NO>10</NO>
<PG>1430-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santo-1985" MODIFIED="2010-02-15 11:56:00 +0100" MODIFIED_BY="[Empty name]" NAME="Santo 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-02-15 11:56:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0025-7753&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 11:56:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santo Domingo Carrasco J, Bravo Ortiz MF, Barroso Canizares A, Caballero Martin L</AU>
<TI>Double-blind study of the efficacy of Tetrabamate and Tiapride in the treatment of alcohol deprivation syndrome</TI>
<TO>Estudio a doble ciego de la eficacia del tetrabamato y el tiapride en el tratamiento del sindrome de deprivacion alcoholica</TO>
<SO>Medicina Clinica (Barcelona)</SO>
<YR>1985</YR>
<VL>85</VL>
<NO>13</NO>
<PG>533-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schik-2005" MODIFIED="2009-08-18 17:49:23 +0200" MODIFIED_BY="[Empty name]" NAME="Schik 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-18 17:49:23 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schik G, Wedegaertner FR, Liersch J, Hoy L, Emrich HM, Schneider  U</AU>
<TI>Oxcarbazepine versus carbamazepine in the treatment of alcohol withdrawal</TI>
<SO>Addiction Biology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>3</NO>
<PG>283-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seifert-2004" MODIFIED="2010-02-15 13:38:46 +0100" MODIFIED_BY="[Empty name]" NAME="Seifert 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-15 13:38:46 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1355-6215&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:38:46 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seifert J, Peters E, Jahn K, Metzner C, Ohlmeier M, te Wildt B et al</AU>
<TI>Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance-a pilot study</TI>
<SO>Addiction Biology</SO>
<YR>2004</YR>
<VL>9</VL>
<NO>1</NO>
<PG>43-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spies-1996" NAME="Spies 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;0090-3493&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spies CD, Dubisz N, Neumann T, Blum S, Muller C, Rommelspacher H et al</AU>
<TI>Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial</TI>
<SO>Critical Care Medicine</SO>
<YR>1996</YR>
<VL>24</VL>
<NO>3</NO>
<PG>414-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stanhope-1989" MODIFIED="2010-02-15 13:39:06 +0100" MODIFIED_BY="[Empty name]" NAME="Stanhope 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-02-15 13:39:06 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stanhope JM</AU>
<TI>The use of carbamazepine in chormethiazole-modified withdrawal from alcohol</TI>
<SO>Australian Drug and Alcohol Review</SO>
<YR>1989</YR>
<VL>8</VL>
<PG>5-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuppaeck-1992" NAME="Stuppaeck 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW</AU>
<TI>Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1992</YR>
<VL>27</VL>
<NO>2</NO>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stuppaeck-1998" MODIFIED="2010-02-15 13:39:42 +0100" MODIFIED_BY="[Empty name]" NAME="Stuppaeck 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-02-15 13:39:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Stuppaeck C, Whitworth A, Deisenhammer E, Honeder M, Kurz M, Telser S</AU>
<TI>Vigabatrin in the treatment of alcohol withdrawal syndrome : a double-blind , randomized study</TI>
<SO>XXIst Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland.12th-16th July, 1998</SO>
<YR>1998</YR>
<PG>PW13010</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teijeiro-1975" MODIFIED="2010-01-08 12:34:43 +0100" MODIFIED_BY="[Empty name]" NAME="Teijeiro 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-01-08 12:34:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teijeiro J</AU>
<TI>A double-blind comparative study of atrium 300 and Heminiurine in chronic alcoholics</TI>
<TO>Etude comparee en double-aveugle de l'atrium 300 et de l'hemineurine chez des alcooliques chroniques</TO>
<SO>Medicine et Hygiene (Geneve)</SO>
<YR>1975</YR>
<VL>33</VL>
<NO>1164</NO>
<PG>1141-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1975" NAME="Thompson 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;0003-4819&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson WL, Johnson AD, Maddrey WL</AU>
<TI>Diazepam and paraldehyde for treatment of severe delirium tremens. A controlled trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1975</YR>
<VL>82</VL>
<NO>2</NO>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tubridy-1988" MODIFIED="2010-01-08 12:36:29 +0100" MODIFIED_BY="[Empty name]" NAME="Tubridy 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-01-08 12:36:29 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0952-0481&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:36:29 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tubridy P</AU>
<TI>Alprazolam versus Chlormethiazole in acute alcohol withdrawal</TI>
<SO>British Journal of Addiction</SO>
<YR>1988</YR>
<VL>83</VL>
<NO>5</NO>
<PG>581-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-02-15 14:52:19 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addolorato-2002" MODIFIED="2008-03-21 11:28:16 +0100" MODIFIED_BY="[Empty name]" NAME="Addolorato 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-03-21 11:28:16 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:28:16 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L et al</AU>
<TI>Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2002</YR>
<VL>37</VL>
<NO>5</NO>
<PG>504-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Adinoff-1994" NAME="Adinoff 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adinoff B</AU>
<TI>Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>4</NO>
<PG>873-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aliyev-2008" MODIFIED="2009-12-21 09:43:08 +0100" MODIFIED_BY="[Empty name]" NAME="Aliyev 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-12-21 09:43:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aliyev ZN, Aliyev NA</AU>
<TI>Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>4</NO>
<PG>456-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ansoms-2000" MODIFIED="2010-01-08 12:37:11 +0100" MODIFIED_BY="[Empty name]" NAME="Ansoms 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-08 12:37:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1022-6877&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:37:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ansoms C, Deckers F, Lehert P, Pelc I, Potgieter A</AU>
<TI>An open study with Acamprosate in Belgium and Luxemburg: results on socio- demographics, supportive treatment and outcome</TI>
<SO>European Addiction Research</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>3</NO>
<PG>132-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2009" MODIFIED="2010-02-15 12:04:08 +0100" MODIFIED_BY="[Empty name]" NAME="Anton 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-02-15 12:04:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Myrick H, Baros AM, Latham PK, Randall PK, Wright TM et al</AU>
<TI>Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>4</NO>
<PG>334-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Athen-1976" MODIFIED="2010-02-15 13:41:09 +0100" MODIFIED_BY="[Empty name]" NAME="Athen 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-02-15 13:41:09 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0033-264x&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:41:09 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Athen D, Bender W, Meyendorf R</AU>
<TI>Criteria of the efficacy of therapeutic measures in alcoholic delirium. Study on the effectiveness of aprotinin in alcoholic delirium</TI>
<TO>Beurteilung der Wirksamkeit therapeutischer Massnahmen beim Alkoholdelir. Untersuchung uber die Wirksamkeit von Aprotinin beim Alkoholdelir</TO>
<SO>Psychiatria Clinica</SO>
<YR>1976</YR>
<VL>9</VL>
<NO>3-4</NO>
<PG>183-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Athen-1977" MODIFIED="2010-02-15 14:34:42 +0100" MODIFIED_BY="[Empty name]" NAME="Athen 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-02-15 14:34:42 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0028-2804&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:34:42 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Athen D, Hippius H, Meyendorf R, Riemer C, Steiner C</AU>
<TI>Comparison of the effectiveness of neuroleptics and Chlormethiazole in the treatment of alcoholic delirium (author's translation)</TI>
<TO>Ein Vergleich der Wirksamkeit von Neuroleptika und Chlormethiazol bei der Behandlung des Alkoholdelirs</TO>
<SO>Nervenarzt (Berlin)</SO>
<YR>1977</YR>
<VL>48</VL>
<NO>10</NO>
<PG>528-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Athen-1986" MODIFIED="2010-01-08 12:38:11 +0100" MODIFIED_BY="[Empty name]" NAME="Athen 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-01-08 12:38:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0065-1591&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:38:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Athen D</AU>
<TI>Comparative investigation of Chlormethiazole and neuroleptic agents in the treatment of alcoholic delirium</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1986</YR>
<VL>329</VL>
<PG>167-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balldin-1992" NAME="Balldin 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0006-3223&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balldin J, Berggren U, Engel J, Lindstedt G, Sundkler A, Walinder J</AU>
<TI>Alpha-2-adrenoceptor sensitivity in early alcohol withdrawal</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<NO>7</NO>
<PG>712-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baltieri-2003" MODIFIED="2010-01-08 12:38:57 +0100" MODIFIED_BY="[Empty name]" NAME="Baltieri 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-08 12:38:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1516-4446&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:38:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baltieri DA, de Andrade AG</AU>
<TI>Efficacy of Acamprosate in the treatment of alcohol-dependent outpatients</TI>
<SO>Revista Brasileira de Psiquiatria</SO>
<YR>2003</YR>
<VL>25</VL>
<NO>3</NO>
<PG>156-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Banki-1983" MODIFIED="2010-01-08 12:39:30 +0100" MODIFIED_BY="[Empty name]" NAME="Banki 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-01-08 12:39:30 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0133-3909&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:39:30 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Banki CM</AU>
<TI>Comparative study with Grandaxin and diazepam in alcohol withdrawal syndrome and geronto psychiatric diseases</TI>
<SO>Therapia Hungarica</SO>
<YR>1983</YR>
<VL>31</VL>
<NO>3</NO>
<PG>120-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Block-1974" MODIFIED="2010-01-08 12:39:53 +0100" MODIFIED_BY="[Empty name]" NAME="Block 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-01-08 12:39:53 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0300-9718&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:39:53 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Block C, Borendal-Jansson B, Carlsson C</AU>
<TI>A double-blind crossover comparison between Chlothiapine and diazepam in the treatment of mental symptoms in chronic alcoholics</TI>
<SO>International Journal of Clinical Pharmacology</SO>
<YR>1974</YR>
<VL>9</VL>
<NO>4</NO>
<PG>321-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonnet-2009" MODIFIED="2010-02-15 12:32:11 +0100" MODIFIED_BY="[Empty name]" NAME="Bonnet 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-02-15 12:32:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet U, Hamzavi-Abedi R, Specka M, Wiltfang J, Lieb B, Scherbaum N</AU>
<TI>An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol</TI>
<SO>Alcohol &amp; Alcoholism</SO>
<YR>2010</YR>
<VL>45</VL>
<PG>143-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borg-1980" MODIFIED="2010-02-15 12:20:38 +0100" MODIFIED_BY="[Empty name]" NAME="Borg 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-02-15 12:20:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0029-2001&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 12:20:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borg V</AU>
<TI>Clinical trial of Tegretol and Anafranil/Sinequan in alcohol abstinence symptoms</TI>
<TO>Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke</TO>
<SO>Tidsskrift for den Norske Laegeforening</SO>
<YR>1980</YR>
<VL>100</VL>
<NO>5</NO>
<PG>277-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brady-2002" NAME="Brady 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;0376-8716&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brady KT, Myrick H, Henderson S, Coffey SF</AU>
<TI>The use of divalproex in alcohol relapse prevention: a pilot study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2002</YR>
<VL>67</VL>
<NO>3</NO>
<PG>323-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bullock-1989" NAME="Bullock 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0140-6736&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bullock ML, Culliton PD, Olander RT</AU>
<TI>Controlled trial of acupuncture for severe recidivist alcoholism</TI>
<SO>The Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8652</NO>
<PG>1435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caspari-1992" MODIFIED="2010-02-15 12:37:00 +0100" MODIFIED_BY="[Empty name]" NAME="Caspari 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-02-15 12:37:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0303-4259&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 12:37:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caspari D, Wappler M, Bellaire W</AU>
<TI>Treatment of delirium tremens--a comparison between Chlormethiazole and clorazepate with reference to effectiveness and rate of side effects</TI>
<TO>Zur Behandlung des Delirium tremens--ein Vergleich zwischen Clomethiazol und Clorazepat hinsichtlich Effektivitat und Nebenwirkungsrate</TO>
<SO>Psychiatrische Praxis</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cazzato-1982" MODIFIED="2010-02-15 12:41:32 +0100" MODIFIED_BY="[Empty name]" NAME="Cazzato 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-02-15 12:41:32 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0035-6344&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 12:41:32 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cazzato G, Gioseffi M, Torre P, Coppola N</AU>
<TI>Prevention and therapy of delirium tremens with tiapride and chlordesmethyldiazepam</TI>
<TO>Prevenzione e terapia del delirium tremens con tiapride e clordemetildiazepam</TO>
<SO>Rivista di Neurologia</SO>
<YR>1982</YR>
<VL>52</VL>
<NO>6</NO>
<PG>331-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chick-2000" MODIFIED="2010-01-08 12:40:55 +0100" MODIFIED_BY="[Empty name]" NAME="Chick 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-08 12:40:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:40:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chick J, Howlett H, Morgan MY, Ritson B</AU>
<TI>United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of Acamprosate versus placebo in preventing relapse after withdrawal from alcohol</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>176-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cushman-1985" NAME="Cushman 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0048-5764&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cushman P Jr, Lerner W, Cramer M</AU>
<TI>Adrenergic agonist therapy in alcohol withdrawal states in man</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1985</YR>
<VL>21</VL>
<NO>3</NO>
<PG>651-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delamaire-1986" MODIFIED="2010-02-15 12:47:27 +0100" MODIFIED_BY="[Empty name]" NAME="Delamaire 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-02-15 12:47:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delamaire D, Carpentier MC, Eudier F</AU>
<TI>Trial of Tiapride in patients discharged after hospitalisation for alcohol withdrawal. A randomised, double-blind trial in fifty-one patients with alcohol related liver disease</TI>
<SO>La semaine des hopitaux: organe fonde par l' Association d' enseignement medical des hopitaux de Paris</SO>
<YR>1986</YR>
<VL>62</VL>
<NO>39</NO>
<PG>3109-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demmel-2000" NAME="Demmel 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Demmel R, Rist F, Olbrich R</AU>
<TI>Autonomic reactivity to mental stressors after single administration of lorazepam in male alcoholics and healthy controls</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>6</NO>
<PG>617-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dobrydnjov-2004" MODIFIED="2010-01-08 12:41:40 +0100" MODIFIED_BY="[Empty name]" NAME="Dobrydnjov 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-08 12:41:40 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-2999&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:41:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dobrydnjov I, Axelsson K, Berggren L, Samarutel J, Holmstrom B</AU>
<TI>Intrathecal and oral clonidine as prophylaxis for postoperative alcohol withdrawal syndrome: a randomised double-blinded study</TI>
<SO>Anesthesia and Analgesia</SO>
<YR>2004</YR>
<VL>98</VL>
<NO>3</NO>
<PG>738-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franz-2001" MODIFIED="2010-02-15 14:36:41 +0100" MODIFIED_BY="[Empty name]" NAME="Franz 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-02-15 14:36:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0940-1334&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:36:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B</AU>
<TI>Treatment of alcohol withdrawal: tiapride and carbamazepine versus chlormethiazole. A pilot study</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2001</YR>
<VL>251</VL>
<NO>4</NO>
<PG>185-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frecker-1982" MODIFIED="2010-01-08 12:51:26 +0100" MODIFIED_BY="[Empty name]" NAME="Frecker 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-01-08 12:51:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0271-0749&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:51:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frecker RC, Shaw JM, Zilm DH, Jacob MS, Sellers EM, Degani N</AU>
<TI>Nonpharmacological supportive care compared to Chlormethiazole infusion in the management of severe acute alcohol withdrawal</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>4</NO>
<PG>277-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1989" NAME="Gallant 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM</AU>
<TI>Improvements in treatment of alcohol withdrawal syndromes</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1989</YR>
<VL>13</VL>
<NO>5</NO>
<PG>721-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallant-1992" NAME="Gallant 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallant DM</AU>
<TI>One more look at carbamazepine in the treatment of alcohol withdrawal</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1174-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glatt-1965" MODIFIED="2010-01-08 12:42:41 +0100" MODIFIED_BY="[Empty name]" NAME="Glatt 1965" YEAR="1965">
<REFERENCE MODIFIED="2010-01-08 12:42:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glatt MM, George HR, Frisch EP</AU>
<TI>Controlled trial of Chlormethiazole in treatment of the alcoholic withdrawal phase</TI>
<SO>British Medical Journal</SO>
<YR>1965</YR>
<VL>2</VL>
<PG>401-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2006" MODIFIED="2009-12-21 09:46:37 +0100" MODIFIED_BY="[Empty name]" NAME="Gordon 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-12-21 09:46:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon SM, Sterling R, Siatkowski C, Raively K, Weinstein S, Hill PC</AU>
<TI>Inpatient desire to drink as a predictor of relapse to alcohol use following treatment</TI>
<SO>The American Journal on Addictions</SO>
<YR>2006</YR>
<VL>15</VL>
<NO>3</NO>
<PG>242-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gottesleben-1995" MODIFIED="2010-02-15 14:31:52 +0100" MODIFIED_BY="[Empty name]" NAME="Gottesleben 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-02-15 14:31:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottesleben A, Willemsen D, Wolf C</AU>
<TI>Slow-release carbamazepine for therapy of alcoholic predelirium- results of a double-blind clinical trial using timonol 150 retard</TI>
<TO>Retardiertes Carbamazepin in der Therapie des alkoholischen Pradelirs</TO>
<SO>Aktuelle Neurologie</SO>
<YR>1995</YR>
<VL>22</VL>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griffith-1986" NAME="Griffith 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;0002-9343&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Griffith JD, Jasinski DR, Casten GP, McKinney GR</AU>
<TI>Investigation of the abuse liability of buspirone in alcohol-dependent patients</TI>
<SO>American Journal of Medicine</SO>
<YR>1986</YR>
<VL>80</VL>
<NO>3B</NO>
<PG>30-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gual-2001" NAME="Gual 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gual A, Lehert P</AU>
<TI>Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>5</NO>
<PG>413-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gual-2002" MODIFIED="2010-02-15 12:48:32 +0100" MODIFIED_BY="[Empty name]" NAME="Gual 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-02-15 12:48:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gual A, Monras M, Ortega L</AU>
<TI>Efficacy of tiapride in the maintenance of abstinence in weaned alcoholics. Results of a double-blind trial against placebo.</TI>
<TO>Eficacia de tiapride en el mantenimiento de la abstinencia en alcoholicos desintoxicados. Resultados de un ensayo clinico a doble ciego frente a placebo</TO>
<SO>Adicciones</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>3</NO>
<PG>321-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guarino-1989" NAME="Guarino 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;1046-9516&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guarino JJ, Roache JD, Kirk WT, Griffiths RR</AU>
<TI>Comparison of the behavioral effects and abuse liability of ethanol and pentobarbital in recreational sedative abusers</TI>
<SO>NIDA Research Monograph</SO>
<YR>1989</YR>
<VL>95</VL>
<PG>453-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hague-1976" NAME="Hague 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;0022-3018&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hague WH, Wilson LG, Dudley DL, Cannon DS</AU>
<TI>Post-detoxification drug treatment of anxiety and depression in alcohol addicts</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1976</YR>
<VL>162</VL>
<NO>5</NO>
<PG>354-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harfst-1967" MODIFIED="2010-01-08 12:43:04 +0100" MODIFIED_BY="[Empty name]" NAME="Harfst 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-01-08 12:43:04 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0033-5649&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:43:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harfst MJ, Greene JG, Lassae FG</AU>
<TI>Controlled trial comparing amobarbital and Chlormethiazole in alcohol withdrawal symptoms</TI>
<SO>Quarterly Journal of Studies on Alcohol</SO>
<YR>1967</YR>
<VL>28</VL>
<NO>4</NO>
<PG>641-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heil-1990" MODIFIED="2010-02-15 14:52:19 +0100" MODIFIED_BY="[Empty name]" NAME="Heil 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-02-15 14:52:19 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0173-0541&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:52:19 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heil T, Martens D, Eyrich K</AU>
<TI>Alcohol withdrawal syndrome in the postoperative phase--therapy or prevention?</TI>
<TO>Das Alkoholentzugssyndrom in der postoperativen Phase--Therapie oder Prophylaxe?</TO>
<SO>Langenbecks Archiv fur Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft fur Chirurgie. Deutsche Gesellschaft fur Chirurgie. Kongress</SO>
<YR>1990</YR>
<VL>Supplement II</VL>
<PG>1137-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hillbom-1989" NAME="Hillbom 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;0741-8329&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hillbom M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A et al</AU>
<TI>Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid</TI>
<SO>Alcohol</SO>
<YR>1989</YR>
<VL>6</VL>
<NO>3</NO>
<PG>223-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hutchison-2001" NAME="Hutchison 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;0033-3158&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A</AU>
<TI>Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol</TI>
<SO>Psychopharmacology (Berlin)</SO>
<YR>2001</YR>
<VL>155</VL>
<NO>1</NO>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ilyuchina-1995" NAME="Ilyuchina 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;0741-8329&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ilyuchina VA, Nikitina LI</AU>
<TI>Clinical physiological study of the therapeutic effects of phenytoin in acute alcohol withdrawal and the asthenic-autonomic syndrome in patients with chronic alcoholism</TI>
<SO>Alcohol</SO>
<YR>1995</YR>
<VL>12</VL>
<NO>6</NO>
<PG>511-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janiri-1996" NAME="Janiri 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;0268-1315&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Janiri L, Gobbi G, Mannelli P, Pozzi G, Serretti A, Tempesta E</AU>
<TI>Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>109-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2003" MODIFIED="2010-02-15 14:38:17 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-02-15 14:38:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0140-6736&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:38:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K et al</AU>
<TI>Oral topiramate for treatment of alcohol dependence: a randomised controlled trial</TI>
<SO>The Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9370</NO>
<PG>1677-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" MODIFIED="2010-02-15 14:38:39 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-02-15 14:38:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-990x&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:38:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ</AU>
<TI>Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>9</NO>
<PG>905-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaim-1974" NAME="Kaim 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;0065-2229&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaim SC</AU>
<TI>Prevention of delirium tremens: use of phenothiazines versus drugs cross-dependent with alcohol</TI>
<SO>Advances in Biochemical Psychopharmacology</SO>
<YR>1974</YR>
<VL>9</VL>
<NO>0</NO>
<PG>685-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1972" NAME="Kaplan 1972" YEAR="1972">
<REFERENCE NOTES="&lt;p&gt;0033-5649&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan R, Blume S, Rosenberg S, Pitrelli J, Turner WJ</AU>
<TI>Phenytoin, Metronidazole and multivitamins in the treatment of alcoholism</TI>
<SO>Quarterly Journal of Studies on Alcohol</SO>
<YR>1972</YR>
<VL>33</VL>
<NO>1</NO>
<PG>94-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karam_x002d_Hage-2003" NAME="Karam-Hage 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;1323-1316&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karam-Hage M, Brower KJ</AU>
<TI>Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients</TI>
<SO>Psychiatry and Clinical Neurosciences</SO>
<YR>2003</YR>
<VL>57</VL>
<NO>5</NO>
<PG>542-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karst-2002" MODIFIED="2010-01-08 12:43:17 +0100" MODIFIED_BY="[Empty name]" NAME="Karst 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-08 12:43:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1355-6215&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:43:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karst M, Passie T, Friedrich S, Wiese B, Schneider U</AU>
<TI>Acupuncture in the treatment of alcohol withdrawal symptoms: a randomised, placebo-controlled inpatient study</TI>
<SO>Addiction Biology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>4</NO>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Keaney-2001" MODIFIED="2010-01-08 12:48:31 +0100" MODIFIED_BY="[Empty name]" NAME="Keaney 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-08 12:48:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:48:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keaney F, Strang J, Gossop M, Marshall EJ, Farrell M, Welch S et al</AU>
<TI>A double-blind randomised placebo-controlled trial of Lofexidine in alcohol withdrawal: Lofexidine is not a useful adjunct to chlordiazepoxide</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>5</NO>
<PG>426-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiefer-2003" MODIFIED="2010-01-08 12:48:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kiefer 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-08 12:48:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-990x&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:48:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R et al</AU>
<TI>Comparing and combining naltrexone and Acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>92-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramp-1979" NAME="Kramp 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;0001-690x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kramp P, Ronsted P, Hansen T</AU>
<TI>Barbital and diazepam plasma levels during treatment of delirium tremens</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>3</NO>
<PG>263-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-1996" NAME="Kranzler 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Burleson JA, Brown J, Babor TF</AU>
<TI>Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>9</NO>
<PG>1534-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kraus-1985" NAME="Kraus 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0028-4793&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kraus ML, Gottlieb LD, Horwitz RI, Anscher M</AU>
<TI>Randomized clinical trial of atenolol in patients with alcohol withdrawal</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1985</YR>
<VL>313</VL>
<NO>15</NO>
<PG>905-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange_x002d_Ass-2003" MODIFIED="2010-01-08 12:49:01 +0100" MODIFIED_BY="[Empty name]" NAME="Lange-Ass 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-08 12:49:01 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1022-6877&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:49:01 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange-Asschenfeldt C, Muller MJ, Szegedi A, Anghelescu I, Klawe C, Wetzel H</AU>
<TI>Symptom-triggered versus standard Chlormethiazole treatment of inpatient alcohol withdrawal: clinical implications from a chart analysis</TI>
<SO>European Addiction Research</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Bon-2003" MODIFIED="2009-09-24 12:12:58 +0200" MODIFIED_BY="[Empty name]" NAME="Le Bon 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;0271-0749&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M et al</AU>
<TI>Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>4</NO>
<PG>377-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Fauve-2004" MODIFIED="2009-09-24 12:13:09 +0200" MODIFIED_BY="[Empty name]" NAME="Le Fauve 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-24 12:11:22 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" NOTES_MODIFIED="2009-09-24 12:11:22 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI</AU>
<TI>Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>2</NO>
<PG>302-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leivonen-1966" NAME="Leivonen 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;0065-1591&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leivonen P, Stenij P, Thesleff CJ</AU>
<TI>Experience with three drugs in ambulatory treatment of alcohol patients</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1966</YR>
<VL>192</VL>
<PG>177-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loo-1986" MODIFIED="2010-01-08 12:49:17 +0100" MODIFIED_BY="[Empty name]" NAME="Loo 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-01-08 12:49:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0013-7006&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:49:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loo H, Guelfi JD, Malka R, Brion S, Cottin M, Gailledreau J et al</AU>
<TI>[Anxiolytic efficacy and tolerance of Tetrabamate in anxious patients abusing alcohol. Multicenter double-blind versus placebo study]</TI>
<SO>L' encephale</SO>
<YR>1986</YR>
<VL>12</VL>
<NO>5</NO>
<PG>291-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malcolm-1992" NAME="Malcolm 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malcolm R, Anton RF, Randall CL, Johnston A, Brady K, Thevos A</AU>
<TI>A placebo-controlled trial of buspirone in anxious inpatient alcoholics</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1992</YR>
<VL>16</VL>
<NO>6</NO>
<PG>1007-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinotti-2007" MODIFIED="2010-01-08 13:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="Martinotti 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-01-08 13:30:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinotti G, Romanelli R, Di Nicola M, Reina D, Mazza M, Janiri L</AU>
<TI>Oxcarbazepine at high dosages for the treatment of alcohol dependence</TI>
<SO>The American Journal on Addictions</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>3</NO>
<PG>247-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendels-1985" NAME="Mendels 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;0160-6689&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendels J, Wasserman TW, Michals TJ, Fine EW</AU>
<TI>Halazepam in the management of acute alcohol withdrawal syndrome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<NO>5</NO>
<PG>172-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1988" NAME="Miller 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;0302-282x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller TP, Taylor JL, Tinklenberg JR</AU>
<TI>A comparison of assessment techniques measuring the effects of methylphenidate, secobarbital, diazepam and diphenhydramine in abstinent alcoholics</TI>
<SO>Neuropsychobiology</SO>
<YR>1988</YR>
<VL>19</VL>
<NO>2</NO>
<PG>90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Montejo-2007" MODIFIED="2009-12-21 09:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="Montejo 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-12-21 09:50:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montejo JZ and Galligo FC</AU>
<TI>Treatment of the alcohol withdrawal syndrome and other drugs</TI>
<SO>Formacion Medica Continuada En Atencion Primaria</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>1</NO>
<PG>40-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mueller-1997" NAME="Mueller 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA et al</AU>
<TI>A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1997</YR>
<VL>21</VL>
<NO>1</NO>
<PG>86-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mukherjee-1983" NAME="Mukherjee 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0300-0605&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mukherjee PK</AU>
<TI>A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism</TI>
<SO>Journal of International Medical Research</SO>
<YR>1983</YR>
<VL>11</VL>
<NO>4</NO>
<PG>205-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1969" NAME="Muller 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;0038-4348&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller DJ</AU>
<TI>A comparison of three approaches to alcohol-withdrawal states</TI>
<SO>Southern Medical Journal</SO>
<YR>1969</YR>
<VL>62</VL>
<NO>4</NO>
<PG>495-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrick-2009" MODIFIED="2010-02-15 12:55:46 +0100" MODIFIED_BY="[Empty name]" NAME="Myrick 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-02-15 12:55:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC et al</AU>
<TI>A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1582-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naranjo-2000" NAME="Naranjo 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;1180-4882&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naranjo CA, Knoke DM, Bremner KE</AU>
<TI>Variations in response to citalopram in men and women with alcohol dependence</TI>
<SO>Journal of Psychiatry &amp; Neuroscience: JPN</SO>
<YR>2000</YR>
<VL>25</VL>
<NO>3</NO>
<PG>269-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newman-1995" NAME="Newman 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;0023-852x&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newman JP, Terris DJ, Moore M</AU>
<TI>Trends in the management of alcohol withdrawal syndrome</TI>
<SO>The Laryngoscope</SO>
<YR>1995</YR>
<VL>105</VL>
<NO>1</NO>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettinati-2000" NAME="Pettinati 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A</AU>
<TI>Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>7</NO>
<PG>1041-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponce-2005" MODIFIED="2009-12-21 09:52:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ponce 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-21 09:52:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponce G, Rodriguez-Jimenez R, Ortiz H, Rubio G, Jimenez-Arriero MA, and Palomo T</AU>
<TI>Oxcarbazepine in the prevention of epileptic syndromes in alcohol detoxification</TI>
<SO>Revista de Neurologia</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>10</NO>
<PG>577-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodgers-1999" NAME="Rodgers 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;1079-2082&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodgers JE, Crouch MA</AU>
<TI>Phenobarbital for alcohol withdrawal syndrome</TI>
<SO>American Journal of Health-System Pharmacy: AJHP</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>2</NO>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-2002" MODIFIED="2010-02-15 14:40:09 +0100" MODIFIED_BY="[Empty name]" NAME="Rubio 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-02-15 14:40:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio G, Ponce G, Ortiz S, Oliva J, Manzanares J, Jimenez-Arriero M et al</AU>
<TI>Comparison between gabapentin and Acamprosate in the treatment of alcohol dependence patients</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>12 Suppl 3</VL>
<PG>S397</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rychlik-2001" MODIFIED="2010-01-08 12:50:31 +0100" MODIFIED_BY="[Empty name]" NAME="Rychlik 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-08 12:50:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0012-0472&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:50:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rychlik R, Paschen B, Kirchhoff D, Daniel D, Pfeil T, Kilburg A</AU>
<TI>Adjuvant drug treatment of alcoholism with Acamprosate: between sectorial budgets and disease management</TI>
<SO>Deutsche Medizinische Wochenschrift</SO>
<YR>2001</YR>
<VL>126</VL>
<NO>33</NO>
<PG>899-904</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sass-1996" MODIFIED="2010-01-08 12:52:39 +0100" MODIFIED_BY="[Empty name]" NAME="Sass 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-08 12:52:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0003-990x&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:52:39 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sass H, Soyka M, Mann K, Zieglgansberger W</AU>
<TI>Relapse prevention by Acamprosate. Results from a placebo-controlled study on alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>8</NO>
<PG>673-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmidt-1994" MODIFIED="2008-03-21 11:29:12 +0100" MODIFIED_BY="[Empty name]" NAME="Schmidt 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-03-21 11:29:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0176-3679&lt;/p&gt;" NOTES_MODIFIED="2008-03-21 11:29:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmidt LG, Dufeu P, Kuhn S, Rommelspacher H</AU>
<TI>Relapse prevention in alcoholics with an anti craving drug treatment: first results of the Berlin Study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1994</YR>
<VL>27 Suppl 1</VL>
<PG>21-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schulte-1987" MODIFIED="2010-01-08 12:53:15 +0100" MODIFIED_BY="[Empty name]" NAME="Schulte 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-01-08 12:53:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0015-8178&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:53:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schulte RM</AU>
<TI>Therapy of pre-delirium alcohol withdrawal syndrome. Results of a comparative study of carbamazepine and Chlormethiazole</TI>
<SO>Fortschritte der Medizin</SO>
<YR>1987</YR>
<VL>105</VL>
<NO>25</NO>
<PG>493-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwarz-1982" NAME="Schwarz 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;0278-5846&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwarz E, Kielholz P, Hobi V, Goldberg L, Hofstetter M, Ladewig D</AU>
<TI>Changes in EEG, blood levels, mood scales and performance scores during long term treatment with diazepam, phenobarbital or placebo in patients</TI>
<SO>Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry</SO>
<YR>1982</YR>
<VL>6</VL>
<NO>3</NO>
<PG>249-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-See-2002" NAME="See 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>See S</AU>
<TI>Carbamazepine effective for alcohol withdrawal</TI>
<SO>The Journal of Family Practise</SO>
<YR>2002</YR>
<VL>51</VL>
<NO>9</NO>
<PG>778</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaw-1994" NAME="Shaw 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;0007-1250&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaw GK, Waller S, Majumdar SK, Alberts JL, Latham CJ, Dunn G</AU>
<TI>Tiapride in the prevention of relapse in recently detoxified alcoholics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>165</VL>
<NO>4</NO>
<PG>515-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sillanpaa-1979" NAME="Sillanpaa 1979" YEAR="1979">
<REFERENCE NOTES="&lt;p&gt;0300-0605&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sillanpaa M, Sonck T</AU>
<TI>Finnish experiences with carbamazepine (Tegretol) in the treatment of acute withdrawal symptoms in alcoholics</TI>
<SO>Journal of International Medical Research</SO>
<YR>1979</YR>
<VL>7</VL>
<NO>3</NO>
<PG>168-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1987" NAME="Smith 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;0013-9580&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B</AU>
<TI>Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone</TI>
<SO>Epilepsia</SO>
<YR>1987</YR>
<VL>28 Suppl 3</VL>
<PG>S50-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Snel-1983" MODIFIED="2010-02-15 12:59:28 +0100" MODIFIED_BY="[Empty name]" NAME="Snel 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-02-15 12:59:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0341-3098&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 12:59:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Snel H, Lehmann E, Velikonja M</AU>
<TI>Piracetam in the treatment of alcohol-induced delirium</TI>
<TO>Piracetam in der Behandlung des alkoholbedingten Delirs</TO>
<SO>MMW. Munchener Medizinische Wochenschrift</SO>
<YR>1983</YR>
<VL>125</VL>
<NO>42</NO>
<PG>947-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sobcyzk-1980" MODIFIED="2010-02-15 14:44:28 +0100" MODIFIED_BY="[Empty name]" NAME="Sobcyzk 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-02-15 14:44:28 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0033-2674&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:44:28 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sobcyzk P, Jena K, Klir T</AU>
<TI>Comparative evaluation of the effectiveness of various methods of treating delirium tremens</TI>
<TO>Porownawcza ocena skutecznosci niektorych metod leczenia majaczenia dezennego</TO>
<SO>Psychiatria Polska</SO>
<YR>1980</YR>
<VL>14</VL>
<NO>5</NO>
<PG>481-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Solomon-1983" NAME="Solomon 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0149-2918&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Solomon J, Rouck LA, Koepke HH</AU>
<TI>Double-blind comparison of lorazepam and chlordiazepoxide in the treatment of the acute alcohol abstinence syndrome</TI>
<SO>Clinical Therapeutics</SO>
<YR>1983</YR>
<VL>6</VL>
<NO>1</NO>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spies-1995" NAME="Spies 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;0007-0912&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spies CD, Dubisz N, Funk W, Blum S, Muller C, Rommelspacher H et al</AU>
<TI>Prophylaxis of alcohol withdrawal syndrome in alcohol-dependent patients admitted to the intensive care unit after tumour resection</TI>
<SO>British Journal of Anaesthesia</SO>
<YR>1995</YR>
<VL>75</VL>
<NO>6</NO>
<PG>734-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sternebring-1983" NAME="Sternebring 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;0031-6970&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sternebring B, Holm R, Wadstein J</AU>
<TI>Reduction in early alcohol abstinence fits by administration of carbamazepine syrup instead of tablets</TI>
<SO>European Journal Clinical Pharmacology</SO>
<YR>1983</YR>
<VL>24</VL>
<NO>5</NO>
<PG>611-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stojek-1987" NAME="Stojek 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;0033-2674&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stojek A, Bilikiewicz A, Lerch A</AU>
<TI>Carbamazepine and physostigmine eyedrops in the treatment of early alcohol withdrawal and alcohol-related hypertension</TI>
<SO>Psychiatria Polska</SO>
<YR>1987</YR>
<VL>21</VL>
<NO>5</NO>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streeton-2001" MODIFIED="2010-01-08 12:54:36 +0100" MODIFIED_BY="[Empty name]" NAME="Streeton 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-08 12:54:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:54:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streeton C, Whelan G</AU>
<TI>Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomised controlled trials</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>6</NO>
<PG>544-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swift-2003" NAME="Swift 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;0140-6736&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swift RM</AU>
<TI>Topiramate for the treatment of alcohol dependence: initiating abstinence</TI>
<SO>The Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<NO>9370</NO>
<PG>1666-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tacke-1975" MODIFIED="2010-02-15 14:48:15 +0100" MODIFIED_BY="[Empty name]" NAME="Tacke 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-02-15 14:48:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0020-8272&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 14:48:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tacke B, Kempf H</AU>
<TI>Double-blind study of Aprotininum (Trasylol) in the management of alcoholic delirium</TI>
<TO>Doppelblindstudie uber Aprotinium (Trasylol) in der Behandlung des Alkoholdelirs</TO>
<SO>International Pharmacopsychiatry</SO>
<YR>1975</YR>
<VL>10</VL>
<NO>1</NO>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Teijeiro-1976" MODIFIED="2010-01-08 12:55:10 +0100" MODIFIED_BY="[Empty name]" NAME="Teijeiro 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-01-08 12:55:10 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1013-2058&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:55:10 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Teijeiro J</AU>
<TI>A comparative double-blind study of atrium 300 and Hemineurine in chronic alcoholics</TI>
<SO>Schweizerische Rundschau fur Medizin Praxis</SO>
<YR>1976</YR>
<VL>65</VL>
<NO>14</NO>
<PG>420-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tempesta-2000" NAME="Tempesta 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;0735-0414&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A</AU>
<TI>Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>202-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thomas-1964" NAME="Thomas 1964" YEAR="1964">
<REFERENCE NOTES="&lt;p&gt;0098-7484&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thomas DW, Freedman DX</AU>
<TI>Treatment of the Alcohol Withdrawal Syndrome. Comparison of Promazine and Paraldehyde</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1964</YR>
<VL>188</VL>
<PG>316-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tress-1977" NAME="Tress 1977" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tress W</AU>
<TI>New type of treatment for alcohol withdrawal syndrome</TI>
<TO>Ein neuartiges therapie verfahren des alkoholischen entzugs syndroms</TO>
<SO>TherapieWoche</SO>
<YR>1977</YR>
<VL>27</VL>
<NO>51</NO>
<PG>9304-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wadstein-1986" MODIFIED="2010-01-08 12:53:47 +0100" MODIFIED_BY="[Empty name]" NAME="Wadstein 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-01-08 12:53:47 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0065-1591&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:53:47 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wadstein J, Manhem P, Nilsson LH, Moberg AL, Hokfelt B</AU>
<TI>Clonidine versus Chlormethiazole in alcohol withdrawal</TI>
<SO>Acta Psychiatrica Scandinavica Supplementum</SO>
<YR>1986</YR>
<VL>327</VL>
<PG>144-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegner-1965" NAME="Wegner 1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;0043-6542&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegner ME, Fink DW</AU>
<TI>Chlordiazepoxide (librium) compared with meprobamate and promazine (prozine) for the withdrawal symptoms of acute alcoholism</TI>
<SO>Wisconsin Medical Journal</SO>
<YR>1965</YR>
<VL>64</VL>
<NO>11</NO>
<PG>436-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Welbel-1982" MODIFIED="2010-02-15 13:05:05 +0100" MODIFIED_BY="[Empty name]" NAME="Welbel 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-02-15 13:05:05 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0033-2674&lt;/p&gt;" NOTES_MODIFIED="2010-02-15 13:05:05 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welbel L, Zareba J, Kowalewska I</AU>
<TI>Clomethiazole (Chlormethiazole) in the treatment of delirium tremens</TI>
<TO>Klometiazol (chlorometiazol) w leczeniu majaczenia alkoholowego</TO>
<SO>Psychiatria Polska</SO>
<YR>1982</YR>
<VL>16</VL>
<NO>1-2</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitworth-1996" MODIFIED="2010-01-08 12:55:35 +0100" MODIFIED_BY="[Empty name]" NAME="Whitworth 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-01-08 12:55:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;0140-6736&lt;/p&gt;" NOTES_MODIFIED="2010-01-08 12:55:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitworth AB, Fischer F, Lesch OM, Nimmerrichter A, Oberbauer H, Platz T et al</AU>
<TI>Comparison of Acamprosate and placebo in long-term treatment of alcohol dependence</TI>
<SO>The Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>9013</NO>
<PG>1438-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wiesbeck-1999" NAME="Wiesbeck 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;0145-6008&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wiesbeck GA, Weijers HG, Chick J, Naranjo CA, Boening J</AU>
<TI>Ritanserin in relapse prevention in abstinent alcoholics: results from a placebo-controlled double-blind international multicenter trial. Ritanserin in Alcoholism Work Group</TI>
<SO>Alcoholism, Clinical and Experimental Research</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>2</NO>
<PG>230-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-02-15 13:06:13 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Gottesleben-1994" MODIFIED="2010-01-08 12:56:00 +0100" MODIFIED_BY="[Empty name]" NAME="Gottesleben 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-01-08 12:56:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gottesleben A, Wolf C, Willemsen D</AU>
<TI>Slow-release carbamazepine for therapy of alcoholic pre delirium: Results of a double blind clinical trial using Timonil 150 retard</TI>
<SO>European Journal of Clinical Research</SO>
<YR>1994</YR>
<VL>5</VL>
<PG>51-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-1964" MODIFIED="2010-01-08 12:20:17 +0100" MODIFIED_BY="[Empty name]" NAME="Hart 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-01-08 12:20:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hart WT</AU>
<TI>A comparison of promazine and paraldehyde in 175 cases of alcohol withdrawal</TI>
<SO>Psychiatric Quarterly</SO>
<YR>1964</YR>
<VL>38</VL>
<PG>619-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trevisan-2008" MODIFIED="2010-02-15 13:06:13 +0100" MODIFIED_BY="[Empty name]" NAME="Trevisan 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-02-15 13:06:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trevisan L.A., Ralevski E., Keegan K., Oville A., Vuppalapati D., Gonzalez G., et al Addictive Disorders and their Treatment 2008 7:3 (119-128).</AU>
<TI>Alcohol detoxification and relapse prevention using valproic acid versus gabapentin in alcohol-dependent patients</TI>
<SO>Addictive Disorders and their Treatment</SO>
<YR>2008</YR>
<VL>7</VL>
<NO>3</NO>
<PG>119-128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Amato-2010" MODIFIED="2010-02-15 13:06:42 +0100" MODIFIED_BY="[Empty name]" NAME="Amato 2010" TYPE="COCHRANE_REVIEW">
<AU>Amato L, Minozzi S, Vecchi S, Davoli M</AU>
<TI>Benzodiazepines for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-12-14 13:27:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-12-14 13:27:02 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-De-Witte-2003" MODIFIED="2010-01-08 12:56:38 +0100" MODIFIED_BY="[Empty name]" NAME="De Witte 2003" TYPE="JOURNAL_ARTICLE">
<AU>De Witte P, Pinto E, Ansseau M, Verbanck P</AU>
<TI>Alcohol and withdrawal: from animal research to clinical issues</TI>
<SO>Neuroscience and Biobehavioral Reviews</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>3</NO>
<PG>189-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dodd-2000" NAME="Dodd 2000" TYPE="JOURNAL_ARTICLE">
<AU>Dodd PR, Beckmann AM, Davidson MS, Wilce PA</AU>
<TI>Glutamate-mediated transmission, alcohol, and alcoholism</TI>
<SO>Neurochemistry International</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>5-6</NO>
<PG>509-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DSM_x002d_IV_x002d_R" MODIFIED="2010-02-15 13:07:34 +0100" MODIFIED_BY="[Empty name]" NAME="DSM-IV-R" TYPE="BOOK">
<AU>AA VV</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders., Fourth Edition-revised</SO>
<YR>1995</YR>
<PB>American Psychiatric Association </PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fox-2003" MODIFIED="2010-02-15 13:18:38 +0100" MODIFIED_BY="[Empty name]" NAME="Fox 2003" TYPE="COCHRANE_PROTOCOL">
<AU>Fox C, Cook C, Loughlin P, Mangal R</AU>
<TI>Acamprosate for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-02-15 13:17:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-15 13:17:29 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004332"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gillman-2007" MODIFIED="2010-02-15 11:14:38 +0100" MODIFIED_BY="[Empty name]" NAME="Gillman 2007" TYPE="COCHRANE_REVIEW">
<AU>Gillman MA, Lichtigfeld F, Young T</AU>
<TI>Psychotropic analgesic nitrous oxide for alcoholic withdrawal states</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-01-15 11:12:05 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-15 11:12:05 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005190.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gilman-1996" NAME="Gilman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Gilman S, Koeppe RA, Adams K, Johnson-Greene D, Junck L, Kluin KJ et al</AU>
<TI>Positron emission tomographic studies of cerebral benzodiazepine-receptor binding in chronic alcoholics</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>40</VL>
<NO>2</NO>
<PG>163-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasin-1990" NAME="Hasin 1990" TYPE="JOURNAL_ARTICLE">
<AU>Hasin DS, Grant B, Endicott J</AU>
<TI>The natural history of alcohol abuse: implications for definitions of alcohol use disorders</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<NO>11</NO>
<PG>1537-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-02-15 11:18:18 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</TI>
<SO>The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohl-1998" NAME="Kohl 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kohl RR, Katner JS, Chernet E, McBride WJ</AU>
<TI>Ethanol and negative feedback regulation of mesolimbic dopamine release in rats</TI>
<SO>Psychopharmacology</SO>
<YR>1998</YR>
<VL>139</VL>
<NO>1-2</NO>
<PG>79-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koob-1997" NAME="Koob 1997" TYPE="JOURNAL_ARTICLE">
<AU>Koob GF, LeMoal M</AU>
<TI>Drug abuse: hedonic homeostatic dysregulation</TI>
<SO>Science</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>5335</NO>
<PG>52-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leggio-2008" MODIFIED="2010-02-15 13:13:00 +0100" MODIFIED_BY="[Empty name]" NAME="Leggio 2008" TYPE="JOURNAL_ARTICLE">
<AU>Leggio L, Kenna GA, Swift RM.</AU>
<TI>New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergicmedications</TI>
<SO>Progress in Neuro-psychopharmacology &amp; Biological Psychiatry</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>5</NO>
<PG>1106-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leone-2010" MODIFIED="2010-02-15 11:14:17 +0100" MODIFIED_BY="[Empty name]" NAME="Leone 2010" TYPE="COCHRANE_REVIEW">
<AU>Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F</AU>
<TI>Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-01-15 11:13:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-01-15 11:13:40 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006266"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mayo_x002d_Smith-1997" NAME="Mayo-Smith 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mayo-Smith MF</AU>
<TI>Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>2</NO>
<PG>144-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nutt-1999" NAME="Nutt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Nutt D</AU>
<TI>Alcohol and the brain. Pharmacological insights for psychiatrists</TI>
<SO>The British Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>175</VL>
<PG>114-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petty-1993" NAME="Petty 1993" TYPE="JOURNAL_ARTICLE">
<AU>Petty F, Fulton M, Moeller FG, Kramer G, Wilson L, Fraser K et al</AU>
<TI>Plasma gamma-aminobutyric acid (GABA) is low in alcoholics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<NO>2</NO>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polycarpou-2005" MODIFIED="2010-02-15 13:13:38 +0100" MODIFIED_BY="[Empty name]" NAME="Polycarpou 2005" TYPE="COCHRANE_REVIEW">
<AU>Polycarpou A, Papanikolau P, Ioannidis JP, Contopoulos Ioannidis D</AU>
<TI>Anticonvulsants for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-02-15 13:13:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-15 13:13:38 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005064.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Slawecki-1999" NAME="Slawecki 1999" TYPE="JOURNAL_ARTICLE">
<AU>Slawecki CJ, Somes C, Ehlers CL</AU>
<TI>Effects of chronic ethanol exposure on neurophysiological responses to corticotropin-releasing factor and neuropeptide Y</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>1999</YR>
<VL>34</VL>
<NO>3</NO>
<PG>289-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tejani-2010" MODIFIED="2010-02-15 11:17:13 +0100" MODIFIED_BY="[Empty name]" NAME="Tejani 2010" TYPE="COCHRANE_PROTOCOL">
<AU>Tejani AM, Chan AHill Wah, Kuo IF, Li J</AU>
<TI>Magnesium for alcohol withdrawal</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-15 11:17:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-15 11:17:13 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008358 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tsai-1995" NAME="Tsai 1995" TYPE="JOURNAL_ARTICLE">
<AU>Tsai G, Gastfriend DR, Coyle JT</AU>
<TI>The glutamatergic basis of human alcoholism</TI>
<SO>The American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>3</NO>
<PG>332-40</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-01-08 12:28:27 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-01-08 12:14:22 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-12-15 14:10:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Agricola-1982">
<CHAR_METHODS MODIFIED="2009-12-15 12:15:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:16:02 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 60; age = 20-64 years (mean: 44.28)</P>
<P>
<B>Inclusion criteria: </B>alcoholic hospitalised patients with a severe withdrawal syndrome proceeding delirium tremens.<BR/>
<B>Exclusion criteria:</B> severe heart, liver or kidney diseases; use of psychotropic drugs; addicted or chronic abusers of other gender = 53 males; 7 females</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(30) carbamazepine 200mg tid (no. = 30); <B>Group B </B>(30) Tiapride 200mg tid</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 12:16:48 +0100" MODIFIED_BY="[Empty name]">
<P>Withdrawal symptoms; overall evaluation of the clinical condition; assessment of therapeutic effectiveness both by the doctor and the patient; blood pressure and heart rate; SGOT, SGPT; tolerability; seizures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:39:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alldredge-1989">
<CHAR_METHODS MODIFIED="2008-08-18 11:00:03 +0200" MODIFIED_BY="[Empty name]">
<P> Randomized controlled trial<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:15:54 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 90; gender = 85 males, 5 females; age = 30.3-50.9.</P>
<P>
<B>Inclusion criteria: </B>patients admitted to the Emergency Department for a recent seizure occurred in the setting of acute withdrawal from alcohol.<BR/>
<B>Exclusion criteria</B>: history of seizures unrelated to alcohol use, severe head trauma, sedative or anticonvulsant use within 14 days, stimulant drug use within 3 days, significant electrolyte abnormalities, second-or third-degree atrioventricular heart block, bradycardia, or known hypersensitivity to hydantoin derivatives.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:10:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(45) diphenylhydantoin sodium 1000mg intravenously over 20 minutes; <B>Group B </B>(45) equivalent volume of 0.9% sodium chloride</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:39:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy :</B> Seizure Recurrence; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:42:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balldin-1986">
<CHAR_METHODS MODIFIED="2008-08-18 11:21:24 +0200" MODIFIED_BY="[Empty name]">
<P> Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:17:45 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 38; Age = 28-57</P>
<P>
<B>Inclusion criteria:</B>  Patients alcohol dependent (DMS-III)<BR/>
<B>Exclusion Criteria:</B> somatic diseases; psychotic symptoms; use of alcohol together with sedatives and anxiolytics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:10:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> chlorprothixene 50mg x 3 daily+ Carbamazepin 200mg x 2 daily; <B>Group B </B>clonidine 300ìg x 2 daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:42:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Psychiatric rating CPRS; mood: (pleasantness-unpleasantness) and somatic symptoms (including symptoms in the abstinence situation but also side-effects from the medication) (self-rating scales developed by Sjoberg and Persson &amp; Sjoberg were used)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:44:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bjorkqvist-1976">
<CHAR_METHODS MODIFIED="2009-12-15 12:22:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:22:36 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 105; Gender: all male.; age 20-60 years</P>
<P>
<B>Inclusion criteria: </B>out-patients volunteers who sought treatment for alcohol withdrawal symptoms at five clinics;  drinking for at least three days;  cooperative;  not in need of hospitalisation.<BR/>
<B>Exclusion criteria:</B> heart, liver, renal insufficiency;  antihypertensive treatment; chronic narcotics; use of drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:10:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34) carbamazepine; <B>Group B</B> (35)  placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Symptoms related to abstinence; evaluation of the patient's global feelings; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:46:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blanchard-1985">
<CHAR_METHODS MODIFIED="2009-12-15 12:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:33:31 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 38; Gender:29 males/9 females;  Age: 38 years;</P>
<P>
<B>Inclusion criteria:</B> Hospitalized patients for alcohol withdrawal symptoms; severity score for AWS minimum of 2.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:10:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>Atrium 300 mg; <B>Group B</B> (18)  placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:46:29 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Evaluation of global efficacy; <B>Safety</B>: side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:48:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonnet-2003">
<CHAR_METHODS MODIFIED="2009-12-15 12:34:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:34:47 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 61; Age = 36.8-51.8;  Gender: 43 males/18 females; All Caucasian</P>
<P>
<B>Inclusion criteria: </B>Inpatients suffering from alcohol dependence (ICD-10) with moderate or severe AWS (MAWS = or &gt; 4)<BR/>
<B>Exclusion Criteria:</B> psychiatric condition requiring medication; abuse or dependence of other substances;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:11:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (32) gabapentin 400mg qid for 7 days; <B>Group B</B> (29) placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:48:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Amount of CLO required (first 24 h); course of MAWS (first 48 h); <B>Accecptability</B>: premature discontinuations (first 48h);drop out: <B>Safety</B>: adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 08:50:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borg-1986">
<CHAR_METHODS MODIFIED="2009-12-15 10:48:12 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 10:48:22 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 45; Gender: 100% male; age range: 29-73 years</P>
<P>
<B>Inclusion criteria</B>: WHO criteria for alcohol dependence. <B>Exclusion criteria:</B> history of liver cirrhosis or psychotic disorders</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 12:36:45 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(15) amobarbital; initial dose=800 mg/day reduced in steps of 100 mg/day during the week.<B>Group B</B> (15) oxazepam; initial dose=120 mg/day reduced in steps of 10 mg/day during the week, <B>Group C</B> (15) Melperone; 200 mg/day throughout the week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:50:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures,<B> </B>CPRS scores ;  <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burroughs-1985a">
<CHAR_METHODS MODIFIED="2009-12-15 10:54:19 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 44</P>
<P>
<B>Inclusion criteria:</B> history of alcohol drinking in excess of 80 g/day for five or more years; history of previous alcohol withdrawal. Patient with minimal withdrawal syndrome</P>
<P>
<B>Exclusion criteria: </B>participants who had taken psychotropic drugs within 48h of hospital administration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-04 16:40:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(12) Chlormethiazole, <B>Group B</B> (11) placebo, <B>Group C</B> (10) chlordiazepoxide, <B>Group D </B>(11) bromocriptine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:52:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement, Changes in Gross scale and Borg scale; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts , dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:07:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burroughs-1985b">
<CHAR_METHODS MODIFIED="2009-12-15 10:57:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:07:50 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 27</P>
<P>
<B>Inclusion criteria:</B> history of alcohol drinking in excess of 80 g/day for five or more years; history of previous alcohol withdrawal. Patients with intense withdrawal syndrome. <B>Exclusion criteria: </B>participants who had taken psychotropic drugs within 48h of hospital administration</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 12:37:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (8) Chlormethiazole, <B>Group B</B> (10) chlordiazepoxide, <B>Group C </B>(9) bromocriptine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 10:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>global improvement, Changes in Gross scale and Borg scale; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 10:59:01 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:21:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chance-1991">
<CHAR_METHODS MODIFIED="2009-12-15 12:37:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:37:57 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 55.</P>
<P>
<B>Inclusion criteria: </B>patients with a complaint of seizure due exclusively to alcohol withdrawal </P>
<P>
<B>Exclusion criteria:</B> patients with seizure unrelated to alcohol withdrawal;  detectable phenytoin levels (&gt; 2.5 ìg/ml) or allergies or contraindications to hydantoin derivatives; women due the inability to detect early pregnancy and the teratogenic risk of phenytoin.</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:12:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (27) phenytoin 50 mg/ml; <B>Group B</B> (27) 0.9% normal saline</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:21:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Seizure </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 14:12:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choi-2005">
<CHAR_METHODS MODIFIED="2009-12-15 12:38:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:39:18 +0100" MODIFIED_BY="[Empty name]">
<P>No: 52. . Gender: male:93%; mean age: 46</P>
<P>
<B>Inclusion criteria: </B>meet DSM-IV criteria for alcohol dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:12:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(25) Topiramate fixed, single dose, 50mg; <B>Group B</B> (27): lorazepam 4mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:00:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Withdrawal symptoms (CIWA-Ar scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:01:25 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 10:53:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Croissant-2009">
<CHAR_METHODS MODIFIED="2010-01-05 16:26:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-05 16:46:03 +0100" MODIFIED_BY="[Empty name]">
<P>No: 56; Gender: male 82,25%; mean age: 45</P>
<P>
<B>Inclusion criteria</B>: patients with diagnosis of alcohol dependence according to both ICD-10 and DSM-IV,<BR/>18 - 65 years of age , who knew enough German to fill in the questionnaires provided and who declared their commitment to the goal of total abstinence.</P>
<P>
<B>Exclusion criteria</B>: patients with positive screening results for opiates, amphetamine and cocaine ; severe somatic, psychiatric, or terminal diseases ; pregnancy, lactation period, suicidal tendencies, and legal or illegal drug addiction (except nicotine dependence and infrequent THC consumption) within the previous six months. . Patients taking anti-psychotic drugs or antidepressants, AEDs or benzodiazepines, and patients for whom OXC, Tiaprid or CLO were contraindicated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 10:53:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(27) Oxcarbazepine + Tiapride <B>Group B</B> (29): Chlormethiazole </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-05 16:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Ciwa-Ar score;delirium, seizures <B>Safety</B>: adverse events, severe adverse events; <B>Acceptability</B>: drop out</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:25:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dencker-1978">
<CHAR_METHODS MODIFIED="2009-12-15 12:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:48:20 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 63; Gender: 59 males/1 female; Age (mean): Chlormethiazole, 37 years, Piracetam, 39 years;</P>
<P>
<B>Inclusion criteria:</B> In-patients, with diagnosis of chronic alcoholism and a previous history of at least 10 years alcohol abuse; had been drinking for at least 7 days; in an acute alcohol withdrawal state.</P>
<P>
<B>Exclusion criteria</B>: history of heavy drug addiction</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:12:31 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B>  (29) Chlormethiazole; <B>Group B </B>(34) Piracetam 1600 mg three times daily<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:25:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Comprehensive Psychiatric Rating Scale (CPRS); Adjective Check-List (ACL); Estimation Scale (DES); Memory Test;  laboratory examination; physical, including neurological examination; <B>Safety</B>: Clinical Side-Effect Scale (CSE)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:26:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elsing-1996">
<CHAR_METHODS MODIFIED="2009-12-15 12:51:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:51:17 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 21; Gender: 18 males/3 females; mean age: GHB, 43.5; Clomethiazole, 42.2</P>
<P>
<B>Inclusion criteria: </B>Patients with severe alcohol withdrawal syndrome.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:12:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(10) Chlomethiazole 250 mg every 4 hours as a mixture ; <B>Group B </B>(11)  GHB initially 30 mg/kg BW followed by 15 mg/kg BW i.v.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:26:52 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Tremor; sweating; nausea; restlessness; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Meeting Abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 09:38:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elsing-2009">
<CHAR_METHODS MODIFIED="2010-01-05 20:26:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controle trail</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-05 21:06:52 +0100" MODIFIED_BY="[Empty name]">
<P>No: 26; Gender: 22 male, 4 female. Age: mean 45</P>
<P>
<B>Inclusion criteria:</B> Alcohol addicted patients admitted to the intermediate and intensive<BR/>care unit of the medical department either because of severe withdrawal syndrome or because of additional concomitant life threatening diseases</P>
<P>
<B>Exclusion criteria</B>: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 09:38:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group a:</B> (12) Chlormethiazole; <B>Group B:</B>(14) Gamma-Hydroxybutyric acid (GHB)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:14:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Ciwa-Ar score; <B>Safety</B>: side effects, severe side effects <B>Acceptability</B>:. drop out; drop out due to side effect. <B>Other</B>: mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:28:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Flygering-1984">
<CHAR_METHODS MODIFIED="2009-12-15 13:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 13:49:04 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 72; Age = 19-62; Gender = 65 males/7 females</P>
<P>
<B>Inclusion criteria:</B> Patients requiring hospitalisation for alcohol withdrawal symptoms<BR/>
<B>Exclusion Criteria:</B> Concomitant abuse of drugs; full-blown or incipient delirium tremens; concomitant treatment with antiepileptics, barbital or other psychoactive drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(37) carbamazepine; <B>Group B</B> (35)  barbital<BR/>The daily dose individual</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:28:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Alcohol withdrawal symptoms; visual analogue scale expressing the patient's subjective feeling; consumption of trial medication and duration of treatment; cure rate during treatment; <B>Safety</B>: adverse drug reactions<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:29:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gann-2004">
<CHAR_METHODS MODIFIED="2009-12-15 13:51:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-09 15:15:21 +0200" MODIFIED_BY="[Empty name]">
<P>No.= 20 Gender: not reported; mean age: 41.</P>
<P>
<B>Inclusion criteria:</B> meet diagnosis of alcohol dependence according to DSM-IV criteria</P>
<P>
<B>Exclusion criteria: </B>psychotic features; clinically significant cognitive impairment; abuse of other substances other than alcohol; significant medical problem</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (11) Chlormethiazole capsule of 384mg; 3 cps on day one, 4 cps on day two, 3 cps on day three, 2 cps on day four, 1 cps on day five; <B>Group B</B> (9): placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:29:32 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Withdrawal symptoms (CIWA-Ar scale); Sleep (polysomnography, total sleep time, sleep efficiency, latency to stage 2, latency to REM, number of wake period, PSQI);</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-09 15:15:34 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:30:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glatt-1966">
<CHAR_METHODS MODIFIED="2009-12-15 13:51:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 13:52:50 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 97; Gender=53 males/44 females</P>
<P>
<B>Inclusion criteria: </B>Alcoholics admitted to the St. Bernard's Hospital in varying states of alcoholic intoxication.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (49) Chlormethiazole; <B>Group B</B> (48)  placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:30:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Individual psychiatric symptoms; prevalence of sedation; over-all effect of treatment assessed by the doctor and by the patient</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:09:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Golbert-1967">
<CHAR_METHODS MODIFIED="2010-01-02 08:18:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:09:10 +0100" MODIFIED_BY="[Empty name]">
<P>N=49, Gender: 100% male; age range: 31-71 years</P>
<P>
<B>Inclusion criteria: </B>patients admitted to the Veterans Administration Hospital, and in whom alcohol withdrawal syndromes subsequently developed. 47 were classified as in the "tremulous state" and 2 patients were classified as in "acute hallucination"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B>(12) paraldehyde and chloral hydrate, <B>Group B</B> (12) chlordiazepoxide, <B>Group C </B>(13) promazine. <B>Group D</B> (12) alcohol.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 08:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>delirium, global improvement; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:04:27 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:09:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaim-1972">
<CHAR_METHODS MODIFIED="2009-12-15 11:06:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 202, Gender: 100% male</P>
<P>
<B>Inclusion criteria</B>: patients with a clearly established history of alcoholism and manifested all three of the cardinal symptoms of delirium tremens - disorientation, tremor, and hallucinations - during the episode that led to their hospitalisation. <B>Exclusion criteria</B>: frank schizophrenic reaction; obvious chronic brain syndrome; serious medical or surgical conditions; diabetes mellitus; or a diagnosis of epilepsy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (46) chlordiazepoxide, <B>Group B</B> (14) placebo, <B>Group C</B> (55) paraldehyde, <B>Group D</B> (41) pentobarbital, <B>Group E</B> (46) perphenazine,<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures; Nurse Rating Scale; Physicians Symptom Recor d;symptoms checklist; global rating; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events; <B>Other:</B> Treatment Booklet</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:06:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:10:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kalyoncu-1996">
<CHAR_METHODS MODIFIED="2009-12-15 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 83, Gender: 100% male; age range: 18-65 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34) diazepam; max. 80 mg/day for 7 days, <B>Group B </B>(33) carbamazepine; max. 800mg/day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:10:54 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium, MMSE; CIWA score; SCL-90-R; Beck depression inventory; global pathology assessment; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Meeting Abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:50:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koethe-2007">
<CHAR_METHODS MODIFIED="2009-10-09 15:16:30 +0200" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-10-09 15:17:36 +0200" MODIFIED_BY="[Empty name]">
<P>No.= 50 Gender: 80 % male; mean age: 46.</P>
<P>
<B>Inclusion criteria:</B> meet diagnosis of alcohol dependence according to DSM-IV criteria; age between 18 and 60 years; symptoms of alcohol addiction persisting for a period of six months; willing to be hospitalised for alcohol withdrawal; having a history of severe AWS during former detoxification treatments; mentally competent to give written informed consent.</P>
<P>
<B>Esxclusion criteria:</B> patients showing severe alcohol withdrawal symptoms requiring the administration of CLO  to avoid withdrawal seizures; using illicit drugs, except nicotine; history of drug abuse within the past year; psychiatric disorders or mental impairment limiting the ability to comply with study; acute illness of the respiratory system or reduced breath function or with a known hypersensitivity to CBZ, OXC, or CLO; history of a laboratory abnormality consistent with,or other evidence of a severe medical or neurological disease or malignancy; showing signs of renal or liver insufficiency; hyponatraemia; breath alcohol concentration more than 1.5%;  positive urine drug screening at baseline. pregnancy; breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:13:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (24) Oxcarbazepine on titration dosage starting with 600 mg the first day. Reaching the final dose of 900 mg OXC at day 2, the medication was applied over 2 days and tapered off the following 2 days (days 4 and 5).; <B>Group B</B> (26) placebo</P>
<P>CLO was permitted (192 mg CLO per capsule, up to 18 capsules a day), and administered to the subjects in a symptom-triggered manner according to the SAB score</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:50:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B>Amount of CLO capsules taken to limit the alcohol withdrawal symptoms; intensity of withdrawal syndrome (AES); anxiety (STAI);  depression (BDI); sleep (PSQI); <B>Safety</B>: adverse effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:51:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koppi-1987">
<CHAR_METHODS MODIFIED="2009-12-15 14:06:27 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:06:16 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 20; Gender: 19 males/1 female; Age: 21-65.</P>
<P>
<B>Inclusion criteria: </B>Patients with chronic alcoholism presenting mild to moderate withdrawal symptoms (DSM III criteria), Exclusion criteria: other forms of addiction; psychoses; dementias; known epilepsy; severe medical or neurological illnesses; pregnancy.</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:13:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (10) meprobamate mean 2400 mg/24h; <B>Group B</B> (10) Caroverine mean 120 mg/24h<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Intensity of clouded consciousness in organic brain syndromes (SKT)-; Webster rating scale; nurse's observation scale for inpatient evaluation (NOSIE); severity of illness (NGI)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 14:13:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramp-1978">
<CHAR_METHODS MODIFIED="2009-12-15 11:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 91, Gender: 89% male; age range: 21-62 years</P>
<P>
<B>Inclusion criteria: </B>delirium tremens; history of alcohol abuse; actual condition was related to alcohol abuse; severity of the symptoms permitted admission and treatment according to the general routine of the department; intense gross tremor of the extremities and intense perspiration; duration of the symptoms should be at least some hours. <B>Exclusion criteria:</B> intake of psychoactive drugs during the last 24 hours before treatment; alcohol in the blood at the time of treatment; acute event in chronic alcoholic hallucinosis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:13:59 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(44) diazepam 20 mg i.m. plus placebo p.os; <B>Group B</B> (47) barbital 500 mg p.os plus placebo i.m.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:29:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>seizures, global improvement, doctor's assessment of efficacy; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts; <B>Other:</B> Physical status; mental condition<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:29:40 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 14:14:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krupitsky-2007">
<CHAR_METHODS MODIFIED="2009-12-15 11:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 127 Gender: 100 % male; mean age: 43.</P>
<P>
<B>Inclusion criteria:</B> meet DSM-IV criteria for alcohol dependence; history of most recent alcohol consumption between 8 and 48 hours before study entry; clinically significant alcohol withdrawal symptoms on the basis of the CIWA-Ar. <B>Exclusion criteria </B>: use of  psychoactive or anticonvulsant medications other than those prescribed in the study; opiate dependence; need of urgent treatment for other symptoms; to be at high risk for untoward side effects from study medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:14:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (26) Topiramate 25mg every 6 hours for a total of 100 mg/d, <B>Group B </B>(26) Memantine 10 mg every 8 hours for a total of 30 mg/d, <B>Group C </B>(25) lamotrigine 25 mg every 6 hours for a total daily dose of 100 mg/d, <B>Group D</B> (25) diazepam 10 mg every 8 hours for a total daily dose of 30 mg/d, <B>Group E </B>(25) placebo,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:30:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Withdrawal symptom (CIVA-Ar observer and self rated); Dysphoric mood (MADRS scale); <B>Safety</B>: adverse events; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:30:47 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 09:56:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lambie-1980">
<CHAR_METHODS MODIFIED="2009-12-15 14:14:29 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:14:56 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 48; Gender = 44 males/4 females; Age = 22-60 (mean 46) years</P>
<P>
<B>Inclusion criteria: </B>Alcohol dependents showing symptoms of withdrawal; had been drinking within the last 48 hours.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(22): sodium valproate 400 mg eight hourly; <B>Group B</B> (27) control.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 09:56:12 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Symptoms of withdrawal; degree of severity of symptoms</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 14:16:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lapierre-1983">
<CHAR_METHODS MODIFIED="2009-12-15 11:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 40, Gender: 83% male; age range: 24-60 years</P>
<P>
<B>Inclusion criteria: </B>patients admitted to hospital for moderate to acute symptoms of alcohol withdrawal; history of alcohol abuse of at least 5 years; current episode of heavy drinking of at least 10 days duration. <B>Exclusion criteria:</B> history or positive urine drug screen for other substances' addiction; acute infections; head or major bony injures; medical conditions involving the cardiovascular; endocrine; pulmonary; and nervous system; gross and severe physical deterioration secondary to excessive alcohol intake resulting in severe renal, hepatic, nutritional, hematological and electrolytic disturbances; and schizophrenic illness</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:16:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(20) Chlormethiazole, <B>Group B</B> (20) chlordiazepoxide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:42:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Changes in AWS; TSA; SSA; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events; <B>Other</B>: psychophysiological assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:42:16 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:46:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Longo-2002">
<CHAR_METHODS MODIFIED="2009-12-15 11:43:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:43:41 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 16, Gender: 50% male; age: 18-65</P>
<P>
<B>Inclusion criteria:</B> DSM-IV criteria for alcohol dependence; desire to quit drinking; acceptable health; reliable and compliant; CIWA-Ar score &gt; 8 and &lt; 20 on entry. <B>Exclusion criteria: </B>history of seizures or delirium tremens; significant medical co-morbidity; abuse or dependence on drugs other than alcohol, cannabis, nicotine or caffeine; DSM-IV diagnosis of an Axis I psychiatric disorder for which pharmacotherapy was required; pregnancy or lack of birth control; treatment within the month prior to screening and during the six week period with medications which might influence drinking outcomes; no fixed domicile or collateral informant</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (5) Depakote 5-day detoxification, <B>Group B</B> (5) Depakote plus 6-week maintenance, <B>Group C </B>(7) chlordiazepoxide</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:43:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, ADS; TLFB, drinking diary; treatment utilization; CGI; ASI; VCS; OCDS; VSS; SIP; Laboratory values; <B>Safety:</B> adverse events, mortality;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:43:41 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:47:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lucht-2003">
<CHAR_METHODS MODIFIED="2009-12-15 11:45:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:47:15 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 127, Gender: 93% male; mean age = 43.1 years</P>
<P>
<B>Inclusion criteria</B>: patients with alcohol dependence (ICD-10) admitted for alcohol detoxification therapy; alcohol withdrawal syndrome; age &gt; or = 18 years; direct admission. <B>Exclusion criteria:</B> delirium on admission; contraindications or severe side effects against the study medications; other drug/substance dependence; pregnancy and lactation; psychosis; severe physical diseases; more than 5 single doses of study medications 2 weeks prior to study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:47:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (31) Chlormethiazole (max. 3840 mg/day) for 9 days, <B>Group B </B>(28) carbamazepine (max. 1200 mg/day) for 9 days, <B>Group C</B> (34) diazepam (max. 80 mg/day) for 9 days,</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:47:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B>
<I> </I>seizure; delirium; CIWA-Ar score; global improvement, VAS; SCL-90-R; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:45:08 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:02:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Madden-1969">
<CHAR_METHODS MODIFIED="2009-12-15 14:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:16:57 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 100; Gender: 73 males/27 females</P>
<P>
<B>Inclusion criteria</B>: alcoholics in treatment of dependency on alcohol and drugs showing alcohol withdrawal features on the day of admission;</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-02 10:01:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A:</B>  Chlormethiazole; <B>Group B:</B> trifluoperazine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:02:24 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Overall degree of improvement on each of the initial three full days of treatment compared with the patients' state on the day of admission; daily assessment of the presence or absence of abstinence features</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:48:21 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-1989">
<CHAR_METHODS MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 66, Gender: 100% male; age range: 18-65 years</P>
<P>
<B>Inclusion criteria: </B>met DSM-III criteria for alcohol dependency, MMSE &gt;25; CIWA = or &gt; 20. <B>Exclusion criteria:</B> history of daily use of CNS active drugs, including prescription, nonprescription, and illicit agents; 5 or more days of illicit drug abuse (other than alcohol) in the 30 days before admission; allergic or adverse reactions to oxazepam or carbamazepine; manic-depressive illness, schizophrenia, or dementia; history of hepatic encephalopathy, jaundice, ascites, diabetes, renal disease, neurologic disease (excluding peripheral neuropathy), or leukopenia; liver function transaminase levels (SGOT, LDH, SGPT) 2.5 times higher than normal; total WBC &lt;4000/mm3; platelet count &lt;100,000/mm3; participating in any drug</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(32) carbamazepine 800 mg/day for 7 days, <B>Group B </B>(34) oxazepam 120 mg/day for 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, physiological measures; neurological measures; self-report measures; standard psychological testing ( SCL-90-R, [Beck depression inventory, State-Trait anxiety inventory, Wechsler Memory scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:49:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:50:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2002">
<CHAR_METHODS MODIFIED="2009-12-15 11:50:10 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:50:10 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 136, Gender: 75% male</P>
<P>
<B>Inclusion criteria: </B>met DSM-IV criteria for alcohol dependence and alcohol withdrawal; blood alcohol level = or &lt;0.1 g/dl; residence within 50 miles of the study site; MMSE = or &gt;26; admission score on CIWA-Ar = or &gt;10. <B>Exclusion criteria:</B> all substance abuse syndromes other than alcohol, nicotine or cannabis; major Axis I psychiatric disorder; use of medication in the preceding 30 days that could alter the withdrawal process; history of head injury or other neurologic illness including idiopathic epilepsy; medical instability; electroencephalogram abnormalities; grossly abnormal laboratory values<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:50:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(61) carbamazepine 600-800 mg on day 1 tapering to 200 mg on day 5, <B>Group B</B> (75) lorazepam 6-8 mg on day 1 tapering to 2 mg on day 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:50:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores; ADS; daily drinking log; Zung Anxiety scale; Beck depression inventory; ability to return to work; sleep quality measures; <B>Safety:</B> mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Malcolm2 2002 is the same RCT assessing different AW outcomes.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:51:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-2007">
<CHAR_METHODS MODIFIED="2009-12-15 11:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 101 Gender: 75 % male; mean age: 41.</P>
<P>
<B>Inclusion criteria:</B> meet DSM-IV1 criteria for alcohol dependence and for current alcohol withdrawal syndrome;  medically stable and not likely to require hospitalisation for medical complications within 10 days of entry into the study;  score of 10 or higher (CIWA-Ar); negative urine drug screens for benzodiazepines, other sedative-hypnotics, opiates, and amphetamine. <B>Exclusion criteria: </B>history of taking medications known to ameliorate or intensify the AWS ; diagnosis of any other substance-dependence syndrome other than alcohol , except cannabis and cocaine; history of idiopathic epilepsy, schizophrenia, bipolar disorder, or dementia; liver function tests 4 times higher than the upper range of normal; history of hepatic encephalopathy, jaundice, ascites, insulin-dependent diabetes mellitus, or renal insufficiency .</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (20) Gabapentin, mid-range dose 300 mg 3 times a day for 3 days and 300 mg twice daily for the last day, <B>Group B </B>(21) lorazepam 2 mg 3 times a day for the first 3 days and 2 mg twice daily on the last day of treat­ment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Insomnia measured by CIWA-AR scale; Quality of sleep measured by Beck Depression Inventory (BDI); Sleepiness measured by the Eporth Sleepiness Scale;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:51:22 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:14:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manhem-1985">
<CHAR_METHODS MODIFIED="2009-12-15 14:18:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>N= 67; Age: 32-60</P>
<P>
<B>Inclusion criteria:</B> alcohol dependents (DSM III) with acute alcohol withdrawal syndrome requiring drug therapy;</P>
<P>
<B>Exclusion criteria: </B>history, medical examination or laboratory evidence suggesting severe neurologic, psychiatric, hepatic or cardio-vascular illness. patients using prescription or illicit drugs</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:19:20 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (10) Chlormethiazole 4 x 500 mg; <B>Group B </B>(10)  clonidine 4 x 150 ìg<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:14:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Withdrawal Assessment Scale;<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:15:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mariani-2006">
<CHAR_METHODS MODIFIED="2010-01-02 10:14:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-02 10:15:09 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 27 Gender: 70 % male; mean age: 44.</P>
<P>
<B>Inclusion criteria:</B> met DSM-IV1 criteria for alcohol dependence; age between 18 and 60 years;  score of ten or higher as measured by the CIWA-Ar); willingness to sign informed consent.</P>
<P>
<B>Exclusion criteria: </B>any major DSM-IV Axis I non-substance-related psychiatric disorder; any known allergy to gabapentin or phenobarbital; pregnancy; documented AIDS (HIV+ status was not an exclusion criterion); severe unstable medical illness; alcohol withdrawal delirium; use of opioids (methadone maintenance was not an exclusion criterion) or sedative-hypnotic agents (eg, benzodiazepines or barbiturates).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-10-09 15:20:32 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (14) gabapentin Day 1 total of 2400 mg in the first 24 hours Day 2-4. 600 mg</P>
<P>
<B>Group B</B> (13) Phenobarbital Day 1-3 60mg , day 4. 30mg</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:15:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Withdrawal symptom (CIWA-Ar); mood (POMS); craving (ACS); irritability (BDHI);anxiety (Hamilton?A);dysphoria (RDS); sleep (SPS, hours of sleep)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 09:41:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGrath-1975">
<CHAR_METHODS MODIFIED="2010-01-01 19:16:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-01 19:16:15 +0100" MODIFIED_BY="[Empty name]">
<P>No: 100, Gender: not reported, age range: not reported</P>
<P>
<B>Inclusion criteria</B>: patients with acute withdrawals phase of alcoholism. No further detailde given</P>
<P>
<B>Exclusion criteria</B>: not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 09:41:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B>: Chlormethiazole (50)</P>
<P>
<B>group B</B>: Chlordiazepoxide (50)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-01 19:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> delirium</P>
<P>
<B>Acceptaibility</B>: drop out</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-01 18:34:39 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:20:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murphy-1983">
<CHAR_METHODS MODIFIED="2009-12-15 14:20:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:20:46 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 68; Gender: 51 males/17 females; Age: 21-65 years</P>
<P>
<B>Inclusion criteria:</B> addicted to alcohol with withdrawal symptoms</P>
<P>
<B>Exclusion criteria: </B>alcoholic hallucinatory syndrome or delirium; psychosis of any kind or past psychosis not related to alcohol abuse; clinical or documented evidence of brain damage including the Wernicke-Korsakoff syndrome; intercurrent physical illness necessitating intervention; any evidence of epilepsy not related to alcohol abuse; ingestion of psychotropic drugs less than 24 h before admission.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:22:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (29) Chlormethiazole; <B>Group B</B> (30) Tiapride; <B>Group C</B> (9) placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:20:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Depression (Wakefield Inventory of Zung's Self-Rated Depressive Scale); Severity of Alcohol Dependence Questionnaire; withdrawal symptoms (Severity Assessment Scale of Gross); craving for alcohol; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:35:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myrick-2000">
<CHAR_METHODS MODIFIED="2009-12-15 14:22:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:23:15 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 11; Gender = Both males and females. Age = 18-65</P>
<P>
<B>Inclusion criteria: </B>Alcohol dependents (DSM II R) requiring alcohol detoxification; (CIWA-Ar) scale of 6 or higher.<BR/>
<B>Exclusion criteria:</B> serious medical conditions; major psychiatric disorders; liver function tests 3 times greater than normal.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:24:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (6)  divalproex 500mg 3 times a day for 4 days)+Lorazepam 2mg; <B>Group B </B>(5) lorazepam 2mg<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:35:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: CIWA-Ar score; </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 14:24:32 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:11:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nimmerichter-2002">
<CHAR_METHODS MODIFIED="2009-12-15 14:25:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 98; Gender = 89 males/9 females; Age = 31.7-50.7</P>
<P>
<B>Inclusion criteria: </B>Patients meet at least 3 DSM-IV and ICD-10 criteria for the diagnosis of alcohol dependence; severity of withdrawal syndrome = or &gt; 20 points on the CIWA-Ar,; elevated GGT and/or MCV and/or relative carbohydrate-deficient transferrin levels.<BR/>
<B>Exclusion criteria:</B> patients already detoxified or dependent on substances other than alcohol; illnesses such as decompensated liver cirrhosis, acute pancreatitis, reduced respiratory function, acute pulmonary or bronchial disease, myocardial infarction during the preceding 6 months and cardiac arrhythmia; dementia, schizophrenia, polysubstance misuse or dependence or use of benzodiazepines and hypno-sedatives; suspected sleep apnoea syndrome; allergy to either of the study drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(33) Chlormethiazole 1000 mg daily; <B>Group B</B> (33) GHB 50 mg GHB/kg body wt; <B>Group C</B> (32)  GHB 100 mg GHB/kg body wt<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:37:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy: </B>Withdrawal syndrome (CIWA-Ar); clinical and biological parameters; Lubeck Craving-Risk-Relapse questionnaire (LCRR-1); additional study medication; <B>Acceptabilty</B>: side effects;<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 14:27:35 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:54:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<CHAR_METHODS MODIFIED="2009-12-15 11:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 67; Gender: 100% male; age range: 32-60 years</P>
<P>
<B>Inclusion criteria:</B> patients admitted to the detoxification unit of Quebec Hospital; met the DSM-III criteria for alcohol dependence; presented acute alcohol withdrawal syndrome requiring drug therapy. <B>Exclusion criteria: </B>history, medical examination or laboratory evidence suggesting severe neurologic, psychiatric, hepatic or cardiovascular illness and the use of prescription or illicit drugs (polydrug addiction</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (30) oral phenobarbital, <B>Group B</B> (30) oral chlordiazepoxide. Additional medication doses were given according to the clinician judgment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:53:36 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, CIWA-Ar score, REG; vital signs and sleep evaluation; DSST, PPT; HSCL-35, Zung Self Rating Anxiety Scale, Zerssen bipolar mood test-Z; changes in blood alcohol levels; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:53:36 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:41:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rathlev-1994">
<CHAR_METHODS MODIFIED="2009-12-15 14:34:56 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 100; Gender = 96 males/4 females<BR/>Age (mean) = placebo, 41.5 years; phenytoin, 42.4 years.</P>
<P>
<B>Inclusion criteria:</B> Patients with a witnessed generalized seizure in the setting of decreasing alcohol intake, and had no other known or suspected cause of seizures.</P>
<P>
<B>Exclusion criteria: </B>known or potential causes of seizure by head CT scan, EEG, lumbar puncture, or laboratory studies; onset of seizures before age 25; focal seizures or status epilepticus; positive phenytoin level; focal neurologic examination; known ingestion of drugs that potentially cause seizures; treatment with benzodiazepines for alcohol withdrawal symptoms; significant head trauma; pregnancy; phenytoin allergy.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:35:40 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (49)  phenytoin 15 mg/kg at a rate equivalent to 50 mg/min over 20 minutes by iv pump; <B>Group B</B> (51)  placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:41:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: seizure; <B>Acceptability</B>: completion of a six-hour observation period after infusion.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:42:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reoux-2001">
<CHAR_METHODS MODIFIED="2009-12-15 14:36:20 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 36; Gender = 35 males/1 female; Age = 40.8-58</P>
<P>
<B>Inclusion criteria: </B>volunteers seeking treatment for alcohol dependence and withdrawal;  met DSM-IV criteria for alcohol dependence; experiencing at least moderate acute alcohol withdrawal (score of 10 or greater on the CIWA-Ar scale)<BR/>
<B>Exclusion Criteria:</B> 6 or more days of illicit drug use, other than cannabis, in the 30 days before admission; allergic or adverse reaction to prior use of oxazepam or valproate; current use of an anticonvulsant medication or benzodiazepine; pregnancy; medical condition potentially risky</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:37:05 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (18)  divalproex sodium 500 mg 3 times a day; <B>Group B</B> (18)  inactive placebo<BR/>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:42:57 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Total milligrams of oxazepam required to control AWS symptoms; withdrawal symptoms (CIWA-Ar); changes in SCL-90 scores; <B>Acceptability</B>: side-effects<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:12:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ritola-1981">
<CHAR_METHODS MODIFIED="2009-12-15 14:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:37:57 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 68; Gender = 100% males; Age =37.4-41.6.</P>
<P>
<B>Inclusion criteria: </B>patients considered sufficiently severe as to require hospitalisation.<BR/>
<B>Exclusion Criteria:</B> clear abnormalities in cardiac, hepatic or renal functions; using psychoactive agents other than the trial preparations</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (34): carbamazepine 200 mg; <B>Group B</B>: (34) Chlormethiazole 300 mg<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:44:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Withdrawal symptoms; patient's subjective feeling; overall evaluation of the treatment (patient, nurse, physician); <B>Acceptability</B>:side effects;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:46:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-1989">
<CHAR_METHODS MODIFIED="2009-12-15 14:39:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:39:47 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 32; Gender: 26 males/6 females<BR/>Age (mean): Clonidine, 50.8±9.3 years; Chlormethiazole, 44.8 ± 8.4 years.</P>
<P>
<B>Inclusion criteria:</B> patients requiring drug treatment for the suppression of withdrawal symptoms.</P>
<P>
<B>Exclusion Criteria: </B>no significant symptoms of alcohol withdrawal (WSRscore &lt; 3); standing systolic blood pressure &lt; 100 mmHg; major withdrawal symptoms (WSR score &gt; 20); history of previous withdrawal seizures; multidrug dependency problem; taking drugs affecting sympathetic nervous activity  in the week prior to admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:42:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (16):  Chlormethiazole; <B>Group B</B>: (16) clonidine<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:46:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: alcohol withdrawal symptoms (WSR scale);<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:49:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rosenthal-1998">
<CHAR_METHODS MODIFIED="2009-12-15 14:43:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:43:27 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 42; Gender: 36 males/6 females;  Mean age: Valproate group, 43.5±6.7 years; Phenobarbital group, 41.5 ± 10.7 years.<BR/>
<B>Inclusion criteria:</B> alcohol dependents in withdrawal (DSM-IV criteria); willingness to sign informed consent, age between 18 and 55 years; and criteria for alcohol dependence in withdrawal.</P>
<P>
<B>Exclusion criteria: </B>any major DSM-IV Axis I disorder; documented liver disease; known allergy to valproate; pregnancy; documented AIDS (HIV+ not an exclusion criterion); coexisting use of cocaine or illicit opioids (methadone maintenance not an exclusion criterion); abuse of a half-life benzodiazepine</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:44:08 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> phenobarbital; <B>Group B</B> valproate<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:49:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: withdrawal symptoms and signs: Modified Selective Severity Assessment (MSSA); modified Abstinence Symptoms Questionnaire (ASQ);Profile of Mood States (POMS-SF); Buss-Durkee Hostility Index (BDHI).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:49:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rothstein-1973">
<CHAR_METHODS MODIFIED="2009-12-15 14:44:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:45:08 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 200</P>
<P>
<B>Inclusion criteria: </B>have a history of chronic alcoholism; have been drinking heavily every day for at least five days immediately preceding his admission; give written, informed consent </P>
<P>
<B>Exclusion criteria:</B> previous long-term diphenylhydantoin therapy for convulsive disorders (other than withdrawal seizures); seizures during the two weeks just before admission</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:45:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (100) diphenylhydantoin 2 x 200 mg orally; <B>Group B</B> chlordiazepoxide + thiamine(100)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:49:53 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Seizures</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 10:58:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sampliner-1974">
<CHAR_METHODS MODIFIED="2009-12-15 14:48:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>No. =157.</P>
<P>
<B>Inclusion criteria:</B> history of seizures in adulthood; no medications in the two weeks before admission;  steady, heavy alcoholic intake for the preceding four weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:49:34 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(70)  diphenylhydantoin 300 mg/day; <B>Group B</B> (66) placebo</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 10:58:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: seizures </P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 11:00:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santo-1985">
<CHAR_METHODS MODIFIED="2009-12-15 14:50:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 38; Gender: All males<BR/>Age: Group 1: 44 years, Group 2: 43 years.</P>
<P>
<B>Inclusion criteria:</B> Patients with alcohol withdrawal syndrome hospitalised for reasons other than alcoholism</P>
<P>
<B>Exclusion criteria: </B>severe delirium tremens.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:51:11 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(15) Tetrabamate 300 mg; <B>Group B</B> (17)  Tiapride 100 mg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:00:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficay</B>: Number of patients with withdrawal symptoms at day 14; duration of symptoms per group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in Spanish</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:14:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schik-2005">
<CHAR_METHODS MODIFIED="2009-12-15 14:51:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:14:04 +0100" MODIFIED_BY="[Empty name]">
<P>No.= 29 Gender: 83 % male; mean age: 41.</P>
<P>
<B>Inclusion criteria:</B> voluntary admitted to hospital with a alcohol withdrawal syndrome according to ICD-10</P>
<P>
<B>Exclusion criteria: </B>polydrug abuse; delirium tremens upon admission; severe hepatic or haematological complications; hyponatraemia; abnormal ECG; known epileptic seizures;  history of head injury; neuroleptic or antiepileptic medication as well as MAO-inhibitor intake</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:13:58 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (14 ) carbamazepine, 600 mg on days 1 - 3, 300 mg on day 4 and a last dose of 100 mg on day 5.</P>
<P>
<B>Group B </B>(15) oxcarbazepine , 900 mg on days 1 - 3, 450 mg on day 4 and a final dose of 150 mg on day 5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:01:06 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Withdrawal symptom (CIWA-Ar); <B>Acceptability</B>: subjective perception of side affect and symptoms (VAS)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 11:02:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seifert-2004">
<CHAR_METHODS MODIFIED="2009-12-15 14:51:53 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:52:15 +0100" MODIFIED_BY="[Empty name]">
<P>No. =159; Gender = 150 males/9 females; Age = 18-83</P>
<P>
<B>Inclusion criteria: </B>met the DSM-III-R criteria for alcohol dependence.<BR/>
<B>Exclusion criteria:</B> less than 18 years of age; chronic obstructive disease; poor pulmonary function or pneumonia; bradycardia; systolic blood pressure of less than 95 mmHg; second- or third-degree atrioventricular node block; history of current use or abuse of benzodiazepines, barbiturates, clonidine, or beta-adrenergic receptor blockers.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:52:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (21) carbamazepine; <B>Group B</B> (16)  Chlormethiazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:02:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy;</B> Memory test (Benton); Zahlen-Verbindungs test ;Beck Depression Inventory; Anxiety Sensitivity Index; Verbal Lern- und Merkfahigkeitstest; Mehrfach-Wortschatz-Intelligenz test (MWT-B); European Addiction Severity Index (EuropASI); Clinical Institute Withdrawal Scale (CIWA-A); <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:57:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spies-1996">
<CHAR_METHODS MODIFIED="2009-12-15 11:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 159; Gender: 94% male; age range: 18-83 years</P>
<P>
<B>Inclusion criteria:</B> multiple-injured alcohol-dependent patients who met the DSM-III-R criteria for alcohol dependence. <B>Exclusion criteria: </B>age &lt; 18 years; chronic obstructive lung disease and poor pulmonary function or pneumonia; bradycardia (heart rate &lt; 45/min); systolic blood pressure &lt; 95 mmHg; second- or third-degree atrioventricular node block; history of current use or abuse of benzodiazepines, barbiturates, clonidine, or beta-adrenergic receptor blockers</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:57:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (50) Clomethiazole/haloperidol, <B>Group B</B> (55) flunitrazepam/haloperidol, <B>Group C</B> (54) flunitrazepam/clonidine. </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:56:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> changes in CIWA-Ar scores, Duration of controlled or assisted mechanical ventilation; <B>Safety:</B> mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:56:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 11:04:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stanhope-1989">
<CHAR_METHODS MODIFIED="2009-12-15 14:53:48 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 304; Gender = 256 males; 48 females<BR/>age = 40.5 years (mean age for carbamazepine); 39.9 years (mean age for placebo)</P>
<P>
<B>Inclusion criteria </B>Patients presenting for detoxification from alcohol<BR/>
<B>Exclusion criteria:</B> allergy to carbamazepine or Chlormethiazole reported before entry; known use of anticonvulsant before entry; previous repeated early self-discharge; two admissions by Langton Centre terminated under 3 days duration; a previous admission already included in the study; alcohol not the principal drug of dependence.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:54:35 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (157)  carbamazepine; <B>Group B</B> (147) placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:04:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Daily withdrawal scores; seizures;<B>Acceptability</B>: Mode of discharge (completed detoxifications);<BR/>Length of stay;<B>Safety</B>: adverse events;<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 11:59:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stuppaeck-1992">
<CHAR_METHODS MODIFIED="2009-12-15 11:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 11:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 60; Gender: 82% male</P>
<P>
<B>Inclusion criteria:</B> DSM-III criteria for alcohol dependence; CIWA-Ar score &gt; 20 on admission; be able to sign informed consent. <B>Exclusion criteria: </B>age &lt;18 or &gt;65 years; severe somatic illness; polysubstance dependence; pre-treatment with psychotropic drugs; full-blown alcohol delirium</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 11:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(29) carbamazepine, <B>Group B</B> (29) oxazepam<BR/>Additional B-polyvitamin compound was given orally.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 11:59:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, delirium, changes in CIWA-Ar scores; self-rating adjective checklist; CGI scale; <B>Safety:</B> adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 11:59:28 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-02 11:06:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stuppaeck-1998">
<CHAR_METHODS MODIFIED="2009-12-15 14:55:41 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:55:57 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 38.</P>
<P>
<B>Inclusion criteria:</B> Inpatients met DSM-IV criteria for alcohol dependence and a minimum CIWA -A score of 18.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:56:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(19) vigabatrin 2000 mg/day from day1-3, then placebo from day4-7; <B>Group B</B> (19) oxazepam 120 mg/day from day1-3 and 90 mg/day from day 4-</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:06:25 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> Modified German version of the Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-A); Clinical Global Impression Scale (CGI); Visual Analogue Scale (VAS); Fischer's Unwanted Symptoms Check List (FUSCL)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Meeting abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:14:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teijeiro-1975">
<CHAR_METHODS MODIFIED="2009-12-15 14:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized Controlled Trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>No. = 55</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:14:17 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A </B>(30)  atrium 300 mg; <B>Group B</B> (25)  Heminiurine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-02 11:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Tolerance; Tremor; Anxiety</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Study in French</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-08 12:14:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1975">
<CHAR_METHODS MODIFIED="2009-12-15 14:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 14:58:32 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 34; Gender = 26 males/8 females<BR/>Age = 22-58</P>
<P>
<B>Inclusion criteria: </B>Patients admitted consecutively to the Osler Medical Service with advanced delirium tremens</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (17) paraldehyde 10 ml rectally every 30 minutes; <B>Group B</B> (17)  diazepam 10 mg intravenously initially and then mg intravenously every 5 minutes<BR/>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-08 12:14:22 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy</B>: Time for induction of a calm state; duration of delirium ; dose of diazepam and paraldehyde given after initial calming until patient was entirely recovered from delirium tremens; <B>Safety</B>: adverse events .</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-12-15 14:59:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tubridy-1988">
<CHAR_METHODS MODIFIED="2009-12-15 12:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-12-15 12:00:55 +0100" MODIFIED_BY="[Empty name]">
<P>No. = 102; Age range: 21-65 years</P>
<P>
<B>Inclusion criteria:</B> alcohol dependent participants admitted to St John of God Hospital, Dublin. <B>Exclusion criteria: </B>patients sensitive to benzodiazepines or Chlormethiazole; dependent on or abused substances other than alcohol; psychotic or suffered from another mental disorder; serious physical illness; pregnant or lactating; taking other psychotropic drugs; history of withdrawal seizures</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-12-15 14:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Group A</B> (49) Chlormethiazole, <B>Group B</B> (51) alprazolam<BR/>All patients received daily intravenous injections of vitamin B complex and ascorbic acid on days 1-5</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-15 12:00:56 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Efficacy:</B> seizures, global improvement, doctor's assessment of efficacy, patient's assessment of efficacy, Patient's general physical condition; presence of symptoms of alcohol withdrawal throughout the trial; HARS; doctor's and patient's global ratings of well-being; changes in blood tests measures; <B>Safety:</B> adverse events, severe life-treating adverse events, mortality; <B>Acceptability:</B> dropouts, dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-15 12:00:56 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ACL: Adjective Check List; ACS: Alcohol Craving Scale; ADS: Alcohol Dependence Scale; ALT: Alanine Aminotransferase Transaminase; ASI: Addiction Severity Index; ASQ: Abstinence Symptoms Questionnaire; AST: Aspartate Aminotransferase Transaminase; AWS: alcohol withdrawal symptoms; BAC: Blood Alcohol Concentration; BDHI: Buss-Durkee Hostility Inventory BDI: Beck Depression Inventory; CGI: Clinical Global Impression; CIWA-Ar: Rivised Clinical Institude Withdrawal Assessment for Alcohol; CLO: Chlormethiazole; CNS: Central Nervous System CPRS: Comprehensive Psychiatric Rating Scale; CSE: Clinical Side-Effect Scale; DES: Daily Estimation Scale; DOTES: Dosage Record and Treatment Emergent Symptom Scale; DSM III: Diagnostic and Statistical Manual for Mental Disorders, third edition; DSM IV: Diagnostic and Statistical Manual for Mental Disorders, fourth edition; DSST: Digit Symbol Substitution Test; EuropASI: European Addiction Severity Index; FUSCL: Fischer's Unwanted Symptoms Check List; GGT: Gamma Glutamyl Transferase HARS: Hamilton Anxiety Rating Scale; HSCL: Hopkins Symptoms Check List; ICD-10: Internationa Classification of Diseases; LCRR-1: Lubeck Craving-Risk-Relapse questionnaire; MADRS: MontgomeryÅsberg Depression Rating Scale; MAO Inhibitors: Monoamine Oxidase inhibitors; MAWS: Mainz Alcohol Withdrawal Scale; MMSE: Mini-Mental State Examination; MSSA: Modified Selective Severity Assessment; MWT-B: Mehrfach-Wortschatz-Intelligenz test; NGI: Nurse's Global Impression; NOSIE: nurse's observation scale for inpatient evaluation; OCDS: Obsessive Compulsive Drinking Scale; PPT: Purdue Pegboard Test; PSQI: Pittsburgh Sleep Quality Index; RCT: randomised controlled trial; RDS: Reward Deficiency Syndrome REG: Rada-Extensive Grid; SCL-90-R: Symptom Checklist 90 revised SGOT: Serum Glutamate Oxaloacetate Transaminase; SGPT: Serum Glutamic Pyruvic Transaminase; SIP: Short Index of Problems; SKT: Syndrom-kurztest; SPS: Sleep Promoting Substance SSA: Selected Severity Assessment; STAI: State Anxiety Inventory; TLFB: Time Line Follow Back; TSA: Total Severity Assessment; VAS: visual analogue scale; VCS: Visual Craving Scale; VSS: Visual Success Scale; WHO: World Health Organization WSR: Withdrawal Symptom Rating;</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-01-05 15:21:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:03:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addolorato-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:04:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Adinoff-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 09:58:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Aliyev-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 09:58:37 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:04:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ansoms-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:04:23 +0100" MODIFIED_BY="[Empty name]">
<P>Type of study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-01 19:09:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-01 19:09:57 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome measures presented in a way not suitable for meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:04:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Athen-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:04:35 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:06:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Athen-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:06:15 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:06:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Athen-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:06:27 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:06:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balldin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:06:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baltieri-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:06:47 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:06:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Banki-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:06:54 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:07:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Block-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:07:10 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-05 15:21:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bonnet-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-05 15:21:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:07:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Borg-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:07:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:07:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brady-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:07:40 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:07:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bullock-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:07:56 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:08:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caspari-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:08:12 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:08:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cazzato-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:08:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:11:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chick-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:11:42 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:11:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cushman-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:11:46 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:12:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delamaire-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:12:06 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:12:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Demmel-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:12:10 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 12:03:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dobrydnjov-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 12:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:12:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franz-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:12:32 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:12:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frecker-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:12:37 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:13:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallant-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:13:15 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:13:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gallant-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:13:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glatt-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:13:54 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 09:59:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gordon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 09:59:12 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:14:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gottesleben-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:14:20 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:14:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griffith-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:15:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gual-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:15:03 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:15:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gual-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:15:08 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:15:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guarino-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:15:27 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:15:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hague-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Harfst-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:03 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heil-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:17 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hillbom-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:21 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hutchison-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ilyuchina-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:45 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:16:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Janiri-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:17:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:17:04 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:17:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:17:18 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:17:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaim-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:17:26 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:17:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaplan-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:17:32 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:17:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karam_x002d_Hage-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:17:58 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karst-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:09 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Keaney-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiefer-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:17 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kramp-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:39 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kraus-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:55 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lange_x002d_Ass-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:10 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:18:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Bon-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:18:58 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Le-Fauve-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:02 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leivonen-1966">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:16 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Loo-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:38 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Malcolm-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:19:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinotti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:19:58 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:21:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mendels-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:21:20 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:21:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miller-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:21:36 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 09:59:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Montejo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 09:59:51 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:21:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mueller-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:21:44 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:22:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mukherjee-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:22:06 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 12:05:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 12:05:14 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-01 19:10:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myrick-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-01 19:10:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome measures presented in a way not suitable for meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:22:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naranjo-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:22:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newman-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:22:30 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:23:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:23:03 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:00:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponce-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:00:12 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-15 15:22:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rodgers-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-15 15:22:46 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:00:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubio-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:00:35 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:03:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rychlik-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:03:15 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:00:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sass-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:00:45 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:03:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmidt-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:03:21 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:04:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schulte-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:03:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwarz-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:07:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-See-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:07:51 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:01:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaw-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:01:04 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:07:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sillanpaa-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:07:32 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:01:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Smith-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:01:09 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:01:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Snel-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:01:14 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sobcyzk-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:21 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:01:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Solomon-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:01:35 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:04:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Spies-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:04:01 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sternebring-1983">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stojek-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:27 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Streeton-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:31 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Swift-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:34 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:01:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tacke-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:04:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Teijeiro-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>Type of outcome measures not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:02:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tempesta-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:02:03 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thomas-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:05:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tress-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:05:58 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:07:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wadstein-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:07:11 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicate publication</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:06:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wegner-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:06:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:06:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Welbel-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Study design not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:06:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitworth-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:06:46 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-21 10:06:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wiesbeck-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-21 10:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>Type of intervention not in the inclusion criteria</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>AW: alcohol withdrawal<BR/>CCT: controlled clinical trial<BR/>RCT: randomized controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-01-08 12:28:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2010-01-08 12:18:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gottesleben-1994">
<CHAR_METHODS MODIFIED="2010-01-08 12:16:54 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:17:24 +0100" MODIFIED_BY="[Empty name]">
<P>28 patients during drug therapy for alcoholic pre delirium</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:18:13 +0100" MODIFIED_BY="[Empty name]">
<P>slow-release carbamazepine (Timonil registered trade mark 150 retard) versus Chlomethiazole</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-08 12:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>duration and severity of withdrawal symptoms.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-08 12:18:53 +0100" MODIFIED_BY="[Empty name]">
<P>we are trying to find the study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-01-08 12:26:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hart-1964">
<CHAR_METHODS MODIFIED="2010-01-08 12:26:41 +0100" MODIFIED_BY="[Empty name]">
<P>it is impossible from title to know the study design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:23:22 +0100" MODIFIED_BY="[Empty name]">
<P>175 of alcohol withdrawal</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:23:38 +0100" MODIFIED_BY="[Empty name]">
<P>promazine and paraldehyde</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-08 12:26:24 +0100" MODIFIED_BY="[Empty name]">
<P>it is impossible from title to know which outcomes were considered</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-08 12:19:03 +0100" MODIFIED_BY="[Empty name]">
<P>we are trying to find the study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2010-01-08 12:28:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trevisan-2008">
<CHAR_METHODS MODIFIED="2010-01-08 12:27:37 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-08 12:27:34 +0100" MODIFIED_BY="[Empty name]">
<P>Fifty-seven male veterans presenting for alcohol detoxification</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 12:27:59 +0100" MODIFIED_BY="[Empty name]">
<P>valproic acid, gabapentin, or placebo for a total of 4 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-08 12:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>symptoms of physiologic withdrawal during the first 5 days of treatment and doses of benzodiazepine required;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-08 12:19:07 +0100" MODIFIED_BY="[Empty name]">
<P>we are trying to find the study</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-01-08 12:13:36 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-01-08 12:10:28 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 19:20:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agricola-1982">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:17:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alldredge-1989">
<DESCRIPTION>
<P>"patients were randomly assigned to receive either diphenylhydantoin sodium injection or infusion of an equivalent volume of 0.9% sodium chloride"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:21:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Balldin-1986">
<DESCRIPTION>
<P>"patients were treated either with alpha2 agonist clonidine or chlorprothixene"</P>
<P>COMMENT: it was not stated if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:20:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjorkqvist-1976">
<DESCRIPTION>
<P>"Patients were randomly allocated to two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:33:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blanchard-1985">
<DESCRIPTION>
<P>"patients were randomised in two parallel group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:36:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonnet-2003">
<DESCRIPTION>
<P>"patients were randomised to receive either P or GP"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:36:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"the patients were randomly assigned to treatment with either amobarbital, oxazepam or Melperone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 08:04:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 10:59:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 08:08:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chance-1991">
<DESCRIPTION>
<P>"Patients were randomly assigned to phenytoin or normal saline. The drugs solutions were in identical vials prepared by the pharmacy in an order determined by random-number tables and sent to the ED labelled only by test solution numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:44:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>"Fifty-two patients after providing written informed consent are randomised to either lorazepam (N=27) or Topiramate (N=25) groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:08:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Croissant-2009">
<DESCRIPTION>
<P>"We used a table of randomisation to assign subjects to the OXC / TIA or to the CLO-group. Randomization was effected block by block by five patients, i.e. every five patients the treatment regime changed from OXC / TIA to CLO and vice versa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:50:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dencker-1978">
<DESCRIPTION>
<P>"patients were randomly allocated to either Piracetam or Chlormerhiazole"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 21:57:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>"randomised prospective study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:08:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-2009">
<DESCRIPTION>
<P>"Patients were randomised to receive either GHB (initially 30 mg/kg BWfollowed by 15 mg/kg BW i. v.) or CLO (250 mg every 4 hours as a liquid)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-19 07:07:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flygering-1984">
<DESCRIPTION>
<P>"Patients were randomly allocated to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:02:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gann-2004">
<DESCRIPTION>
<P>"patients were randomised to group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:03:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glatt-1966">
<DESCRIPTION>
<P>"The test tablets for each patients were provided with a serial number and distributed within the series by mean of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-19 07:38:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>"Random selection was achieved by assigning each patients medication by rotation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:10:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The random assignment of patients to treatments was controlled by a study code number;; patients were assigned consecutive numbers. Prepackaged box of study medication corresponding to the patient's code number."</P>
<P>COMMENT: it is not clear how the code numbers were generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:11:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>"patients were randomly assigned to either carbamazepine or diazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-07 10:47:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koethe-2007">
<DESCRIPTION>
<P>"After admission, subjects were randomly assigned to the 2 treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:09:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koppi-1987">
<DESCRIPTION>
<P>"On a random number basis patients were either assigned to Caroverine or meprobamate"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:30:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment"</P>
<P>COMMENT: it was not state if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>Block randomisation was used with block sizes of 15, 20, and 25 randomly varied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:16:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambie-1980">
<DESCRIPTION>
<P>"Pateints were randomly allocated to one of the two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 07:42:43 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Treatment were randomly administered sequentially as the patients were included in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:44:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"Patients were sequentially randomised into one of three group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 08:14:06 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"Assignment took place in blocks of 10 in order of admission ( first 10 patients into group A, next 10 patients into group B, etc)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 08:19:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madden-1969">
<DESCRIPTION>
<P>"Patients were randomly allocated to one or other preparation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:10:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>"Subjetcs were blindly assigned to a group who received carbamazepine or to a group who received oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:50:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Subjects randomisation was based on on a computer generated schedule administered by a research pharmacist not involved in data collection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:10:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>Subjects were randomised using a stratified permuted block method in which individuals with particular characteristics were assigned to medication groups with constraint that the assignment was balanced within successive blocks of subjects. We used a relatively small block size of q=4in order to promote a high degree of balance. Stratifications were based on the intersection of previous alcohol treatment history (0-1 or more than 1 past treated withdrawals) and sex (male or female).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:14:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manhem-1985">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariani-2006">
<DESCRIPTION>
<P>"patients were randomised to receive one of the two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 19:16:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"One hundred consecutive admissions to a specialized unit for the treatment of alcoholism in a psychiatric hospital were allotted code numbers and in accordance with a list of randomised numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 06:44:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-1983">
<DESCRIPTION>
<P>"Patients were randomly assigned to one of the treatment group after stratification for age, sex and blood alcohol concentration"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myrick-2000">
<DESCRIPTION>
<P>"Subjects were placed randomly on Depakote group. The CIWA-ar only group is the comparison group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:27:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerichter-2002">
<DESCRIPTION>
<P>"Participants were randomised to one of the three treatments by means of a computerized randomisation schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:54:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>"After enrolment, patients were assigned to receive the next in a sequentially numbered supply of medication. The sequence was previously determined by the hospital pharmacist from a table of random numbers with a blocked design to ensure a roughly equal numbers in the two treatment group and in the different season of the year"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:36:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rathlev-1994">
<DESCRIPTION>
<P>"Patients were randomised to receive either phenytoin or saline placebo according to a table of random number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 07:31:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reoux-2001">
<DESCRIPTION>
<P>"Subjects were randomly assigned to either a placebo or divalproex sodium condition."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 07:41:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ritola-1981">
<DESCRIPTION>
<P>"The patients were randomly allocated to two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1989">
<DESCRIPTION>
<P>"Medication was administered in a randomised double blind manner".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenthal-1998">
<DESCRIPTION>
<P>"Patients were randomised on day 1 to receive either phenobarbital or valproate"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:47:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothstein-1973">
<DESCRIPTION>
<P>"The 200 patients were randomly assigned to either a diphenylhydantoin group or a control group using the following procedure:at the start of the study we obtained a random number list of 200 number balanced after each 20 to assure equal odd and even numbers.Upon admission each new patient eligible was assigned the nest available number in the random number list; cases with odd numbers received diphenylhydantoin and cases with even numbers served as control. "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 07:24:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sampliner-1974">
<DESCRIPTION>
<P>"Patients were assigned randomly to diphenylhydantoin or placebo according to a computer generated set of numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 07:41:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santo-1985">
<DESCRIPTION>
<P>a tables of random numbers was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-07 12:41:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schik-2005">
<DESCRIPTION>
<P>"14 patients were assigned randomly to each of the two treatment groups".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:53:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seifert-2004">
<DESCRIPTION>
<P>study described as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:58:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>"Patient was randomised to receive one of the three treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 17:31:27 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stanhope-1989">
<DESCRIPTION>
<P>"Alternate allocation was used rather than random allocation for logistic reason. The initial case was allocated randomly; and on five subsequent occasions, when the code was inadvertently broken, a fresh random start was made"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 07:15:48 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"Patients were randomly allocated to a double blind study comparing CBZ abs oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 11:06:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1998">
<DESCRIPTION>
<P> unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 11:07:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teijeiro-1975">
<DESCRIPTION>
<P>B Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1975">
<DESCRIPTION>
<P>"17 patients have delirium tremens not complicated by other serious illnesses; 17 patients had delirium tremens complicated by serious ilness. The two groups were allocated to therapy by means of separate series of sealed envelopes ordered from random number tables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:01:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Patients were randomised to one or the two treatment group by consecutive assignment of patients identification numbers that had previously been distributed between the two treatments by a computer generated list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-01-08 12:11:07 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-01 19:20:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agricola-1982">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:17:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alldredge-1989">
<DESCRIPTION>
<P>"patients were randomly assigned to receive either diphenylhydantoin sodium injection or infusion of an equivalent volume of 0.9% sodium chloride"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:21:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Balldin-1986">
<DESCRIPTION>
<P>"patients were treated either with alpha2 agonist clonidine or chlorprothixene"</P>
<P>COMMENT: it was not state if the study was randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 11:21:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bjorkqvist-1976">
<DESCRIPTION>
<P>"Patients were randomly allocated to two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:33:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blanchard-1985">
<DESCRIPTION>
<P>"patients were randomised in two parallel group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:36:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bonnet-2003">
<DESCRIPTION>
<P>"patients were randomised to receive either P or GP"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:36:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"the patients were randomly assigned to treatment with either amobarbital, oxazepam or Melperone"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 08:04:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 10:59:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment using a pre-fixed code devised by the hospital pharmacy from a random number table, with a blocked design to ensure roughly equal numbers in the different treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 08:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chance-1991">
<DESCRIPTION>
<P>"Patients were randomly assigned to phenytoin or normal saline. The drugs solutions were in identical vials prepared by the pharmacy in an order determined by random-number tables and sent to the ED labelled only by test solution numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:44:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>"Fifty-two patients after providing written informed consent are randomised to either lorazepam (N=27) or Topiramate (N=25) groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:08:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Croissant-2009">
<DESCRIPTION>
<P>Information on allocation concealment not reported</P>
<P>COMMENT: the concealment is judged inadequate given the type of block randomisation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:50:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dencker-1978">
<DESCRIPTION>
<P>"patients were randomly allocated to either Piracetam or Chlormerhiazole"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-18 21:58:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>"randomised prospective study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:08:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Elsing-2009">
<DESCRIPTION>
<P>"Patients were randomised to receive either GHB (initially 30 mg/kg BWfollowed by 15 mg/kg BW i. v.) or CLO (250 mg every 4 hours as a liquid)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-19 07:07:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Flygering-1984">
<DESCRIPTION>
<P>"Patients were randomly allocated to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:02:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gann-2004">
<DESCRIPTION>
<P>the randomisation list was prepared by the pharmacy. Investigators were unaware of the randomisation code"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:03:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glatt-1966">
<DESCRIPTION>
<P>"The test tablets for each patients were provided with a serial number and distributed within the series by mean of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-19 07:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>"Random selection was achieved by assigning each patients medication by rotation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:10:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The random assignment of patients to treatments was controlled by a study code number;; patients were assigned consecutive numbers. Prepackaged box of study medication corresponding to the patient's code number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:11:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>"patients were randomly assigned to either carbamazepine or diazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-07 10:47:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koethe-2007">
<DESCRIPTION>
<P>"After admission, subjects were randomly assigned to the 2 treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:09:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koppi-1987">
<DESCRIPTION>
<P>"On a random number basis patients were either assigned to Caroverine or meprobamate"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 09:52:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>patients randomly chose from blocks of 15, 20, or 25 envelopes, each envelope containing 1 treatment<BR/>assignment. Assessors were unaware of block sizes and were not involved with any aspect of the randomisation. Patient treatment assignment was kept under lock and key throughout the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:16:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lambie-1980">
<DESCRIPTION>
<P>"Pateints were randomly allocated to one of the two groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 07:42:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Treatment were randomly administered sequentially as the patients were included in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:44:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"Patients were randomised to receive a standard benzodiazepine detoxification or Depakote detox plus maintenance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 08:14:19 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"Assignment took place in blocks of 10 in order of admission ( first 10 patients into group A, next 10 patients into group B, etc)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-22 08:20:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madden-1969">
<DESCRIPTION>
<P>"Patients were randomly allocated to one or other preparation"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:10:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>"Subjetcs were blindly assigned to a group who received carbamazepine or to a group who received oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:51:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Subjects randomisation was based on on a computer generated schedule administered by a research pharmacist not involved in data collection"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:11:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>not specified if providers including subjects were aware of the criteria used to allocate patients to groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:14:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manhem-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-07 11:33:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariani-2006">
<DESCRIPTION>
<P>"The principal investigator conducted all screening interviews and administered all rating scales. The study was<BR/>open-label&#8212;all participants, research staff, and clinical staff were aware of the identity of the treatment medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 12:11:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"The true nature of the medication was known only to the hospital pharmacist who packaged them for each patient according to number. It was agreed that the code could be broken only if a patient's condition deteriorated to the extent that knowledge of the medication he was receiving was essential."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 06:45:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Murphy-1983">
<DESCRIPTION>
<P>"Patients were randomly assigned to one of the treatment group after stratification for age, sex and blood alcohol concentration"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 10:36:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Myrick-2000">
<DESCRIPTION>
<P>"Subjects were placed randomly on Depakote group. The CIWA-ar only group is the comparison group".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:27:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nimmerichter-2002">
<DESCRIPTION>
<P>"Participants were randomised to one of the three treatments by means of a computerized randomisation schedule"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:54:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>"After enrolment, patients were assigned to receive the next in a sequentially numbered supply of medication. The sequence was previously determined by the hospital pharmacist from a table of random numbers with a blocked design to ensure a roughly equal numbers in the two treatment group and in the different season of the year"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:36:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rathlev-1994">
<DESCRIPTION>
<P>"Patients were randomised to receive either phenytoin or saline placebo according to a table of random number"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 07:32:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Reoux-2001">
<DESCRIPTION>
<P>"Subjects were randomly assigned to either a placebo or divalproex sodium condition."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-23 07:41:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ritola-1981">
<DESCRIPTION>
<P>"The patients were randomly allocated to two treatments"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:42:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-1989">
<DESCRIPTION>
<P>"Medication was administered in a randomised double blind manner".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:44:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rosenthal-1998">
<DESCRIPTION>
<P>"Patients were randomised on day 1 to receive either phenobarbital or valproate"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:47:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rothstein-1973">
<DESCRIPTION>
<P>"The 200 patients were randomly assigned to either a diphenylhydantoin group or a control group using the following procedure:at the start of the study we obtained a random number list of 200 number balanced after each 20 to assure equal odd and even numbers.Upon admission each new patient eligible was assigned the nest available number in the random number list; cases with odd numbers received diphenylhydantoin and cases with even numbers served as control. "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 07:24:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sampliner-1974">
<DESCRIPTION>
<P>"Patients were assigned randomly to diphenylhydantoin or placebo according to a computer generated set of numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 07:41:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Santo-1985">
<DESCRIPTION>
<P>a tables of random numbers was used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-12-07 12:41:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schik-2005">
<DESCRIPTION>
<P>"14 patients were assigned randomly to each of the two treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:53:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seifert-2004">
<DESCRIPTION>
<P>study described as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 11:58:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>"Patient was randomised to receive one of the three treatment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-24 17:31:37 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Stanhope-1989">
<DESCRIPTION>
<P>"Alternate allocation was used rather than random allocation for logistic reason. The initial case was allocated randomly; and on five subsequent occasions, when the code was inadvertently broken, a fresh random start was made"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-25 07:15:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"Patients were randomly allocated to a double blind study comparing CBZ abs oxazepam"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 11:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1998">
<DESCRIPTION>
<P> unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-02 11:07:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teijeiro-1975">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 14:58:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1975">
<DESCRIPTION>
<P>"17 patients have delirium tremens not complicated by other serious illnesses; 17 patients had delirium tremens complicated by serious ilness. The two groups were allocated to therapy by means of separate series of sealed envelopes ordered from random number tables"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-15 12:01:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Patients were randomised to one or the two treatment group by consecutive assignment of patients identification numbers that had previously been distributed between the two treatments by a computer generated list of random numbers"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-01-08 12:10:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>subjective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>Objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-01 19:20:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agricola-1982">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-01 19:20:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agricola-1982">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 11:29:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alldredge-1989">
<DESCRIPTION>
<P>study described as "double blind placebo controlled trial". "Both diphenylhydantoin and sodium chloride had an identical appearance" For patients with recurrent seizures, the treating physician could request that the study code be broken and subsequent treatment administered.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-01 19:21:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alldredge-1989">
<DESCRIPTION>
<P>study described as "double blind placebo controlled trial". "Both diphenylhydantoin and sodium chloride had an identical appearance" For patients with recurrent seizures, the treating physician could request that the study code be broken and subsequent treatment administered.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 11:29:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-1986">
<DESCRIPTION>
<P>"the design was double blind and double dummy".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-01 19:22:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-1986">
<DESCRIPTION>
<P>"the design was double blind and double dummy".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 11:30:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjorkqvist-1976">
<DESCRIPTION>
<P>"a double blind technique was used".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:02:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjorkqvist-1976">
<DESCRIPTION>
<P>"a double blind technique was used".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 19:07:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blanchard-1985">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:02:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blanchard-1985">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 19:07:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2003">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:03:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2003">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 12:36:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"patients were treated with amobarbital, oxazepam and Meplerone in a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:03:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"patients were treated with amobarbital, oxazepam and Meplerone in a double blind design".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 08:05:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:05:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 10:59:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:07:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"the patients in each group were randomised to treatment in double blind fashion using a pre-fixed code devised by the hospital pharmacy" "The drugs were masked in the same size capsule and were pre-packaged into daily dosage containers".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 21:41:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chance-1991">
<DESCRIPTION>
<P>"double blind study". "The drugs solutions were in identical vials prepared by the pharmacy". </P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chance-1991">
<DESCRIPTION>
<P>"double blind study". "The drugs solutions were in identical vials prepared by the pharmacy".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-07 12:51:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no information about blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:11:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no information about blindness</P>
<P>COMMENT: objective outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 16:58:30 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Croissant-2009">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-08 12:08:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Croissant-2009">
<DESCRIPTION>
<P>Open label</P>
<P>COMMENT: objective outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-18 21:55:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dencker-1978">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcome assessor: "Al the rating were performed by two psychologists who did not communicate with the nursing staff"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:12:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dencker-1978">
<DESCRIPTION>
<P>study described as "double blind".</P>
<P>Blinding of outcome assessor: "Al the rating were performed by two psychologists who did not communicate with the nursing staff"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 09:27:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>Blindness: not mentioned.</P>
<P>COMMENT: we judged that the study was not blinded because the frequency of drug administration was different between the two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:13:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>Blindness: not mentioned</P>
<P>COMMENT: objective outcomes unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-05 21:15:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Elsing-2009">
<DESCRIPTION>
<P>Open label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-08 12:08:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elsing-2009">
<DESCRIPTION>
<P>Open label</P>
<P>COMMENT: objective outcome unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 13:50:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flygering-1984">
<DESCRIPTION>
<P>a double blind technique were used". Tablets had identical appearance".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:14:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flygering-1984">
<DESCRIPTION>
<P>a double blind technique were used". Tablets had identical appearance".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 11:02:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gann-2004">
<DESCRIPTION>
<P>double blind placebo controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:14:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gann-2004">
<DESCRIPTION>
<P>double blind placebo controlled study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:04:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glatt-1966">
<DESCRIPTION>
<P>"The investigation was carried out as a double blind trial.". To render the placebo indistinguishable in taste from the active tablet, 10 mg of Chlormetiazole was added to the coating of the placebo tablet, an amount that is too small to have any clinical effect". Blindness of outcome assessor: "the outcomes were assessed by a doctor; at the end of the trial he was asked whether he thought the patients had been receiving the active tablet or the placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:15:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glatt-1966">
<DESCRIPTION>
<P>"The investigation was carried out as a double blind trial.". To render the placebo indistinguishable in taste from the active tablet, 10 mg of Chlormetiazole was added to the coating of the placebo tablet, an amount that is too small to have any clinical effect". Blindness of outcome assessor: "the outcomes were assessed by a doctor; at the end of the trial he was asked whether he thought the patients had been receiving the active tablet or the placebo"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 11:05:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>Blinding: Not mentioned.</P>
<P>COMMENT:We judged that the study was not blind because the route of administration of treatment was different (alcohol administered orally vs drug administered intramuscularly)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 08:19:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>Blinding: Not mentioned.</P>
<P>COMMENT: objective outcomes unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 08:22:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The parenteral form of chlordiazepoxide is straw-coloured and required to be mixed with an intramuscular diluent; The IM form of prephenazine is a clear fluid supplied in 2cc. ampoules: IM sodium pentobarbital is colourless fluid, supplied in 5cc ampules.To maintain a partial double blind all IM medication was prepared with matching placebo and each patients was supplied with two injections of equivalent amount, one of which was placebo" "Oral medication other than paraldehyde were in capsule of identical appearance"</P>
<P>.Blinding of outcomes assessor: it was not stated if the outcome assessor was blind,</P>
<P>COMMENT: the authors described the study as partial double blind; we judged that physicians could easily understand the type of treatment given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-08 12:09:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"The parenteral form of chlordiazepoxide is straw-coloured and required to be mixed with an intramuscular diluent; The IM form of perphenazine is a clear fluid supplied in 2cc. ampoules: IM sodium pentobarbital is colourless fluid, supplied in 5cc ampules.To maintain a partial double blind all IM medication was prepared with matching placebo and each patients was supplied with two injections of equivalent amount, one of which was placebo" "Oral medication other than paraldehyde were in capsule of identical appearance"</P>
<P>COMMENT: objective outcomes unlikely to be influenced by lack of physician's blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 08:00:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>blinding not mentioned</P>
<P>COMMENT: there are no sufficient information about treatments to judge if the study could be blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:34:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>blinding not mentioned</P>
<P>COMMENT: objective outcomes unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-07 10:52:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koethe-2007">
<DESCRIPTION>
<P>double blind placebo controlled trial</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:50:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koethe-2007">
<DESCRIPTION>
<P>double blind placebo controlled trial</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:09:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koppi-1987">
<DESCRIPTION>
<P>"double blind". "identical capsules were provided".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:51:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koppi-1987">
<DESCRIPTION>
<P>"double blind". "identical capsules were provided".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 11:30:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment with either barbital (by oral route ) or diazepam (by intramuscular route). Patients received tablets as well as injections when medication was given(active tables plus placebo injection or active injection plus placebo tablet) ".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"The patients were allocated double blind to treatment with either barbital (by oral route ) or diazepam (by intramuscular route). Patients received tablets as well as injections when medication was given(active tables plus placebo injection or active injection plus placebo tablet) ".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 11:33:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>placebo-controlled randomised single-blinded</P>
<P>Blinding of outcome assessor: "raters blind to the treatment assignment administered an alcohol withdrawal severity scale ". Patients blinded to treatment completed a self reported withdrawal symptoms checklist "Because study medications were not encapsulated, there was a potential for subjects to learn their group assignment by studying their medications if they were aware of distinctive markings associated with each study medication. We suspect that the blind was largely intact in this patient group based on informal clinical interactions with patients, although the integrity of the blind was not formally assessed. To promote the integrity of the blind, no medication could be identified by its administration schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-08 12:09:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>placebo-controlled randomised single-blinded</P>
<P>Blinding of outcome assessor: "raters blind to the treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:16:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lambie-1980">
<DESCRIPTION>
<P>"Patients were unaware of which group they were as other drugs described below were also given"</P>
<P>COMMENT: physicians were not blind to treatment; The control group received tranquillizer and/or Chlormethiazole, but it is not specified if the drugs were identical in appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:57:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambie-1980">
<DESCRIPTION>
<P>"Patients were unawere of which group they were as other drugs described below were also given"</P>
<P>COMMENT: The outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 09:58:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Double blind was assured by the double dummy technique in which the patient received equal number of either of the two active drugs and the placebo of the other". </P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 09:58:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>"Double blind was assured by the double dummy technique in which the patient received equal number of either of the two active drugs and the placebo of the other".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 09:59:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>"CIWA-Ar raters were unaware of subjects cohort group assignment"</P>
<P>COMMENT: we judged that the study was not blinded because the treatment differed in duration and way and frequency of drug administration.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:00:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>COMMENT: the outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-22 08:10:40 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"patients, physicians and nurses were not blind to the study medication"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-08 12:10:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>"patients, physicians and nurses were not blind to the study medication"</P>
<P>COMMENT: lack of blinding unlikely to influence outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 10:02:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Madden-1969">
<DESCRIPTION>
<P>"identical capsules were used"</P>
<P>COMMENT: it is not clear if personnel and outcome assessor were blind to treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:03:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madden-1969">
<DESCRIPTION>
<P>"identical capsules were used"</P>
<P>COMMENT: outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-22 08:37:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>study described ad "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:04:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>study described ad "double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-22 08:42:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>Study describes as double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>Study describes as double blind".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 10:11:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>"double blind study" "Medications prepared for the project were identical capsules prepared and distributed by the Alcohol Research Center Shared Scientific Core pharmacists under supervision by the University Research Pharmacy Office"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>"double blind study" "Medications prepared for the project were identical capsules prepared and distributed by the Alcohol Research Center Shared Scientific Core pharmacists under supervision by the University Research Pharmacy Office"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 10:14:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manhem-1985">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:14:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manhem-1985">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-07 11:33:41 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariani-2006">
<DESCRIPTION>
<P>"The study was open-label&#8212;all participants, research staff, and clinical staff were aware of the identity of the treatment medication."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:16:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mariani-2006">
<DESCRIPTION>
<P>"The study was open-label&#8212;all participants, research staff, and clinical staff were aware of the identity of the treatment medication".</P>
<P>COMMENT: objective outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-01 19:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"As the two preparations being tested were very different in presentation, one being a tablet and the other a capsule with Arachis oil, it was decided that both tablet and capsule would be given to each patient. Patients received either active capsules and placebo tablets, or vice versa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:17:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>"As the two preparations being tested were very different in presentation, one being a tablet and the other a capsule with Arachis oil, it was decided that both tablet and capsule would be given to each patient. Patients received either active capsules and placebo tablets, or vice versa."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-23 06:46:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murphy-1983">
<DESCRIPTION>
<P>"The study is a double blind, blindness being achieved by the use of double dummy technique".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:34:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murphy-1983">
<DESCRIPTION>
<P>"The study is a double blind, blindness being achieved by the use of double dummy technique".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:24:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Myrick-2000">
<DESCRIPTION>
<P>"Open label clinical trial".</P>
<P>Blindness of outcome assessor: "CIWA-Ar raters were unaware of treatment assignment"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:36:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Myrick-2000">
<DESCRIPTION>
<P>"Open label clinical trial".</P>
<P>COMMENT: objective outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-23 07:03:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerichter-2002">
<DESCRIPTION>
<P>Double blind, double dummy.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:38:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerichter-2002">
<DESCRIPTION>
<P>Double blind, double dummy.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 11:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>Double blind. "Double dummy administration procedure".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:40:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>Double blind. "Double dummy administration procedure".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:36:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rathlev-1994">
<DESCRIPTION>
<P>Double blind study. "The drugs ware prepared in identical ampoules and were administered in a blinded fashion".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:41:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rathlev-1994">
<DESCRIPTION>
<P>Double blind study. "The drugs ware prepared in identical ampoules and were administered in a blinded fashion".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-23 07:35:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reoux-2001">
<DESCRIPTION>
<P>Study described as double blind. </P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:43:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reoux-2001">
<DESCRIPTION>
<P>Study described as double blind.</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-23 07:43:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritola-1981">
<DESCRIPTION>
<P>"The double blind and double dummy technique was achieved by using placebo capsules and placebo tablets which were given toghether with the arrpopiate active drugs".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:45:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritola-1981">
<DESCRIPTION>
<P>"The double blind and double dummy technique was achieved by using placebo capsules and placebo tablets which were given toghether with the arrpopiate active drugs".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:42:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-1989">
<DESCRIPTION>
<P>"Medication was administered in a randomised double blind manner"..</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:47:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-1989">
<DESCRIPTION>
<P>"Medication was administered in a randomised double blind manner"..</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-23 08:11:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rosenthal-1998">
<DESCRIPTION>
<P>"The study was open label"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:49:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosenthal-1998">
<DESCRIPTION>
<P>"The study was open label"</P>
<P>COMMENT:outcomes are unlikely to be influenced by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-15 14:47:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rothstein-1973">
<DESCRIPTION>
<P>blinding not mentioned</P>
<P>COMMENT: we judged that study was not blind because the diphenylhydantoin group received this drug as an adjunct to the drugs received by the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothstein-1973">
<DESCRIPTION>
<P>blinding not mentioned</P>
<P>COMMENT: outcome unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-24 07:36:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sampliner-1974">
<DESCRIPTION>
<P>"Diphenylhydantoin or placebo were blindly administered." " Diphenylhydantoin and placebo were placed in gelatine capsules"</P>
<P>COMMENT: it is not clear if also personnel and outcome assessors were blind to treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 10:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sampliner-1974">
<DESCRIPTION>
<P>"Diphenylhydantoin or placebo were blindly administered." " Diphenylhydantoin and placebo were placed in gelatine capsules"</P>
<P>COMMENT: it is not clear if also personnel and outcome assessors were blind to treatment assignment but outcomes are unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 07:19:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santo-1985">
<DESCRIPTION>
<P>study described as double blind</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santo-1985">
<DESCRIPTION>
<P>study described as double blind</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-12-07 12:42:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Schik-2005">
<DESCRIPTION>
<P>single blind </P>
<P>"The type of medication was not disclosed to the patient, but the physician who measured withdrawal symptoms of the particular patient was aware of the treatment regimen."<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:01:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schik-2005">
<DESCRIPTION>
<P>"The type of medication was not disclosed to the patient, but the physician who measured withdrawal symptoms of the particular patient was aware of the treatment regimen."</P>
<P>COMMENT: obljective outcomes are unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-24 17:06:26 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seifert-2004">
<DESCRIPTION>
<P>study described as single blind</P>
<P>COMMENT: personnel and outcome assessor not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:02:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seifert-2004">
<DESCRIPTION>
<P>study described as single blind</P>
<P>COMMENT: oucomes unlikely to be biased by lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-24 17:27:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>Study reported as blinded. "The investigator who documented the alcoholism related history was unaware of the treatment and of the complication during the ICU stay"</P>
<P>COMMENT: it is not clear if the patients and outcome assessor were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:03:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>Study reported as blinded. "The investigator who documented the alcoholism related history was unaware of the treatment and of the complication during the ICU stay"</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 07:17:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stanhope-1989">
<DESCRIPTION>
<P>"Identical tablets were supplied by Ciba Geigy"</P>
<P>COMMENT: it is not clear if personnel and outcome assessor were blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:05:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stanhope-1989">
<DESCRIPTION>
<P>"Identical tablets were supplied by Ciba Geigy"</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 07:20:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>Study defined as double blind. "Oxazepam and CBZ were administered in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:05:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>Study defined as double blind. "Oxazepam and CBZ were administered in identical capsules".</P>
<P>Blinding of outcomes assessor: it was not stated if the outcome assessor was blind, but because the outcomes were recorded during the treatment we judged that they were assessed by the blind personnel who gave the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 11:06:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1998">
<DESCRIPTION>
<P>double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:06:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1998">
<DESCRIPTION>
<P>double blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-01-02 11:07:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teijeiro-1975">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:07:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teijeiro-1975">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 07:35:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Thompson-1975">
<DESCRIPTION>
<P>blindness not mentioned</P>
<P>COMMENT: the study was judged not blind because the way of administration were different for two treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:09:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1975">
<DESCRIPTION>
<P>blindness not mentioned</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-25 07:43:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>blindness not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-01-02 11:10:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>blindness not mentioned</P>
<P>COMMENT: outcomes unlikely to be biased by lack of blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-01-08 12:13:36 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes except withdrawal</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-01 19:20:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Agricola-1982">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 12:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alldredge-1989">
<DESCRIPTION>
<P>"Ninety eligible patients completed the study between October 1982 and June 1988"</P>
<P>COMMENT: it is not reported if more than 90 patients were randomised during the study period but they did not complete the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 12:21:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-1986">
<DESCRIPTION>
<P>"two patients in the chlorprothixene group were excluded from day two and four in the clonidine group ". reason fro drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-18 11:33:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bjorkqvist-1976">
<DESCRIPTION>
<P>18 patients dropped out from the carbamazepine group and 18 from the the placebo group. Reason fro drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-18 12:33:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blanchard-1985">
<DESCRIPTION>
<P>1 subject interrupted the treatment in the experimental group and 5 in the placebo group. reason for interruption given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 12:36:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bonnet-2003">
<DESCRIPTION>
<P>"efficacy was analysed for the intention to treat sample, including all subject randomised. Missing data were substituted by an estimated value, derived from regressing the number of CLO capsule on baseline MAWS (for primary effectiveness measure) or by carrying last observation forward"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 12:37:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Borg-1986">
<DESCRIPTION>
<P>"four patients were excluded before the study was finished from the Melperone group because of epileptic fits"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 08:05:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985a">
<DESCRIPTION>
<P>"three patients withdrawn from the study: Two in the minor withdrawal group from the placebo group. One in the major withdrawal group taking chlordiazepoxide". " Analysis of difference between groups was based on intent to treat regardless of subsequent withdrawal from the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 11:00:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burroughs-1985b">
<DESCRIPTION>
<P>"three patients withdrawn from the study: Two in the minor withdrawal group from the placebo group. One in the major withdrawal group taking chlordiazepoxide". " Analysis of difference between groups was based on intent to treat regardless of subsequent withdrawal from the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-18 21:41:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chance-1991">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-07 12:51:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Choi-2005">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-05 16:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Croissant-2009">
<DESCRIPTION>
<P>analysis on an intention-to-treat basis (ITT), including all patients who received at least one dose<BR/>of medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:08:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dencker-1978">
<DESCRIPTION>
<P>"three patients dropped out from trial". One from the Piracetam group, one from the Chlormethiazole group and the third od not stated from which group. Reason fro drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 08:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elsing-1996">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-05 21:20:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Elsing-2009">
<DESCRIPTION>
<P>1 patient dropped out. Reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 08:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Flygering-1984">
<DESCRIPTION>
<P>6 patients dropped out from treatment from each group. Reason fro drop out given.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-07 12:07:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gann-2004">
<DESCRIPTION>
<P>two patients (15%) in the experimental group and four in the placebo group (31%) excluded before the first night because the withdrawal symptoms reached an extent when medication was considered necessary </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 14:04:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glatt-1966">
<DESCRIPTION>
<P>"three patients did not complete the trial, two from the Chlormethiazole and one from the placebo group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-19 07:47:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Golbert-1967">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:09:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kaim-1972">
<DESCRIPTION>
<P>"There were 21 early terminators. 13 for administrative reason and they were not included in the analysis, 8 for treatment failure and they were included in the analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-21 08:56:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kalyoncu-1996">
<DESCRIPTION>
<P>16 patients dropped out from studies. reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-07 10:56:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koethe-2007">
<DESCRIPTION>
<P>3 patients were excluded from the studies from each group; reason given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 14:10:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Koppi-1987">
<DESCRIPTION>
<P>only one patient dropped out from treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:09:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kramp-1978">
<DESCRIPTION>
<P>"18 patients were excluded for reasons unrelated to te treatment, 10 in the diazepam group and 8 in the barbital group". Reason fro exclusion reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 09:55:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krupitsky-2007">
<DESCRIPTION>
<P>"All analyses were performed on an intent-to-treat basis"</P>
<P>133 patients recruited, data presented for 127 patients. No information about the 5 patients not included; the number is small, so it is inlikely that this could bias the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-21 09:33:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lambie-1980">
<DESCRIPTION>
<P>no drop out from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 11:42:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lapierre-1983">
<DESCRIPTION>
<P>No withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-22 08:08:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Longo-2002">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-22 08:16:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lucht-2003">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-22 08:28:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Madden-1969">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-27 08:31:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-1989">
<DESCRIPTION>
<P>20 subjects dropped out from the study. Reason for drop out give, No difference in number of subjects dropped out between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-22 08:48:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Malcolm-2002">
<DESCRIPTION>
<P>"Retention rate did not differ between the groups". Reported flow chart of treatment retention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 11:52:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Malcolm-2007">
<DESCRIPTION>
<P>reported the number of subjects excluded or who dropped out for treatment but not divided for group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 10:14:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manhem-1985">
<DESCRIPTION>
<P> Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-07 11:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mariani-2006">
<DESCRIPTION>
<P>The proportion of completers did not differ between treatment groups: gabapentin, 71%; phenobarbital,<BR/>62%( p : 0.70). reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGrath-1975">
<DESCRIPTION>
<P>14 patients dropped out from Chlordiazepoxide group and 7 from Chlormethiazole because feelings of tension and restlessness or to breaking of the code due to the development of delirium tremens</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 14:22:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Murphy-1983">
<DESCRIPTION>
<P>11 patients dropped out of the trial. Rason for drop out given. Number of drop out balanced among group (5 from Tiapride, 4 from Chlormethiazole, 2 from placebo)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 14:24:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Myrick-2000">
<DESCRIPTION>
<P>no withdrawn from the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 10:38:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nimmerichter-2002">
<DESCRIPTION>
<P>"11 patients discontinued the study prematurely". Reason for drop out given. Analysis performed on the intention to treat basis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 11:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Radouco_x002d_Thomas-1989">
<DESCRIPTION>
<P>7 patients drop out from the study. Reason for drop out given. No differences in the number of drop out between groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-23 07:25:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rathlev-1994">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:12:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Reoux-2001">
<DESCRIPTION>
<P>"7 subjects (3 in the divalproex, 4 in the placebo) dropped out before the remission of the acute withdrawal symptoms and were not included in the analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 14:39:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ritola-1981">
<DESCRIPTION>
<P>5 patients (44 from Chlormethiazole and 1 from carbamazepine) dropped out from the study. Reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-23 07:58:53 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-1989">
<DESCRIPTION>
<P>"The study was stopped when 25% of the patients had been withdrawn from the trial. All 16 patients who received chlormethiazole completed the trial uneventfully. However there was a significant number (8) of withdrawals for the clonidine group (P:0.002) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-23 08:16:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rosenthal-1998">
<DESCRIPTION>
<P>5 patients dropped out from study, 4 from valproate and one from control. Reason fro drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-24 07:22:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rothstein-1973">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-24 07:32:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sampliner-1974">
<DESCRIPTION>
<P>8 patients from diphenylhydantoin group and 13 from the placebo group were excluded from the study. Reason for exclusion given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-08 12:13:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Santo-1985">
<DESCRIPTION>
<P>3 patients from each group were excluded from the study. Reason for exclusion given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-12-07 12:45:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schik-2005">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-24 17:07:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seifert-2004">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-15 11:58:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Spies-1996">
<DESCRIPTION>
<P>6 patients from the flunitrazepam/clonidine group, 10 patients from the Chlormethiazole/haloperidol group, 5 patients in the flunitrazepam/haloperidol group were excluded from the studies for medical reasons described in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-24 17:36:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stanhope-1989">
<DESCRIPTION>
<P>7 patients withdrawn from the study. Reason for withdrawn given. Not specified form which group patients withdrawn, but numbers are small</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-25 07:21:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Stuppaeck-1992">
<DESCRIPTION>
<P>"4 patients from each group dropped out from treatment." Reason for drop out given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 11:06:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Stuppaeck-1998">
<DESCRIPTION>
<P> unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-02 11:07:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Teijeiro-1975">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-25 07:32:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Thompson-1975">
<DESCRIPTION>
<P>no withdrawn from the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-25 07:44:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tubridy-1988">
<DESCRIPTION>
<P>"Data from two patients in each group were lost"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-01-27 11:37:10 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-01-08 14:10:29 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-01-08 14:10:03 +0100" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2010-01-08 14:09:58 +0100" MODIFIED_BY="Grade Profiler">Anticonvulsant versus Placebo for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="7">
<TR>
<TD COLSPAN="7">
<P>
<B>Anticonvulsant versus Placebo for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with alcohol withdrawal<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Anticonvulsant versus Placebo<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anticonvulsant versus Placebo</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol Withdrawal Seizures post treatment - Any Anticonvulsant vs. Placebo</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.61 </B>
<BR/>(0.31 to 1.2)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>883<BR/>(9 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>110 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>67 per 1000</B>
<BR/>(34 to 132)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>102 per 1000</B>
<BR/>(52 to 200)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol Withdrawal Seizures post treatment - Phenytoin vs. Placebo</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.78 </B>
<BR/>(0.35 to 1.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>381<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>180 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>140 per 1000</B>
<BR/>(63 to 319)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>176 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>137 per 1000</B>
<BR/>(62 to 312)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.56 </B>
<BR/>(0.74 to 3.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>663<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>50 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>78 per 1000</B>
<BR/>(37 to 165)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>34 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(25 to 113)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropout - Any Anticonvulsant vs. Placebo</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.82 </B>
<BR/>(0.5 to 1.34)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>344<BR/>(7 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>208 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>171 per 1000</B>
<BR/>(104 to 279)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>182 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>149 per 1000</B>
<BR/>(91 to 244)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropout - Chlormethiazole vs. Placebo</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 1.05 </B>
<BR/>(0.22 to 5.11)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>140<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>46 per 1000</B>
<BR/>(10 to 225)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>21 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>22 per 1000</B>
<BR/>(5 to 107)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealmnt adequate only in 1 on 9 included studies<BR/>
<SUP>2</SUP> Allcation concealment adequate in 1/4 studies<BR/>
<SUP>3</SUP> In 3 studies results were not estimable due no adverse events occurred<BR/>
<SUP>4</SUP> Allocation concealment adequate in 2 on 7 included studies<BR/>
<SUP>5</SUP> only 3 studies considered</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-01-08 14:10:29 +0100" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2010-01-08 14:10:22 +0100" MODIFIED_BY="Grade Profiler">Anticonvulsant versus Other Drugs for alcohol withdrawal</TITLE>
<TABLE COLS="7" ROWS="5">
<TR>
<TD COLSPAN="7">
<P>
<B>Anticonvulsant versus Other Drugs for alcohol withdrawal</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with alcohol withdrawal<BR/>
<B>Settings:</B> <BR/>
<B>Intervention:</B> Anticonvulsant versus Other Drugs<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Anticonvulsant versus Other Drugs</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Alcohol withdrawal seizures - Any Anticonvulsant vs any Other</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.58 </B>
<BR/>(0.22 to 1.58)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>880<BR/>(12 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>27 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
<BR/>(6 to 43)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>19 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>11 per 1000</B>
<BR/>(4 to 30)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Adverse events - Any Anticonvulsant vs any Other</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.71 </B>
<BR/>(0.45 to 1.12)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>726<BR/>(14 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>287 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>204 per 1000</B>
<BR/>(129 to 321)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>188 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
<BR/>(85 to 211)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Dropout - Any Anticonvulsant vs any Other</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>RR 0.92 </B>
<BR/>(0.67 to 1.26)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>1359<BR/>(20 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>114 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>105 per 1000</B>
<BR/>(76 to 144)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Medium risk population</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>99 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>91 per 1000</B>
<BR/>(66 to 125)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; </P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect. <BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment adequate in 2 on 12 included studies<BR/>
<SUP>2</SUP> In 5 studies no events and results not estimable<BR/>
<SUP>3</SUP> Allocation concealment adeqate in 4/14 included studies<BR/>
<SUP>4</SUP> Allocation concealment adequate in 5 on 20 included studies</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-01-08 11:46:14 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2010-01-08 11:24:45 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-01-08 11:15:35 +0100" MODIFIED_BY="[Empty name]">Comparisons Anticonvulsants versus placebo</TITLE>
<TABLE COLS="3" ROWS="18">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (Anticonvulsant)</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Alldredge 1989</P>
</TD>
<TD>
<P>Phenytoin  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Bjorkvist 1976</P>
</TD>
<TD>
<P>Carbamazepine  (34)</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Blanchard 1985</P>
</TD>
<TD>
<P>Phenobarbital</P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Bonnet 2003</P>
</TD>
<TD>
<P>Gabapentin </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985 a </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Chance 1991</P>
</TD>
<TD>
<P>Phenytoin </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Gann 2004</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Glatt 1966</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Golbert 1967  </P>
</TD>
<TD>
<P>Promazine  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Koethe 2007</P>
</TD>
<TD>
<P>Oxcarbazepine </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupitsky 2007</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Lambie 1980</P>
</TD>
<TD>
<P>Valproate  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Murphy 1983</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Rathlev 1994</P>
</TD>
<TD>
<P>Phenytoin </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Reoux 2001</P>
</TD>
<TD>
<P>Divalproex </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Sampliner 1974</P>
</TD>
<TD>
<P>Phenytoin  </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Stanhope 1989 </P>
</TD>
<TD>
<P>Carbamazepine </P>
</TD>
<TD>
<P>Placebo</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-01-08 11:39:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-01-08 11:37:19 +0100" MODIFIED_BY="[Empty name]">Comparisons Anticonvulsants versus Other</TITLE>
<TABLE COLS="3" ROWS="38">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (Anticonvulsant)</P>
</TH>
<TH>
<P>Control (Other)</P>
</TH>
</TR>
<TR>
<TD>
<P>Borg 1986  </P>
</TD>
<TD>
<P>Amobarbital </P>
</TD>
<TD>
<P>Oxazepam  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Borg 1986  </P>
</TD>
<TD>
<P>Amobarbital </P>
</TD>
<TD>
<P>Melperone (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Kramp 1978</P>
</TD>
<TD>
<P>Barbital</P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Agricola 1982  </P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
<TD>
<P>Tiapride (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Kalyoncu 1996</P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 1989</P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
<TD>
<P>Oxazepam  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 2002</P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
<TD>
<P>Lorazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Stuppaeck 1992</P>
</TD>
<TD>
<P>Carbamazepine</P>
</TD>
<TD>
<P>Oxazepam  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985 a </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Bromocriptine (dopamine agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985 a </P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Chlordiazepoxide  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985  b</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Bromocriptine (dopamine agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>Burroughs 1985  b</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Dencker 1978</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Piracetam (CNS stimulant) </P>
</TD>
</TR>
<TR>
<TD>
<P>Elsing 1996</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>GHB (gamma-Hydroxybutyric acid)</P>
</TD>
</TR>
<TR>
<TD>
<P>Elsing 2009</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>GHB (gamma-Hydroxybutyric acid)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lapierre 1983</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Chlordiazepoxide  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Lucht 2003</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Madden 1969</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Trifluoperazine (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Manhem 1985</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Clonidine (adrenergic agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>McGrath 1975</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Murphy 1983</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Tiapride (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Nimmerichter 2002</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>GHB (gamma-Hydroxybutyric acid)</P>
</TD>
</TR>
<TR>
<TD>
<P>Robinson 1989</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Clonidine (adrenergic agonist) </P>
</TD>
</TR>
<TR>
<TD>
<P>Tubridy 1988</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Alprazolam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Longo 2002</P>
</TD>
<TD>
<P>Depakote </P>
</TD>
<TD>
<P>Chlordiazepoxide or Loranzepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Malcom 2007</P>
</TD>
<TD>
<P>Gabapentin</P>
</TD>
<TD>
<P>Lorazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Koppi 1987</P>
</TD>
<TD>
<P>Meprobamate </P>
</TD>
<TD>
<P>Caroverine (spasmolytic) </P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1972</P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
<TD>
<P>Perhenazine  (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1972</P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
<TD>
<P>Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Thompson 1975</P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golbert 1967 a </P>
</TD>
<TD>
<P>Promazine</P>
</TD>
<TD>
<P>Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Raduco-Thomas 1989</P>
</TD>
<TD>
<P>Tetrabamate </P>
</TD>
<TD>
<P>Chlordiazepoxide  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Santo 1985</P>
</TD>
<TD>
<P>Tetrabamate </P>
</TD>
<TD>
<P>Tiapride (Antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Choi 2005</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
<TD>
<P>Lorazepam  (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupitsky 2007</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Author</P>
</TD>
<TD>
<P>Treatment (Anticonvulsant)</P>
</TD>
<TD>
<P>Control</P>
</TD>
</TR>
<TR>
<TD>
<P>Stuppaeck 1998</P>
</TD>
<TD>
<P>Vigabatrin </P>
</TD>
<TD>
<P>Oxazepam  (benzodiazepine)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-01-08 11:41:10 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-01-08 11:39:45 +0100" MODIFIED_BY="[Empty name]">Comparisons Anticonvulsant 1 versus Anticonvulsant 2</TITLE>
<TABLE COLS="3" ROWS="12">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (Anticonvulsant 1)</P>
</TH>
<TH>
<P>Control (Anticonvulsant 2)</P>
</TH>
</TR>
<TR>
<TD>
<P>Flygering 1984</P>
</TD>
<TD>
<P>Carbamazepine  </P>
</TD>
<TD>
<P>Barbital</P>
</TD>
</TR>
<TR>
<TD>
<P>Scik 2005</P>
</TD>
<TD>
<P>Carbamazepine  </P>
</TD>
<TD>
<P>Oxcarbazepine </P>
</TD>
</TR>
<TR>
<TD>
<P>Mariani 2006</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Phenobarbital </P>
</TD>
</TR>
<TR>
<TD>
<P>Ritola 1981</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Carbamazepine  </P>
</TD>
</TR>
<TR>
<TD>
<P>Seifert 2004</P>
</TD>
<TD>
<P>Chlormethiazole </P>
</TD>
<TD>
<P>Carbamazepine </P>
</TD>
</TR>
<TR>
<TD>
<P>Teijeiro 1975</P>
</TD>
<TD>
<P>Heminiurine </P>
</TD>
<TD>
<P>Phenobarbital+ Ferbamate (tranquillizes)</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaim 1972</P>
</TD>
<TD>
<P>Paraldehyde </P>
</TD>
<TD>
<P>Pentobarbital </P>
</TD>
</TR>
<TR>
<TD>
<P>Golbert 1967  b</P>
</TD>
<TD>
<P>Promazine  </P>
</TD>
<TD>
<P>Paraldehyde and Chloral hydrate (sedative)</P>
</TD>
</TR>
<TR>
<TD>
<P>Krupitsky 2007</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
<TD>
<P>Memantine </P>
</TD>
</TR>
<TR>
<TD>
<P>Krupitsky 2007</P>
</TD>
<TD>
<P>Topiramate </P>
</TD>
<TD>
<P>Lamotrigine</P>
</TD>
</TR>
<TR>
<TD>
<P>Rosenthal 1998</P>
</TD>
<TD>
<P>Valproate  </P>
</TD>
<TD>
<P>Phenobarbital </P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2010-01-08 11:46:14 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-01-08 11:41:45 +0100" MODIFIED_BY="[Empty name]">Anticonvulsant + Other versus Other</TITLE>
<TABLE COLS="3" ROWS="8">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (Anticonvulsant+Other)</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<TR>
<TD>
<P>Balldin 1986</P>
</TD>
<TD>
<P>Carbamazepine +Chlorprothixen (antipsychotic)</P>
</TD>
<TD>
<P>Clonidine (adrenergic agonist)  </P>
</TD>
</TR>
<TR>
<TD>
<P>Lucht 2003</P>
</TD>
<TD>
<P>Carbamazepine+Tiapride (antipsychotic)</P>
</TD>
<TD>
<P>Diazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Spies 1996</P>
</TD>
<TD>
<P>Chlormethiazole+Haloperidol (antipsychotic)</P>
</TD>
<TD>
<P>Clonidine (adrenergic agonist)+fFunitrazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Spies 1996</P>
</TD>
<TD>
<P>Chlormethiazole+Haloperidol (antipsychotic)</P>
</TD>
<TD>
<P>Funitrazepam (benzodiazepine)+ Haloperidol (antipsychotic)</P>
</TD>
</TR>
<TR>
<TD>
<P>Rothstein 1973</P>
</TD>
<TD>
<P>Diphenylhydantoin </P>
</TD>
<TD>
<P>Tiamine (antipsychotic)+ Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Myrick 2000</P>
</TD>
<TD>
<P>Divalproex+Lorazepam (benzodiazepine)</P>
</TD>
<TD>
<P>Lorazepam (benzodiazepine)</P>
</TD>
</TR>
<TR>
<TD>
<P>Golbert 1967  </P>
</TD>
<TD>
<P>Paraldehyde and Chloral hydrate (sedative)</P>
</TD>
<TD>
<P>Chlordiazepoxide (benzodiazepine)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2010-01-08 11:45:48 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-01-08 11:43:52 +0100" MODIFIED_BY="[Empty name]">Comparison Anticonvulsant 1 + Other versus Anticonvulsant 2</TITLE>
<TABLE COLS="3" ROWS="2">
<TR>
<TH>
<P>Author</P>
</TH>
<TH>
<P>Treatment (Anticonvulsant 1+other)</P>
</TH>
<TH>
<P>Control (Anticonvulsant 2)</P>
</TH>
</TR>
<TR>
<TD>
<P>Croissant 2009</P>
</TD>
<TD>
<P>Oxcarbazepine + Tiapride (antipsychotic)</P>
</TD>
<TD>
<P>Chlormethiazole</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-01-08 13:08:27 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-01-08 13:08:27 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Anticonvulsant versus Placebo</NAME>
<DICH_OUTCOME CHI2="17.917296558950426" CI_END="1.136684999604609" CI_START="0.3993254466657519" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6737263874789011" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="81" I2="38.606809549596655" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.055640128814986575" LOG_CI_START="-0.3986730138868227" LOG_EFFECT_SIZE="-0.1715164425359181" METHOD="MH" MODIFIED="2010-01-03 15:00:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.08351961751904435" P_Q="0.0" P_Z="0.13890341353091665" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.2504559489162294" TOTALS="SUB" TOTAL_1="648" TOTAL_2="616" WEIGHT="200.0" Z="1.4798869701529966">
<NAME>Alcohol Withdrawal Seizures post treatment</NAME>
<GROUP_LABEL_1>Any Anticonvulsants</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours anticonvulsants</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="11.605938658592233" CI_END="1.1985664435351313" CI_START="0.3070382991182543" DF="7" EFFECT_SIZE="0.6066348178296741" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="47" I2="39.68605034098052" ID="CMP-001.01.01" LOG_CI_END="0.07866211451553909" LOG_CI_START="-0.5128074484371685" LOG_EFFECT_SIZE="-0.21707266696081473" MODIFIED="2009-04-28 09:17:37 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.11428553474852443" P_Z="0.15025377089376582" STUDIES="9" TAU2="0.33778049404956356" TOTAL_1="456" TOTAL_2="427" WEIGHT="99.99999999999999" Z="1.4386356827807651">
<NAME>Any Anticonvulsant vs. Placebo</NAME>
<DICH_DATA CI_END="3.3485519533246864" CI_START="0.39986824469224624" EFFECT_SIZE="1.1571428571428573" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5248570414735398" LOG_CI_START="-0.39808308374475404" LOG_EFFECT_SIZE="0.06338697886439296" ORDER="138" O_E="0.0" SE="0.5421395981805276" STUDY_ID="STD-Chance-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.29391534391534396" WEIGHT="19.108737302608912"/>
<DICH_DATA CI_END="2.867524138797526" CI_START="0.3487328969510758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4575070824765104" LOG_CI_START="-0.45750708247651045" LOG_EFFECT_SIZE="0.0" ORDER="136" O_E="0.0" SE="0.53748384988657" STUDY_ID="STD-Alldredge-1989" TOTAL_1="45" TOTAL_2="45" VAR="0.2888888888888889" WEIGHT="19.262006652091944"/>
<DICH_DATA CI_END="0.8757742131628097" CI_START="0.012219526012517176" EFFECT_SIZE="0.10344827586206896" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="-0.057607846590767224" LOG_CI_START="-1.9129456397678202" LOG_EFFECT_SIZE="-0.9852767431792937" ORDER="140" O_E="0.0" SE="1.089834603782396" STUDY_ID="STD-Murphy-1983" TOTAL_1="29" TOTAL_2="9" VAR="1.1877394636015324" WEIGHT="7.912652838320704"/>
<DICH_DATA CI_END="1.821522578711069" CI_START="0.41300103605390304" EFFECT_SIZE="0.8673469387755102" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.26043455891521244" LOG_CI_START="-0.3840488588716167" LOG_EFFECT_SIZE="-0.061807149978202136" ORDER="141" O_E="0.0" SE="0.3785727498523531" STUDY_ID="STD-Rathlev-1994" TOTAL_1="49" TOTAL_2="51" VAR="0.14331732693077232" WEIGHT="25.090343993298198"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="137" O_E="0.0" SE="0.0" STUDY_ID="STD-Bonnet-2003" TOTAL_1="32" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.8980892234779834" CI_START="0.006452951438985161" EFFECT_SIZE="0.11067193675889328" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.2783166234513302" LOG_CI_START="-2.1902416031185274" LOG_EFFECT_SIZE="-0.9559624898335987" ORDER="139" O_E="0.0" SE="1.4500433218474305" STUDY_ID="STD-Lambie-1980" TOTAL_1="22" TOTAL_2="27" VAR="2.1026256352343307" WEIGHT="4.94627090055903"/>
<DICH_DATA CI_END="16.375032987266717" CI_START="0.07167076316876522" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2141821835446438" LOG_CI_START="-1.14465797102622" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2009-04-28 09:17:04 +0200" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="1.385594383242006" STUDY_ID="STD-Koethe-2007" TOTAL_1="24" TOTAL_2="26" VAR="1.9198717948717947" WEIGHT="5.346664710972814"/>
<DICH_DATA CI_END="0.6826272649403843" CI_START="0.002466003027288192" EFFECT_SIZE="0.04102878138395591" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.16581636947565842" LOG_CI_START="-2.6080063945960252" LOG_EFFECT_SIZE="-1.3869113820358416" ORDER="142" O_E="0.0" SE="1.434554509791297" STUDY_ID="STD-Sampliner-1974" TOTAL_1="70" TOTAL_2="66" VAR="2.0579466415625487" WEIGHT="5.038516132906215"/>
<DICH_DATA CI_END="3.0846995872036467" CI_START="0.15986191683935122" EFFECT_SIZE="0.7022292993630573" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.48921287534736907" LOG_CI_START="-0.7962549838860842" LOG_EFFECT_SIZE="-0.15352105426935758" ORDER="143" O_E="0.0" SE="0.7550901836822576" STUDY_ID="STD-Stanhope-1989" TOTAL_1="157" TOTAL_2="147" VAR="0.5701611854933055" WEIGHT="13.294807469242178"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.051947031164019" CI_END="1.77334445167843" CI_START="0.34616445915462996" DF="3" EFFECT_SIZE="0.7834978130219175" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="34" I2="50.429176188229356" ID="CMP-001.01.02" LOG_CI_END="0.2487931004818442" LOG_CI_START="-0.46071752336232347" LOG_EFFECT_SIZE="-0.10596221144023965" NO="2" P_CHI2="0.10911011864446629" P_Z="0.5582629528514151" STUDIES="4" TAU2="0.3292834469836151" TOTAL_1="192" TOTAL_2="189" WEIGHT="100.00000000000001" Z="0.5854235614397278">
<NAME>Phenytoin vs. Placebo</NAME>
<DICH_DATA CI_END="3.3485519533246864" CI_START="0.39986824469224624" EFFECT_SIZE="1.1571428571428573" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5248570414735398" LOG_CI_START="-0.39808308374475404" LOG_EFFECT_SIZE="0.06338697886439296" ORDER="145" O_E="0.0" SE="0.5421395981805276" STUDY_ID="STD-Chance-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.29391534391534396" WEIGHT="27.8718892373371"/>
<DICH_DATA CI_END="1.821522578711069" CI_START="0.41300103605390304" EFFECT_SIZE="0.8673469387755102" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.26043455891521244" LOG_CI_START="-0.3840488588716167" LOG_EFFECT_SIZE="-0.061807149978202136" ORDER="146" O_E="0.0" SE="0.3785727498523531" STUDY_ID="STD-Rathlev-1994" TOTAL_1="49" TOTAL_2="51" VAR="0.14331732693077232" WEIGHT="36.75348969260206"/>
<DICH_DATA CI_END="2.867524138797526" CI_START="0.3487328969510758" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.4575070824765104" LOG_CI_START="-0.45750708247651045" LOG_EFFECT_SIZE="0.0" ORDER="144" O_E="0.0" SE="0.53748384988657" STUDY_ID="STD-Alldredge-1989" TOTAL_1="45" TOTAL_2="45" VAR="0.2888888888888889" WEIGHT="28.098519886468427"/>
<DICH_DATA CI_END="0.6826272649403843" CI_START="0.002466003027288192" EFFECT_SIZE="0.04102878138395591" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="11" LOG_CI_END="-0.16581636947565842" LOG_CI_START="-2.6080063945960252" LOG_EFFECT_SIZE="-1.3869113820358416" ORDER="147" O_E="0.0" SE="1.434554509791297" STUDY_ID="STD-Sampliner-1974" TOTAL_1="70" TOTAL_2="66" VAR="2.0579466415625487" WEIGHT="7.276101183592425"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.093089967026098" CI_END="3.312697343856411" CI_START="0.7359630316135095" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5614169142168866" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" I2="26.705740060248438" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.5201817594867536" LOG_CI_START="-0.1331440002949562" LOG_EFFECT_SIZE="0.19351887959589864" METHOD="MH" MODIFIED="2010-01-08 13:06:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.25158606304042985" P_Q="0.0" P_Z="0.24559905836273166" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.15754374725792447" TOTALS="YES" TOTAL_1="362" TOTAL_2="301" WEIGHT="100.0" Z="1.161105401578635">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Any Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 09:52:31 +0200" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.0" STUDY_ID="STD-Chance-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.952692241593713" CI_START="0.0648728281429768" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1123600467297645" LOG_CI_START="-1.187937168508564" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-01-05 15:03:19 +0100" MODIFIED_BY="[Empty name]" ORDER="162" O_E="0.0" SE="1.3512059708858513" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="11" VAR="1.825757575757576" WEIGHT="7.425848195552381"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 09:54:44 +0200" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.0" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="77" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="12.359538083505925" CI_START="1.1527068539003789" EFFECT_SIZE="3.7745098039215685" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" LOG_CI_END="1.0920022400462344" LOG_CI_START="0.06171887544693179" LOG_EFFECT_SIZE="0.5768605577465831" MODIFIED="2009-04-28 09:52:09 +0200" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.6051935483505366" STUDY_ID="STD-Bjorkqvist-1976" TOTAL_1="34" TOTAL_2="35" VAR="0.36625923096511326" WEIGHT="28.116859130343055"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 09:53:04 +0200" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="0.0" STUDY_ID="STD-Lambie-1980" TOTAL_1="22" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.2131669549257493" CI_START="0.25770293807556227" EFFECT_SIZE="0.7552083333333334" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.34501417708497534" LOG_CI_START="-0.5888806300221248" LOG_EFFECT_SIZE="-0.12193322646857468" MODIFIED="2009-04-28 09:52:17 +0200" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.5485744325485622" STUDY_ID="STD-Bonnet-2003" TOTAL_1="32" TOTAL_2="29" VAR="0.300933908045977" WEIGHT="32.123036707184916"/>
<DICH_DATA CI_END="4.912563888043162" CI_START="0.578192113263868" EFFECT_SIZE="1.6853503184713376" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.6913082114331898" LOG_CI_START="-0.23792783654869276" LOG_EFFECT_SIZE="0.22669018744224845" MODIFIED="2010-01-08 13:06:00 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.5458378543771798" STUDY_ID="STD-Stanhope-1989" TOTAL_1="157" TOTAL_2="147" VAR="0.2979389632710834" WEIGHT="32.33425596691964"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.4262979236699" CI_END="1.3391495576708878" CI_START="0.5196276497154414" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8341817171755782" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.12682908219804265" LOG_CI_START="-0.28430774790047825" LOG_EFFECT_SIZE="-0.07873933285121784" METHOD="MH" MODIFIED="2010-01-04 20:42:26 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.49182072330448845" P_Q="0.0" P_Z="0.4528155209328223" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="248" TOTAL_2="236" WEIGHT="200.0" Z="0.7507294178345307">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Any Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.504191224993314" CI_END="1.339215611971214" CI_START="0.49656749343464013" DF="6" EFFECT_SIZE="0.8154820289896543" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="35" I2="7.751789693019558" ID="CMP-001.03.01" LOG_CI_END="0.1268505034877671" LOG_CI_START="-0.30402171386730314" LOG_EFFECT_SIZE="-0.088585605189768" MODIFIED="2010-01-04 20:38:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3691377770333779" P_Z="0.4202881105341567" STUDIES="7" TAU2="0.04834988086948492" TOTAL_1="176" TOTAL_2="168" WEIGHT="100.0" Z="0.8059215179221011">
<NAME>Any Anticonvulsant vs. Placebo</NAME>
<DICH_DATA CI_END="54.867363612714385" CI_START="0.11391106822839378" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7393140927647355" LOG_CI_START="-0.9434340754206603" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-04-28 10:02:07 +0200" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Gann-2004" TOTAL_1="11" TOTAL_2="9" VAR="2.483333333333333" WEIGHT="2.530246456223867"/>
<DICH_DATA CI_END="3.4686205243967656" CI_START="0.00982605044194444" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5401567895580695" LOG_CI_START="-2.007621010748531" LOG_EFFECT_SIZE="-0.7337321105952308" MODIFIED="2010-01-04 20:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="1.4965772916036075" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="11" VAR="2.2397435897435893" WEIGHT="2.799615733924435"/>
<DICH_DATA CI_END="1.726682756420425" CI_START="0.0761032966312917" EFFECT_SIZE="0.3625" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.23721255193216262" LOG_CI_START="-1.1185965301181375" LOG_EFFECT_SIZE="-0.4406919890929875" ORDER="166" O_E="0.0" SE="0.7964089661595419" STUDY_ID="STD-Bonnet-2003" TOTAL_1="32" TOTAL_2="29" VAR="0.6342672413793103" WEIGHT="9.384151484385704"/>
<DICH_DATA CI_END="20.900106829084805" CI_START="0.18365459553763844" EFFECT_SIZE="1.9591836734693877" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201485059753346" LOG_CI_START="-0.735998199953225" LOG_EFFECT_SIZE="0.29207515301105474" ORDER="168" O_E="0.0" SE="1.2077907531527805" STUDY_ID="STD-Glatt-1966" TOTAL_1="49" TOTAL_2="48" VAR="1.4587585034013606" WEIGHT="4.250379433803835"/>
<DICH_DATA CI_END="2.8839888386619457" CI_START="0.19504236370795983" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.45999357528563434" LOG_CI_START="-0.7098710485022344" LOG_EFFECT_SIZE="-0.12493873660829993" ORDER="169" O_E="0.0" SE="0.6871842709362767" STUDY_ID="STD-Reoux-2001" TOTAL_1="18" TOTAL_2="18" VAR="0.4722222222222221" WEIGHT="12.305274222290874"/>
<DICH_DATA CI_END="1.398823591243451" CI_START="0.023162320254549597" EFFECT_SIZE="0.18" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.145762948101359" LOG_CI_START="-1.635217937894747" LOG_EFFECT_SIZE="-0.744727494896694" ORDER="165" O_E="0.0" SE="1.046156988431681" STUDY_ID="STD-Blanchard-1985" TOTAL_1="20" TOTAL_2="18" VAR="1.0944444444444443" WEIGHT="5.605367771894072"/>
<DICH_DATA CI_END="1.6172858126844822" CI_START="0.6552265363386417" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.20878677680374455" LOG_CI_START="-0.18360852218770363" LOG_EFFECT_SIZE="0.012589127308020467" ORDER="164" O_E="0.0" SE="0.2304949410156331" STUDY_ID="STD-Bjorkqvist-1976" TOTAL_1="34" TOTAL_2="35" VAR="0.05312791783380018" WEIGHT="63.124964897477206"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9458719184542979" CI_END="5.1112104897809765" CI_START="0.21592949998469793" DF="2" EFFECT_SIZE="1.0505527713422822" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.7085237664312755" LOG_CI_START="-0.6656880209109115" LOG_EFFECT_SIZE="0.021417872760182068" MODIFIED="2010-01-04 20:42:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.37797178476427884" P_Z="0.9512841020805793" STUDIES="3" TAU2="0.0" TOTAL_1="72" TOTAL_2="68" WEIGHT="100.0" Z="0.06109430820209589">
<NAME>Chlormethiazole vs. Placebo</NAME>
<DICH_DATA CI_END="54.867363612714385" CI_START="0.11391106822839378" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7393140927647355" LOG_CI_START="-0.9434340754206603" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2010-01-04 20:39:41 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="1.5758595538097082" STUDY_ID="STD-Gann-2004" TOTAL_1="11" TOTAL_2="9" VAR="2.483333333333333" WEIGHT="26.239014817996768"/>
<DICH_DATA CI_END="3.4686205243967656" CI_START="0.00982605044194444" EFFECT_SIZE="0.18461538461538463" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5401567895580695" LOG_CI_START="-2.007621010748531" LOG_EFFECT_SIZE="-0.7337321105952308" MODIFIED="2010-01-04 20:42:26 +0100" MODIFIED_BY="[Empty name]" ORDER="607" O_E="0.0" SE="1.4965772916036075" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="11" VAR="2.2397435897435893" WEIGHT="29.092714197172146"/>
<DICH_DATA CI_END="20.900106829084805" CI_START="0.18365459553763844" EFFECT_SIZE="1.9591836734693877" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3201485059753346" LOG_CI_START="-0.735998199953225" LOG_EFFECT_SIZE="0.29207515301105474" ORDER="171" O_E="0.0" SE="1.2077907531527805" STUDY_ID="STD-Glatt-1966" TOTAL_1="49" TOTAL_2="48" VAR="1.4587585034013606" WEIGHT="44.668270984831096"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.246846443655531" CI_END="3.3611640504079174" CI_START="0.13390237906785998" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.67087097327801" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.5264897098655518" LOG_CI_START="-0.8732117067305979" LOG_EFFECT_SIZE="-0.17336099843252312" METHOD="MH" MODIFIED="2010-01-08 13:08:27 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5361064085857566" P_Q="0.0" P_Z="0.6273178694549854" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="329" TOTAL_2="320" WEIGHT="100.0" Z="0.4855054216890684">
<NAME>Dropout due to adverse events</NAME>
<GROUP_LABEL_1>Any Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="161" O_E="0.0" SE="0.0" STUDY_ID="STD-Chance-1991" TOTAL_1="28" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="6.8502878048371185" CI_START="0.013820522423330348" EFFECT_SIZE="0.3076923076923077" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8357088181240913" LOG_CI_START="-1.8594755400818397" LOG_EFFECT_SIZE="-0.5118833609788743" MODIFIED="2010-01-04 20:44:06 +0100" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="1.583164633387904" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="11" VAR="2.506410256410256" WEIGHT="26.970801285996803"/>
<DICH_DATA CI_END="4.73832260562281" CI_START="0.043332268128250896" EFFECT_SIZE="0.453125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6756246260516263" LOG_CI_START="-1.3631885782214883" LOG_EFFECT_SIZE="-0.3437819760849311" ORDER="159" O_E="0.0" SE="1.197608968478155" STUDY_ID="STD-Bonnet-2003" TOTAL_1="32" TOTAL_2="29" VAR="1.4342672413793103" WEIGHT="47.132006516313965"/>
<DICH_DATA CI_END="73.21457045001645" CI_START="0.13005106216612491" EFFECT_SIZE="3.085714285714286" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864597518713366" LOG_CI_START="-0.8858860964400181" LOG_EFFECT_SIZE="0.4893557111366741" ORDER="157" O_E="0.0" SE="1.6156476906545747" STUDY_ID="STD-Bjorkqvist-1976" TOTAL_1="34" TOTAL_2="35" VAR="2.6103174603174604" WEIGHT="25.897192197689236"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="162" O_E="0.0" SE="0.0" STUDY_ID="STD-Lambie-1980" TOTAL_1="22" TOTAL_2="27" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-08 13:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.0" STUDY_ID="STD-Koethe-2007" TOTAL_1="24" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="158" O_E="0.0" SE="0.0" STUDY_ID="STD-Blanchard-1985" TOTAL_1="20" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="163" O_E="0.0" SE="0.0" STUDY_ID="STD-Stanhope-1989" TOTAL_1="157" TOTAL_2="147" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-01-06 10:19:34 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Anticonvulsant versus Other Drugs</NAME>
<DICH_OUTCOME CHI2="3.5510093575918034" CI_END="1.4394185436435243" CI_START="0.21662639075971962" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5584049103492095" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.15818709328699032" LOG_CI_START="-0.6642886360618326" LOG_EFFECT_SIZE="-0.2530507713874211" METHOD="MH" MODIFIED="2010-01-03 15:03:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8951950120529684" P_Q="0.0" P_Z="0.22780107356922275" Q="0.0" RANDOM="YES" SCALE="1000000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="469" TOTAL_2="566" WEIGHT="200.0" Z="1.2060426356218386">
<NAME>Alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4654279041793252" CI_END="1.5770414917882971" CI_START="0.21683870332165678" DF="7" EFFECT_SIZE="0.5847765660180182" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="13" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.19784311971929736" LOG_CI_START="-0.6638631984304261" LOG_EFFECT_SIZE="-0.23301003935556439" MODIFIED="2009-09-21 15:11:07 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8388737567152932" P_Z="0.28915840897426615" STUDIES="12" TAU2="0.0" TOTAL_1="394" TOTAL_2="486" WEIGHT="100.0" Z="1.059969680050125">
<NAME>Any Anticonvulsant vs any Other</NAME>
<DICH_DATA CI_END="13.06153111919288" CI_START="0.11192415445828816" EFFECT_SIZE="1.209090909090909" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="1.1159940894689777" LOG_CI_START="-0.9510761778512562" LOG_EFFECT_SIZE="0.08245895580886071" MODIFIED="2009-09-08 11:59:37 +0200" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.2142073071867507" STUDY_ID="STD-Kaim-1972" TOTAL_1="55" TOTAL_2="133" VAR="1.4742993848257007" WEIGHT="17.378331375867823"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="227" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="219" O_E="0.0" SE="0.0" STUDY_ID="STD-Agricola-1982" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.859591833249636" CI_START="0.01413700780758877" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8953999927098686" LOG_CI_START="-1.8496425021491938" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="229" O_E="0.0" SE="1.61245154965971" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.6" WEIGHT="9.854178175668885"/>
<DICH_DATA CI_END="1.9767747378552125" CI_START="0.005671396163491954" EFFECT_SIZE="0.10588235294117647" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.2959571823736946" LOG_CI_START="-2.24631001492363" LOG_EFFECT_SIZE="-0.9751764162749679" ORDER="228" O_E="0.0" SE="1.4933403361180344" STUDY_ID="STD-Robinson-1989" TOTAL_1="16" TOTAL_2="8" VAR="2.2300653594771243" WEIGHT="11.4888396198156"/>
<DICH_DATA CI_END="14.515071470356197" CI_START="0.06037963154781152" EFFECT_SIZE="0.9361702127659575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1618191785834624" LOG_CI_START="-1.2191095414825224" LOG_EFFECT_SIZE="-0.02864518144953002" ORDER="223" O_E="0.0" SE="1.3985693159540025" STUDY_ID="STD-Kramp-1978" TOTAL_1="47" TOTAL_2="44" VAR="1.9559961315280465" WEIGHT="13.098626752765504"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="222" O_E="0.0" SE="0.0" STUDY_ID="STD-Koppi-1987" TOTAL_1="10" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="220" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="12.042911822479029"/>
<DICH_DATA CI_END="15.773173963622442" CI_START="0.06784649559762428" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1979190932141033" LOG_CI_START="-1.1684725795726907" LOG_EFFECT_SIZE="0.014723256820706378" ORDER="225" O_E="0.0" SE="1.3900301824226613" STUDY_ID="STD-Murphy-1983" TOTAL_1="29" TOTAL_2="30" VAR="1.9321839080459768" WEIGHT="13.260054154290911"/>
<DICH_DATA CI_END="8.325049892469536" CI_START="0.014559328127105092" EFFECT_SIZE="0.34814814814814815" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9203868449362289" LOG_CI_START="-1.836858666054806" LOG_EFFECT_SIZE="-0.45823591055928864" ORDER="230" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="2.6231678486997634" WEIGHT="9.76714596034665"/>
<DICH_DATA CI_END="30.50361238600261" CI_START="0.12718841635339334" EFFECT_SIZE="1.9696969696969697" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.484351273655277" LOG_CI_START="-0.8955524401253407" LOG_EFFECT_SIZE="0.2943994167649681" ORDER="226" O_E="0.0" SE="1.397967222188115" STUDY_ID="STD-Nimmerichter-2002" TOTAL_1="33" TOTAL_2="65" VAR="1.9543123543123544" WEIGHT="13.109912138765594"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="224" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="59" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.325049892469536" CI_START="0.014559328127105092" DF="0" EFFECT_SIZE="0.3481481481481482" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.9203868449362289" LOG_CI_START="-1.836858666054806" LOG_EFFECT_SIZE="-0.4582359105592886" MODIFIED="2009-12-14 13:34:49 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5147457084220499" STUDIES="2" TAU2="0.0" TOTAL_1="75" TOTAL_2="80" WEIGHT="100.00000000000001" Z="0.6514660210989413">
<NAME>Chlormethiazole vs Benzodiazepine</NAME>
<DICH_DATA CI_END="8.325049892469536" CI_START="0.014559328127105092" EFFECT_SIZE="0.34814814814814815" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9203868449362289" LOG_CI_START="-1.836858666054806" LOG_EFFECT_SIZE="-0.45823591055928864" ORDER="244" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="2.6231678486997634" WEIGHT="100.00000000000001"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="243" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="31" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.349461343061376" CI_END="3.1316584318681535" CI_START="0.25786778376525976" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.898639983161015" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" I2="18.361363915947425" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.4957743877268056" LOG_CI_START="-0.5886029122510879" LOG_EFFECT_SIZE="-0.04641426226214118" METHOD="MH" MODIFIED="2010-01-03 15:04:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28973443282595857" P_Q="0.0" P_Z="0.8667536427413983" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.446949234858719" TOTALS="SUB" TOTAL_1="270" TOTAL_2="249" WEIGHT="199.99999999999997" Z="0.16778345028920802">
<NAME>Alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>Anticonvulsants</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.110943235838861" CI_END="3.4160979952829376" CI_START="0.22630010987687652" DF="4" EFFECT_SIZE="0.8792402127306885" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="21.73655985941549" ID="CMP-002.02.01" LOG_CI_END="0.533530320506487" LOG_CI_START="-0.645315235179564" LOG_EFFECT_SIZE="-0.055892457336538526" MODIFIED="2010-01-03 08:30:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.27610237184601105" P_Z="0.8525584282409797" STUDIES="6" TAU2="0.5225779955038713" TOTAL_1="208" TOTAL_2="186" WEIGHT="99.99999999999997" Z="0.18585505600571062">
<NAME>Any Anticonvulsant vs any Other</NAME>
<DICH_DATA CI_END="2.0109804706541157" CI_START="0.006139134214630123" EFFECT_SIZE="0.1111111111111111" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3034078530291955" LOG_CI_START="-2.2118928719078457" LOG_EFFECT_SIZE="-0.9542425094393249" MODIFIED="2010-01-03 08:30:36 +0100" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="1.4775000967674123" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="2.1830065359477127" WEIGHT="17.722619679128403"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="248" O_E="0.0" SE="0.0" STUDY_ID="STD-Murphy-1983" TOTAL_1="29" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="103.32564341375783" CI_START="0.25639535024995097" EFFECT_SIZE="5.147058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.014208118334821" LOG_CI_START="-0.5910898550467422" LOG_EFFECT_SIZE="0.7115591316440394" ORDER="245" O_E="0.0" SE="1.5303649259972893" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="33" TOTAL_2="34" VAR="2.342016806722689" WEIGHT="16.738858013489086"/>
<DICH_DATA CI_END="3.9926554149715763" CI_START="0.01001839523892015" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6012618301457486" LOG_CI_START="-1.9992018388177863" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="249" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="16.789752950828586"/>
<DICH_DATA CI_END="15.193081907400494" CI_START="0.08330271683610938" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1816458791699729" LOG_CI_START="-1.0793408342752102" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="247" O_E="0.0" SE="1.3281147875424355" STUDY_ID="STD-Manhem-1985" TOTAL_1="8" TOTAL_2="9" VAR="1.7638888888888888" WEIGHT="20.971239945766293"/>
<DICH_DATA CI_END="19.794486961825285" CI_START="0.2684290679215455" EFFECT_SIZE="2.305084745762712" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.2965442500874316" LOG_CI_START="-0.5711704566312847" LOG_EFFECT_SIZE="0.36268689672807336" ORDER="246" O_E="0.0" SE="1.097104864063479" STUDY_ID="STD-Lucht-2003" TOTAL_1="59" TOTAL_2="34" VAR="1.203639082751745" WEIGHT="27.777529410787615"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.256226979477961" CI_END="24.434809651540352" CI_START="0.04201641974916146" DF="1" EFFECT_SIZE="1.013243908844253" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="55.67821814490593" ID="CMP-002.02.02" LOG_CI_END="1.3880089602003824" LOG_CI_START="-1.3765809569140621" LOG_EFFECT_SIZE="0.005714001643160085" MODIFIED="2009-12-14 13:44:47 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.13307804729348516" P_Z="0.9935356771539838" STUDIES="2" TAU2="2.9366504922222187" TOTAL_1="62" TOTAL_2="63" WEIGHT="100.0" Z="0.008101915845722075">
<NAME>Carbamazepine vs Benzodiazepine</NAME>
<DICH_DATA CI_END="3.9926554149715763" CI_START="0.01001839523892015" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6012618301457486" LOG_CI_START="-1.9992018388177863" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="257" O_E="0.0" SE="1.5275252316519468" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.3333333333333335" WEIGHT="50.04115916474471"/>
<DICH_DATA CI_END="103.32564341375783" CI_START="0.25639535024995097" EFFECT_SIZE="5.147058823529412" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.014208118334821" LOG_CI_START="-0.5910898550467422" LOG_EFFECT_SIZE="0.7115591316440394" ORDER="256" O_E="0.0" SE="1.5303649259972893" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="33" TOTAL_2="34" VAR="2.342016806722689" WEIGHT="49.958840835255295"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.968410020086601" CI_END="0.3279187773616951" CI_START="-0.952494709332123" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.31228796598521397" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-01-03 15:05:18 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5478711934766384" P_Q="0.8664866375837644" P_Z="0.339044216768567" Q="0.028265303144219267" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="277" TOTAL_2="341" UNITS="" WEIGHT="200.0" Z="0.956055481291025">
<NAME>CIWA-Ar score (48 hrs)</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.4156487653883434" CI_END="0.525929638029083" CI_START="-0.95424582261124" DF="3" EFFECT_SIZE="-0.21415809229107852" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" MODIFIED="2009-12-14 13:47:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4907284614747144" P_Z="0.5706110002583615" STUDIES="4" TAU2="0.0" TOTAL_1="155" TOTAL_2="203" WEIGHT="100.0" Z="0.5671518803679378">
<NAME>Any Anticonvulsant vs Other</NAME>
<CONT_DATA CI_END="0.7214284009545906" CI_START="-0.9014284009545903" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="6.58" MEAN_2="6.67" MODIFIED="2009-12-14 13:47:53 +0100" MODIFIED_BY="[Empty name]" ORDER="485" SD_1="1.95" SD_2="2.86" SE="0.41400168949788574" STUDY_ID="STD-Malcolm-2002" TOTAL_1="61" TOTAL_2="75" WEIGHT="83.18901835303564"/>
<CONT_DATA CI_END="2.933430374170785" CI_START="-2.133430374170788" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="16.9" MEAN_2="16.5" ORDER="190" SD_1="4.9" SD_2="7.83" SE="1.2925902690835964" STUDY_ID="STD-Nimmerichter-2002" TOTAL_1="33" TOTAL_2="65" WEIGHT="8.533917934081884"/>
<CONT_DATA CI_END="2.009679905840742" CI_START="-7.009679905840742" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="15.4" ORDER="191" SD_1="8.3" SD_2="9.2" SE="2.3008993743826527" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="2.693239494151132"/>
<CONT_DATA CI_END="1.2319681376549783" CI_START="-5.0319681376549825" EFFECT_SIZE="-1.9000000000000021" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="19.3" ORDER="188" SD_1="4.9" SD_2="7.83" SE="1.5979722904908178" STUDY_ID="STD-Malcolm-1989" TOTAL_1="32" TOTAL_2="34" WEIGHT="5.583824218731344"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5244959515540386" CI_END="0.6720528473009222" CI_START="-1.8800969234936389" DF="2" EFFECT_SIZE="-0.6040220380963583" ESTIMABLE="YES" I2="20.776264316493258" ID="CMP-002.03.02" MODIFIED="2009-12-14 13:48:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2830171978721615" P_Z="0.35354420269091635" STUDIES="3" TAU2="0.40090224167045874" TOTAL_1="122" TOTAL_2="138" WEIGHT="100.0" Z="0.9277366509480133">
<NAME>Carbamazepine vs. Benzodiazepine</NAME>
<CONT_DATA CI_END="0.7214284009545906" CI_START="-0.9014284009545903" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="6.58" MEAN_2="6.67" MODIFIED="2009-12-14 13:48:53 +0100" MODIFIED_BY="[Empty name]" ORDER="486" SD_1="1.95" SD_2="2.86" SE="0.41400168949788574" STUDY_ID="STD-Malcolm-2002" TOTAL_1="61" TOTAL_2="75" WEIGHT="74.0683495547808"/>
<CONT_DATA CI_END="0.7958172565765289" CI_START="-4.595817256576533" EFFECT_SIZE="-1.9000000000000021" ESTIMABLE="YES" MEAN_1="17.4" MEAN_2="19.3" ORDER="192" SD_1="5.13" SD_2="6.03" SE="1.3754422417150485" STUDY_ID="STD-Malcolm-1989" TOTAL_1="32" TOTAL_2="34" WEIGHT="18.488456272237475"/>
<CONT_DATA CI_END="2.009679905840742" CI_START="-7.009679905840742" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="12.9" MEAN_2="15.4" ORDER="194" SD_1="8.3" SD_2="9.2" SE="2.3008993743826527" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="7.443194172981734"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.17727667908947" CI_END="-0.2622723271911317" CI_START="-1.5733220467665894" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9177971869788606" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2010-01-03 15:05:48 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.5212856922030953" P_Q="0.7217994587906796" P_Z="0.006067037875277405" Q="0.12677515486500646" RANDOM="YES" SCALE="10.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="277" TOTAL_2="341" UNITS="" WEIGHT="200.0" Z="2.744136099084391">
<NAME>CIWA-Ar score (end of treatment)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.562393930805409" CI_END="0.3130987014293348" CI_START="-1.7649205983433411" DF="3" EFFECT_SIZE="-0.7259109484570031" ESTIMABLE="YES" I2="15.786966341430391" ID="CMP-002.04.01" MODIFIED="2009-12-14 13:51:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3127596967130666" P_Z="0.17089246640183917" STUDIES="4" TAU2="0.22772556444791356" TOTAL_1="155" TOTAL_2="203" WEIGHT="100.0" Z="1.3693417718638898">
<NAME>Any Anticonvulsant vs any Other</NAME>
<CONT_DATA CI_END="-0.1645003301896173" CI_START="-1.9954996698103828" EFFECT_SIZE="-1.08" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="5.0" MODIFIED="2009-12-14 13:51:24 +0100" MODIFIED_BY="[Empty name]" ORDER="487" SD_1="2.58" SD_2="2.86" SE="0.4671002513473346" STUDY_ID="STD-Malcolm-2002" TOTAL_1="61" TOTAL_2="75" WEIGHT="63.02277359951902"/>
<CONT_DATA CI_END="2.689334098447079" CI_START="-2.689334098447079" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.5" ORDER="195" SD_1="5.2" SD_2="5.94" SE="1.3721344471940318" STUDY_ID="STD-Malcolm-1989" TOTAL_1="32" TOTAL_2="34" WEIGHT="13.315640051892"/>
<CONT_DATA CI_END="1.1422306211480073" CI_START="-7.142230621148009" EFFECT_SIZE="-3.000000000000001" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="8.8" ORDER="198" SD_1="6.7" SD_2="9.2" SE="2.1134218045950814" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="5.986517282751973"/>
<CONT_DATA CI_END="3.0475546950766645" CI_START="-1.5275546950766614" EFFECT_SIZE="0.7600000000000016" ESTIMABLE="YES" MEAN_1="12.8" MEAN_2="12.04" ORDER="197" SD_1="5.2" SD_2="5.94" SE="1.1671411888792869" STUDY_ID="STD-Nimmerichter-2002" TOTAL_1="33" TOTAL_2="65" WEIGHT="17.67506906583701"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.488107593419055" CI_END="-0.19977799111479355" CI_START="-1.8895941643935479" DF="2" EFFECT_SIZE="-1.0446860777541707" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" MODIFIED="2009-12-14 13:52:12 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.47518380650400094" P_Z="0.015376144698060383" STUDIES="3" TAU2="0.0" TOTAL_1="122" TOTAL_2="138" WEIGHT="100.0" Z="2.4233962485703104">
<NAME>Carbamazepine vs Benzodiazepine</NAME>
<CONT_DATA CI_END="-0.1645003301896173" CI_START="-1.9954996698103828" EFFECT_SIZE="-1.08" ESTIMABLE="YES" MEAN_1="3.92" MEAN_2="5.0" MODIFIED="2009-12-14 13:52:12 +0100" MODIFIED_BY="[Empty name]" ORDER="488" SD_1="2.58" SD_2="2.86" SE="0.4671002513473346" STUDY_ID="STD-Malcolm-2002" TOTAL_1="61" TOTAL_2="75" WEIGHT="85.17311867623194"/>
<CONT_DATA CI_END="2.587032360972927" CI_START="-2.587032360972927" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="7.5" MEAN_2="7.5" ORDER="199" SD_1="4.64" SD_2="6.03" SE="1.319938724067946" STUDY_ID="STD-Malcolm-1989" TOTAL_1="32" TOTAL_2="34" WEIGHT="10.666334788739205"/>
<CONT_DATA CI_END="1.1422306211480073" CI_START="-7.142230621148009" EFFECT_SIZE="-3.000000000000001" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="8.8" ORDER="201" SD_1="6.7" SD_2="9.2" SE="2.1134218045950814" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" WEIGHT="4.160546535028859"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3141334733371002" CI_END="1.0806192141084066" CI_START="0.8760245044382161" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9729588436957297" ESTIMABLE="YES" EVENTS_1="80" EVENTS_2="80" I2="23.904228886232698" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.03367268530855285" LOG_CI_START="-0.057483745437563905" LOG_EFFECT_SIZE="-0.011905530064505525" METHOD="MH" MODIFIED="2009-12-14 12:59:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.25164776044813664" P_Q="0.0" P_Z="0.6086761350611487" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0020826508736293005" TOTALS="YES" TOTAL_1="91" TOTAL_2="90" WEIGHT="100.0" Z="0.5119641028569705">
<NAME>Global Doctor's Assessment of Efficacy</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours treatment</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2936719777560635" CI_START="0.846242485526275" EFFECT_SIZE="1.04630788485607" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.11182417099284653" LOG_CI_START="-0.07250517474279658" LOG_EFFECT_SIZE="0.01965949812502499" MODIFIED="2009-09-08 10:10:15 +0200" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.10827597013009391" STUDY_ID="STD-Kramp-1978" TOTAL_1="47" TOTAL_2="44" VAR="0.011723685707612987" WEIGHT="20.766885631853086"/>
<DICH_DATA CI_END="1.030815993711995" CI_START="0.8840187864352658" EFFECT_SIZE="0.954599761051374" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="46" LOG_CI_END="0.013181148263596275" LOG_CI_START="-0.053538505622133435" LOG_EFFECT_SIZE="-0.020178678679268574" MODIFIED="2009-09-08 10:10:32 +0200" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.039191454960090875" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="0.0015359701418888316" WEIGHT="79.23311436814691"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.904287842997235" CI_END="1.0663026468181322" CI_START="0.4848845958116593" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7190505739621605" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="118" I2="30.144084331825905" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.027880487231293317" LOG_CI_START="-0.31436161266785206" LOG_EFFECT_SIZE="-0.14324056271827942" METHOD="MH" MODIFIED="2010-01-06 10:16:14 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.11631722794534005" P_Q="0.0" P_Z="0.1008742243519833" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="14" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.13863287278343925" TOTALS="SUB" TOTAL_1="478" TOTAL_2="483" WEIGHT="200.0" Z="1.640630092766559">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.813276537962896" CI_END="1.1245174859515414" CI_START="0.4455590889718974" DF="12" EFFECT_SIZE="0.7078410743758355" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="104" I2="44.987631825435706" ID="CMP-002.06.01" LOG_CI_END="0.05096621298927856" LOG_CI_START="-0.351094692720835" LOG_EFFECT_SIZE="-0.15006423986577824" MODIFIED="2010-01-06 10:16:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.03966666200433333" P_Z="0.1434497489546021" STUDIES="14" TAU2="0.23348435141936705" TOTAL_1="363" TOTAL_2="363" WEIGHT="99.99999999999999" Z="1.463064432911398">
<NAME>Any Anticonvulsant vs any Other</NAME>
<DICH_DATA CI_END="33.47682137409783" CI_START="0.16849344616584017" EFFECT_SIZE="2.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.5247442149955166" LOG_CI_START="-0.7734169870737457" LOG_EFFECT_SIZE="0.3756636139608854" MODIFIED="2010-01-04 20:54:33 +0100" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="1.349951266176906" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="19" VAR="1.8223684210526316" WEIGHT="2.7131067844394927"/>
<DICH_DATA CI_END="0.5295782604512338" CI_START="0.0017339715659097227" EFFECT_SIZE="0.030303030303030304" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="-0.2760698512871118" LOG_CI_START="-2.760958028468663" LOG_EFFECT_SIZE="-1.5185139398778875" MODIFIED="2009-04-28 11:16:14 +0200" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="1.4596356156712984" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="77" TOTAL_2="25" VAR="2.1305361305361306" WEIGHT="2.3594330706427105"/>
<DICH_DATA CI_END="115.70110292995908" CI_START="0.22277357152418284" EFFECT_SIZE="5.076923076923077" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0633374989181466" LOG_CI_START="-0.6521363324480826" LOG_EFFECT_SIZE="0.7056005832350318" MODIFIED="2010-01-04 21:04:26 +0100" MODIFIED_BY="[Empty name]" ORDER="609" O_E="0.0" SE="1.595082770356775" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="21" VAR="2.544289044289044" WEIGHT="2.0079924854273563"/>
<DICH_DATA CI_END="1.1531481274998097" CI_START="0.3121888605764218" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.061885098121928904" LOG_CI_START="-0.5055825973546417" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="265" O_E="0.0" SE="0.3333333333333333" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.1111111111111111" WEIGHT="16.186365496061022"/>
<DICH_DATA CI_END="2.2958037120236354" CI_START="0.7743596582177995" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.3609347537480896" LOG_CI_START="-0.11105728053148971" LOG_EFFECT_SIZE="0.12493873660829992" ORDER="268" O_E="0.0" SE="0.2772504573340755" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="0.076867816091954" WEIGHT="17.972318832279637"/>
<DICH_DATA CI_END="5.391052854685162" CI_START="0.049871789665905775" EFFECT_SIZE="0.5185185185185185" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7316735897372958" LOG_CI_START="-1.3021450466987943" LOG_EFFECT_SIZE="-0.2852357284807493" ORDER="258" O_E="0.0" SE="1.1946751346071773" STUDY_ID="STD-Agricola-1982" TOTAL_1="27" TOTAL_2="28" VAR="1.4272486772486772" WEIGHT="3.35860611459991"/>
<DICH_DATA CI_END="1.0431038408503426" CI_START="0.43367026653787755" EFFECT_SIZE="0.672579453067258" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="41" LOG_CI_END="0.018327544537269046" LOG_CI_START="-0.36284035309032775" LOG_EFFECT_SIZE="-0.17225640427652933" ORDER="264" O_E="0.0" SE="0.22389990987797373" STUDY_ID="STD-Nimmerichter-2002" TOTAL_1="33" TOTAL_2="65" VAR="0.050131169643364754" WEIGHT="19.666582716990302"/>
<DICH_DATA CI_END="0.5500690964967846" CI_START="0.002264578665512634" EFFECT_SIZE="0.03529411764705882" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="7" LOG_CI_END="-0.25958275351945875" LOG_CI_START="-2.6450125884698017" LOG_EFFECT_SIZE="-1.4522976709946303" ORDER="266" O_E="0.0" SE="1.4012132931179526" STUDY_ID="STD-Robinson-1989" TOTAL_1="16" TOTAL_2="8" VAR="1.9633986928104576" WEIGHT="2.5389372089937297"/>
<DICH_DATA CI_END="2.938902847851195" CI_START="0.03780700379134716" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46818522971347326" LOG_CI_START="-1.4224277391527982" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="261" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="3.8026185277026485"/>
<DICH_DATA CI_END="1.9864096113072431" CI_START="0.033837614925466344" EFFECT_SIZE="0.25925925925925924" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.2980688078995089" LOG_CI_START="-1.4706002561889702" LOG_EFFECT_SIZE="-0.5862657241447304" ORDER="262" O_E="0.0" SE="1.0389249632986395" STUDY_ID="STD-Longo-2002" TOTAL_1="9" TOTAL_2="7" VAR="1.0793650793650793" WEIGHT="4.248581729185605"/>
<DICH_DATA CI_END="1.752013774454124" CI_START="0.30568130173892816" EFFECT_SIZE="0.7318181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2435375162989004" LOG_CI_START="-0.5147311258796134" LOG_EFFECT_SIZE="-0.13559680479035652" MODIFIED="2009-09-08 10:19:28 +0200" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.44541075390597334" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="0.19839073969508753" WEIGHT="12.915188255958755"/>
<DICH_DATA CI_END="6.603981200184973" CI_START="0.5402652016132279" EFFECT_SIZE="1.8888888888888888" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8198058282692011" LOG_CI_START="-0.2673930043913031" LOG_EFFECT_SIZE="0.27620641193894907" ORDER="267" O_E="0.0" SE="0.6386259760257971" STUDY_ID="STD-Santo-1985" TOTAL_1="15" TOTAL_2="17" VAR="0.40784313725490196" WEIGHT="8.697191689588507"/>
<DICH_DATA CI_END="5.664711459356459" CI_START="0.060069745867768386" EFFECT_SIZE="0.5833333333333334" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7531777933166784" LOG_CI_START="-1.2213442053834143" LOG_EFFECT_SIZE="-0.23408320603336794" MODIFIED="2010-01-06 10:16:14 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="1.1598439960779618" STUDY_ID="STD-Elsing-2009" TOTAL_1="12" TOTAL_2="14" VAR="1.3452380952380953" WEIGHT="3.533077088130319"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="263" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="31" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.2781351216735821" CI_END="1.5877196579335382" CI_START="0.3537103852028273" DF="3" EFFECT_SIZE="0.7493950438865825" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="14" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.20077382191941234" LOG_CI_START="-0.451352188785563" LOG_EFFECT_SIZE="-0.12528918343307535" MODIFIED="2010-01-04 21:30:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7343316453709087" P_Z="0.45138202097563696" STUDIES="5" TAU2="0.0" TOTAL_1="115" TOTAL_2="120" WEIGHT="100.0" Z="0.7531129970288933">
<NAME>Chlormethiazole vs Benzodiazepine</NAME>
<DICH_DATA CI_END="56.25027384808488" CI_START="0.11455565531380806" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7501246411020248" LOG_CI_START="-0.9409834659599233" LOG_EFFECT_SIZE="0.4045705875710507" MODIFIED="2010-01-04 21:30:37 +0100" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="1.5807702232881597" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="10" VAR="2.4988344988344986" WEIGHT="5.872198888697994"/>
<DICH_DATA CI_END="17.019954277591957" CI_START="0.09180400690365825" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2309583890613667" LOG_CI_START="-1.037138363045254" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2010-01-04 21:24:48 +0100" MODIFIED_BY="[Empty name]" ORDER="490" O_E="0.0" SE="1.3322912594474228" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="10" VAR="1.775" WEIGHT="8.266846854702058"/>
<DICH_DATA CI_END="1.752013774454124" CI_START="0.30568130173892816" EFFECT_SIZE="0.7318181818181818" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2435375162989004" LOG_CI_START="-0.5147311258796134" LOG_EFFECT_SIZE="-0.13559680479035652" ORDER="289" O_E="0.0" SE="0.44541075390597334" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="0.19839073969508753" WEIGHT="73.9633976346301"/>
<DICH_DATA CI_END="2.938902847851195" CI_START="0.03780700379134716" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.46818522971347326" LOG_CI_START="-1.4224277391527982" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="287" O_E="0.0" SE="1.1105554165971787" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="1.2333333333333332" WEIGHT="11.897556621969855"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="288" O_E="0.0" SE="0.0" STUDY_ID="STD-Lucht-2003" TOTAL_1="31" TOTAL_2="34" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.081684484508747" CI_END="5.421189456326934" CI_START="0.3145643033680865" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3058762134122426" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="2.00124445725202" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.734094584996809" LOG_CI_START="-0.5022905624815112" LOG_EFFECT_SIZE="0.11590201125764886" METHOD="MH" MODIFIED="2010-01-06 10:16:47 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.39506417679684824" P_Q="0.0" P_Z="0.7132726371135524" Q="0.0" RANDOM="YES" SCALE="1000000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.044104472224425366" TOTALS="SUB" TOTAL_1="384" TOTAL_2="364" WEIGHT="200.0" Z="0.36746440745274495">
<NAME>Severe, life-treatening adverse events</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.8591391747515047" CI_END="17.23596849604394" CI_START="0.3278655353467276" DF="2" EFFECT_SIZE="2.377200041682394" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" I2="30.04887563146256" ID="CMP-002.07.01" LOG_CI_END="1.23643569161227" LOG_CI_START="-0.4843042332098795" LOG_EFFECT_SIZE="0.3760657292011953" MODIFIED="2010-01-06 10:16:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.23941229253202534" P_Z="0.3916130648169448" STUDIES="12" TAU2="0.922374832962055" TOTAL_1="300" TOTAL_2="278" WEIGHT="100.0" Z="0.8566957439896882">
<NAME>Any Anticonvulsant vs anyOther</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="290" O_E="0.0" SE="0.0" STUDY_ID="STD-Agricola-1982" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-14 13:55:36 +0100" MODIFIED_BY="[Empty name]" ORDER="491" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.48271018580264" CI_START="0.03328923695241334" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.217028622529027" LOG_CI_START="-1.4776961595190392" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2009-12-14 13:56:05 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="1.5828946760778355" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="19" VAR="2.5055555555555555" WEIGHT="29.80394002071474"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="293" O_E="0.0" SE="0.0" STUDY_ID="STD-Dencker-1978" TOTAL_1="28" TOTAL_2="32" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-06 10:16:47 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.0" STUDY_ID="STD-Elsing-2009" TOTAL_1="12" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="294" O_E="0.0" SE="0.0" STUDY_ID="STD-Koppi-1987" TOTAL_1="10" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 11:19:43 +0200" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.0" STUDY_ID="STD-Krupitsky-2007" TOTAL_1="77" TOTAL_2="25" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="295" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="296" O_E="0.0" SE="0.0" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="30" TOTAL_2="30" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="297" O_E="0.0" SE="0.0" STUDY_ID="STD-Santo-1985" TOTAL_1="15" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="243.52369366651368" CI_START="0.9239347375706263" EFFECT_SIZE="15.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.386541222339244" LOG_CI_START="-0.03435870422788196" LOG_EFFECT_SIZE="1.1760912590556813" ORDER="298" O_E="0.0" SE="1.4220486005134363" STUDY_ID="STD-Thompson-1975" TOTAL_1="17" TOTAL_2="17" VAR="2.0222222222222226" WEIGHT="34.69603133464064"/>
<DICH_DATA CI_END="16.20424318634117" CI_START="0.06744993851566342" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096287522660267" LOG_CI_START="-1.1710184418752538" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="299" O_E="0.0" SE="1.3984039462322553" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="1.9555335968379446" WEIGHT="35.50002864464463"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.20128565530765985" CI_END="5.334265337803949" CI_START="0.08900196122748924" DF="1" EFFECT_SIZE="0.6890283570161441" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.7270746146305795" LOG_CI_START="-1.0506004232327077" LOG_EFFECT_SIZE="-0.1617629043010641" MODIFIED="2010-01-04 21:33:53 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6536851077715482" P_Z="0.7213154598881539" STUDIES="4" TAU2="0.0" TOTAL_1="84" TOTAL_2="86" WEIGHT="100.0" Z="0.356701263967535">
<NAME>Chlormethiazole vs. Benzodiazepine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-04 21:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="492" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.837849728013516" CI_START="0.018780676377005198" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9463466128803426" LOG_CI_START="-1.726288770881867" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2010-01-04 21:33:53 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="10" VAR="2.4646464646464645" WEIGHT="44.24103927072207"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="313" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="16.20424318634117" CI_START="0.06744993851566342" EFFECT_SIZE="1.0454545454545454" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2096287522660267" LOG_CI_START="-1.1710184418752538" LOG_EFFECT_SIZE="0.019305155195386624" ORDER="314" O_E="0.0" SE="1.3984039462322553" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="1.9555335968379446" WEIGHT="55.75896072927792"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.949668537757594" CI_END="1.1369666828373872" CI_START="0.6478633678062322" CI_STUDY="95" CI_TOTAL="95" DF="22" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8582534964837079" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="108" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.055747738503146724" LOG_CI_START="-0.18851657571045563" LOG_EFFECT_SIZE="-0.06638441860365447" METHOD="MH" MODIFIED="2010-01-06 10:17:51 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.8643889201416253" P_Q="0.0" P_Z="0.2867265682498492" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="20" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="766" TOTAL_2="904" WEIGHT="200.0" Z="1.0653301528443078">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.77021696649578" CI_END="1.2588618246405532" CI_START="0.6665960809580888" DF="18" EFFECT_SIZE="0.9160525960735778" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="85" I2="0.0" ID="CMP-002.08.01" LOG_CI_END="0.0999780636349722" LOG_CI_START="-0.1761372439657372" LOG_EFFECT_SIZE="-0.03807959016538251" MODIFIED="2010-01-06 10:17:51 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8050389754195225" P_Z="0.5887800362667424" STUDIES="20" TAU2="0.0" TOTAL_1="613" TOTAL_2="746" WEIGHT="100.00000000000001" Z="0.5406047634137295">
<NAME>Any Anticonvulsant vs any Other</NAME>
<DICH_DATA CI_END="2.742039507927743" CI_START="0.043521926883320225" EFFECT_SIZE="0.34545454545454546" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.43807370791206457" LOG_CI_START="-1.3612918849948943" LOG_EFFECT_SIZE="-0.4616090885414149" MODIFIED="2009-09-08 11:57:29 +0200" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="1.0569562562768828" STUDY_ID="STD-Kaim-1972" TOTAL_1="55" TOTAL_2="133" VAR="1.1171565276828435" WEIGHT="2.354735574336296"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-14 13:57:46 +0100" MODIFIED_BY="[Empty name]" ORDER="493" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1332499637584637" CI_START="0.22060446326498537" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.054325713841910504" LOG_CI_START="-0.6563857051698729" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-01-03 08:32:32 +0100" MODIFIED_BY="[Empty name]" ORDER="160" O_E="0.0" SE="0.4174754056057845" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="0.1742857142857143" WEIGHT="15.093653708899685"/>
<DICH_DATA CI_END="5.3446083732386045" CI_START="0.31335139405438683" EFFECT_SIZE="1.2941176470588236" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7279158877351333" LOG_CI_START="-0.5039683688472687" LOG_EFFECT_SIZE="0.11197375944393231" ORDER="352" O_E="0.0" SE="0.723614910241919" STUDY_ID="STD-Radouco_x002d_Thomas-1989" TOTAL_1="34" TOTAL_2="33" VAR="0.5236185383244206" WEIGHT="5.023901992192158"/>
<DICH_DATA CI_END="16.48271018580264" CI_START="0.03328923695241334" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.217028622529027" LOG_CI_START="-1.4776961595190392" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2010-01-05 08:53:15 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="1.5828946760778355" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="19" VAR="2.5055555555555555" WEIGHT="1.0499101534603645"/>
<DICH_DATA CI_END="2.890585341281299" CI_START="0.2490590842715743" EFFECT_SIZE="0.8484848484848485" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.46098579595656436" LOG_CI_START="-0.6036976130279008" LOG_EFFECT_SIZE="-0.07135590853566824" ORDER="350" O_E="0.0" SE="0.6254003047053471" STUDY_ID="STD-Murphy-1983" TOTAL_1="33" TOTAL_2="35" VAR="0.3911255411255411" WEIGHT="6.725738774989501"/>
<DICH_DATA CI_END="1.4011173682128448" CI_START="0.005340843044690597" EFFECT_SIZE="0.08650519031141868" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="0.1464745166078401" LOG_CI_START="-2.2723901847768606" LOG_EFFECT_SIZE="-1.0629578340845103" ORDER="353" O_E="0.0" SE="1.4208530991667523" STUDY_ID="STD-Robinson-1989" TOTAL_1="16" TOTAL_2="24" VAR="2.018823529411765" WEIGHT="1.303040201142938"/>
<DICH_DATA CI_END="3.373522942075284" CI_START="0.3211179067619642" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.528083667976661" LOG_CI_START="-0.4933354758378154" LOG_EFFECT_SIZE="0.017374096069422723" ORDER="356" O_E="0.0" SE="0.5999866611829291" STUDY_ID="STD-Tubridy-1988" TOTAL_1="49" TOTAL_2="51" VAR="0.359983993597439" WEIGHT="7.307569960398142"/>
<DICH_DATA CI_END="3.6663526459656133" CI_START="0.2727506316394255" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5642342349937015" LOG_CI_START="-0.5642342349937015" LOG_EFFECT_SIZE="0.0" ORDER="355" O_E="0.0" SE="0.6628679652796169" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="33" TOTAL_2="33" VAR="0.43939393939393945" WEIGHT="5.9869014612837566"/>
<DICH_DATA CI_END="4.823585836618121" CI_START="0.25594400992356753" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.683370011281121" LOG_CI_START="-0.5918550301597707" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="354" O_E="0.0" SE="0.749073501808141" STUDY_ID="STD-Santo-1985" TOTAL_1="18" TOTAL_2="20" VAR="0.561111111111111" WEIGHT="4.6882126654517275"/>
<DICH_DATA CI_END="7.3225436971144395" CI_START="0.015173840636129785" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8646619720038995" LOG_CI_START="-1.8189044814432243" LOG_EFFECT_SIZE="-0.4771212547196625" ORDER="346" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Koppi-1987" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.058659404739201"/>
<DICH_DATA CI_END="8.59468391795795" CI_START="0.2815406720616985" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9342299095034828" LOG_CI_START="-0.5504588570256566" LOG_EFFECT_SIZE="0.19188552623891314" ORDER="339" O_E="0.0" SE="0.8721135307871393" STUDY_ID="STD-Agricola-1982" TOTAL_1="27" TOTAL_2="28" VAR="0.7605820105820106" WEIGHT="3.4586779351036916"/>
<DICH_DATA CI_END="18.687408406451837" CI_START="0.21404787186108687" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2715490770440216" LOG_CI_START="-0.6694890857160593" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="349" O_E="0.0" SE="1.1401754250991378" STUDY_ID="STD-Manhem-1985" TOTAL_1="10" TOTAL_2="10" VAR="1.2999999999999998" WEIGHT="2.023544782951387"/>
<DICH_DATA CI_END="6.603458207923905" CI_START="0.7025187573491686" EFFECT_SIZE="2.1538461538461537" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.8197714336153761" LOG_CI_START="-0.15334207554461124" LOG_EFFECT_SIZE="0.33321467903538243" ORDER="351" O_E="0.0" SE="0.5716116922701343" STUDY_ID="STD-Nimmerichter-2002" TOTAL_1="39" TOTAL_2="70" VAR="0.32673992673992674" WEIGHT="8.051076720509496"/>
<DICH_DATA CI_END="6.1391830112331665" CI_START="0.05597463456229133" EFFECT_SIZE="0.5862068965517241" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7881105800465302" LOG_CI_START="-1.2520087330878946" LOG_EFFECT_SIZE="-0.23194907652068217" ORDER="343" O_E="0.0" SE="1.1983761832886317" STUDY_ID="STD-Dencker-1978" TOTAL_1="29" TOTAL_2="34" VAR="1.436105476673428" WEIGHT="1.831765326827039"/>
<DICH_DATA CI_END="3.874758312210624" CI_START="0.6203488080905866" EFFECT_SIZE="1.550387596899225" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.5882446185980059" LOG_CI_START="-0.20736404786854137" LOG_EFFECT_SIZE="0.19044028536473226" ORDER="345" O_E="0.0" SE="0.46734446900886534" STUDY_ID="STD-Kalyoncu-1996" TOTAL_1="43" TOTAL_2="40" VAR="0.2184108527131783" WEIGHT="12.044310917513663"/>
<DICH_DATA CI_END="8.651509578035272" CI_START="0.01709863379893922" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9370918929226585" LOG_CI_START="-1.7670385888642943" LOG_EFFECT_SIZE="-0.414973347970818" MODIFIED="2010-01-06 10:17:46 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="1.5884196306634222" STUDY_ID="STD-Elsing-2009" TOTAL_1="12" TOTAL_2="14" VAR="2.5230769230769226" WEIGHT="1.0426191107280012"/>
<DICH_DATA CI_END="3.754457918288967" CI_START="0.012343864976933615" EFFECT_SIZE="0.2152777777777778" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.5745472409165846" LOG_CI_START="-1.9085488374385386" LOG_EFFECT_SIZE="-0.6670007982609769" ORDER="340" O_E="0.0" SE="1.4585829279496223" STUDY_ID="STD-Borg-1986" TOTAL_1="15" TOTAL_2="30" VAR="2.1274641577060933" WEIGHT="1.2364994297592382"/>
<DICH_DATA CI_END="1.8386000878494173" CI_START="0.33554814179130743" EFFECT_SIZE="0.7854545454545454" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.26448727653154064" LOG_CI_START="-0.47424516189020416" LOG_EFFECT_SIZE="-0.10487894267933177" ORDER="347" O_E="0.0" SE="0.433935091113479" STUDY_ID="STD-Kramp-1978" TOTAL_1="55" TOTAL_2="54" VAR="0.1882996632996633" WEIGHT="13.970328845731432"/>
<DICH_DATA CI_END="4.286630103887496" CI_START="0.30235747968568594" EFFECT_SIZE="1.1384615384615384" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6321160095728278" LOG_CI_START="-0.5194792833965864" LOG_EFFECT_SIZE="0.056318363088120604" ORDER="348" O_E="0.0" SE="0.6764527755788704" STUDY_ID="STD-Lucht-2003" TOTAL_1="65" TOTAL_2="37" VAR="0.4575883575883576" WEIGHT="5.748853033982289"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5148784652922058" CI_END="1.240687646180551" CI_START="0.3713522055755354" DF="3" EFFECT_SIZE="0.6787724904851897" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.09366245787686853" LOG_CI_START="-0.4302139923315535" LOG_EFFECT_SIZE="-0.16827576722734253" MODIFIED="2010-01-05 15:13:05 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6788407021442044" P_Z="0.2079831761678137" STUDIES="5" TAU2="0.0" TOTAL_1="153" TOTAL_2="158" WEIGHT="100.0" Z="1.2591306332064423">
<NAME>Chlormethiazole vs Benzodiazepine</NAME>
<DICH_DATA CI_END="8.837849728013516" CI_START="0.018780676377005198" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9463466128803426" LOG_CI_START="-1.726288770881867" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2010-01-05 15:12:32 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="10" VAR="2.4646464646464645" WEIGHT="3.8421854623004905"/>
<DICH_DATA CI_END="1.1332499637584637" CI_START="0.22060446326498537" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="14" LOG_CI_END="0.054325713841910504" LOG_CI_START="-0.6563857051698729" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2010-01-03 08:33:26 +0100" MODIFIED_BY="[Empty name]" ORDER="161" O_E="0.0" SE="0.4174754056057845" STUDY_ID="STD-McGrath-1975" TOTAL_1="50" TOTAL_2="50" VAR="0.1742857142857143" WEIGHT="54.33393583051198"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 15:13:05 +0100" MODIFIED_BY="[Empty name]" ORDER="727" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.373522942075284" CI_START="0.3211179067619642" EFFECT_SIZE="1.0408163265306123" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.528083667976661" LOG_CI_START="-0.4933354758378154" LOG_EFFECT_SIZE="0.017374096069422723" ORDER="379" O_E="0.0" SE="0.5999866611829291" STUDY_ID="STD-Tubridy-1988" TOTAL_1="49" TOTAL_2="51" VAR="0.359983993597439" WEIGHT="26.305694099178734"/>
<DICH_DATA CI_END="5.031026768752265" CI_START="0.23539052956719342" EFFECT_SIZE="1.088235294117647" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7016566280970596" LOG_CI_START="-0.62821101404758" LOG_EFFECT_SIZE="0.03672280702473983" ORDER="378" O_E="0.0" SE="0.7811708359467584" STUDY_ID="STD-Lucht-2003" TOTAL_1="34" TOTAL_2="37" VAR="0.6102278749337573" WEIGHT="15.518184608008792"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.597732355681231" CI_END="5.580710961458382" CI_START="0.6605118436264086" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9199285627072125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.7466895299357034" LOG_CI_START="-0.18011939065281568" LOG_EFFECT_SIZE="0.28328506964144384" METHOD="MH" MODIFIED="2010-01-06 10:19:34 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.5874232891355732" P_Q="0.0" P_Z="0.2308582453196888" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="QUALITY" SORT_BY_QUALITY_ITEM_ID="QIT-02" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="329" TOTAL_2="437" WEIGHT="200.0" Z="1.1981510352804623">
<NAME>Dropout due to adverse events</NAME>
<GROUP_LABEL_1>Anticonvulsant</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.446340914629859" CI_END="7.704467108299967" CI_START="0.6734657188060785" DF="5" EFFECT_SIZE="2.277870601923873" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" I2="0.0" ID="CMP-002.09.01" LOG_CI_END="0.8867426054258503" LOG_CI_START="-0.1716845061210542" LOG_EFFECT_SIZE="0.357529049652398" MODIFIED="2010-01-06 10:19:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.48709504780551494" P_Z="0.18546206030860246" STUDIES="10" TAU2="0.0" TOTAL_1="245" TOTAL_2="351" WEIGHT="99.99999999999999" Z="1.324123415019834">
<NAME>Any Anticonvulsant vs any Other</NAME>
<DICH_DATA CI_END="16.48271018580264" CI_START="0.03328923695241334" EFFECT_SIZE="0.7407407407407407" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="1.217028622529027" LOG_CI_START="-1.4776961595190392" LOG_EFFECT_SIZE="-0.13033376849500614" MODIFIED="2010-01-05 08:57:08 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="1.5828946760778355" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="19" VAR="2.5055555555555555" WEIGHT="15.42741203316954"/>
<DICH_DATA CI_END="318.9796571406307" CI_START="0.8795623599165961" EFFECT_SIZE="16.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.50376298690269" LOG_CI_START="-0.05573336415696203" LOG_EFFECT_SIZE="1.224014811372864" MODIFIED="2009-09-08 12:01:21 +0200" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="1.503460826323712" STUDY_ID="STD-Kaim-1972" TOTAL_1="55" TOTAL_2="133" VAR="2.2603944562899785" WEIGHT="17.100660382522964"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-14 14:00:39 +0100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="21" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="17.43606829717581" CI_START="0.07490922992032267" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.241448561482862" LOG_CI_START="-1.1254646675274884" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="318" O_E="0.0" SE="1.3903365471301234" STUDY_ID="STD-Dencker-1978" TOTAL_1="28" TOTAL_2="32" VAR="1.9330357142857142" WEIGHT="19.996649643814727"/>
<DICH_DATA CI_END="74.9254490322258" CI_START="0.1310339531439458" EFFECT_SIZE="3.1333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8746293543755537" LOG_CI_START="-0.8826161566154813" LOG_EFFECT_SIZE="0.4960065988800362" ORDER="323" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="2.6231678486997634" WEIGHT="14.735708943181994"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="320" O_E="0.0" SE="0.0" STUDY_ID="STD-Koppi-1987" TOTAL_1="10" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="321" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="129.74412565322564" CI_START="0.3776664242276759" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1130877036754665" LOG_CI_START="-0.4228916236469528" LOG_EFFECT_SIZE="0.8450980400142568" ORDER="322" O_E="0.0" SE="1.4896468101693163" STUDY_ID="STD-Stuppaeck-1992" TOTAL_1="29" TOTAL_2="29" VAR="2.219047619047619" WEIGHT="17.419291769927124"/>
<DICH_DATA CI_END="8.651509578035272" CI_START="0.01709863379893922" EFFECT_SIZE="0.38461538461538464" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9370918929226585" LOG_CI_START="-1.7670385888642943" LOG_EFFECT_SIZE="-0.414973347970818" MODIFIED="2010-01-06 10:19:34 +0100" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="1.5884196306634222" STUDY_ID="STD-Elsing-2009" TOTAL_1="12" TOTAL_2="14" VAR="2.5230769230769226" WEIGHT="15.320277227383643"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="315" O_E="0.0" SE="0.0" STUDY_ID="STD-Agricola-1982" TOTAL_1="27" TOTAL_2="28" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8188970484455793" CI_END="9.97108403515749" CI_START="0.12014028984116043" DF="1" EFFECT_SIZE="1.094499395164012" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.9987423764555361" LOG_CI_START="-0.9203113246421615" LOG_EFFECT_SIZE="0.039215525906687275" MODIFIED="2010-01-05 08:57:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.36550290173708" P_Z="0.9361553043532544" STUDIES="4" TAU2="0.0" TOTAL_1="84" TOTAL_2="86" WEIGHT="100.0" Z="0.08010304075174139">
<NAME>Chlormethiazole vs Benzodiazepine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 08:57:51 +0100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.0" STUDY_ID="STD-Burroughs-1985a" TOTAL_1="12" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="8.837849728013516" CI_START="0.018780676377005198" EFFECT_SIZE="0.4074074074074074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9463466128803426" LOG_CI_START="-1.726288770881867" LOG_EFFECT_SIZE="-0.3899710790007623" MODIFIED="2009-12-14 14:02:16 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="1.5699192541804385" STUDY_ID="STD-Burroughs-1985b" TOTAL_1="8" TOTAL_2="10" VAR="2.4646464646464645" WEIGHT="51.55785347391187"/>
<DICH_DATA CI_END="74.9254490322258" CI_START="0.1310339531439458" EFFECT_SIZE="3.1333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8746293543755537" LOG_CI_START="-0.8826161566154813" LOG_EFFECT_SIZE="0.4960065988800362" ORDER="338" O_E="0.0" SE="1.6196196617415348" STUDY_ID="STD-Tubridy-1988" TOTAL_1="44" TOTAL_2="46" VAR="2.6231678486997634" WEIGHT="48.44214652608814"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="337" O_E="0.0" SE="0.0" STUDY_ID="STD-Lapierre-1983" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-12-14 12:56:50 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Anticonvulsant 1 versus Anticonvulsant 2</NAME>
<DICH_OUTCOME CHI2="1.782983770612843" CI_END="4.685640562154059" CI_START="0.9230740446932154" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0797098801722655" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.6707689705903821" LOG_CI_START="-0.0347634604996645" LOG_EFFECT_SIZE="0.3180027550453588" METHOD="MH" MODIFIED="2009-12-14 12:56:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6186449730462813" P_Q="0.0" P_Z="0.07725859569121286" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="121" TOTAL_2="117" WEIGHT="300.0" Z="1.7668187014747398">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Anticonvulsant 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticonvulsant 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.621443846334976" CI_END="19.274593189376628" CI_START="0.5047485395919354" DF="1" EFFECT_SIZE="3.1191060840514093" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="3" I2="38.326572193027474" ID="CMP-003.01.01" LOG_CI_END="1.2849852205765169" LOG_CI_START="-0.2969249289431766" LOG_EFFECT_SIZE="0.49403014581667004" NO="1" P_CHI2="0.202890639175771" P_Z="0.22087962995611454" STUDIES="2" TAU2="0.792744728938055" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="1.2241925287245152">
<NAME>Carbamazepine vs. Chlormethiazole</NAME>
<DICH_DATA CI_END="210.07193977426684" CI_START="0.7013281733684793" EFFECT_SIZE="12.137931034482758" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.322368045670798" LOG_CI_START="-0.1540787145124477" LOG_EFFECT_SIZE="1.0841446655791749" ORDER="443" O_E="0.0" SE="1.4546770855408055" STUDY_ID="STD-Lucht-2003" TOTAL_1="28" TOTAL_2="31" VAR="2.116085423197492" WEIGHT="29.68386622234509"/>
<DICH_DATA CI_END="6.4041020119329755" CI_START="0.48235842243955934" EFFECT_SIZE="1.7575757575757576" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8064582412464378" LOG_CI_START="-0.3166301338763382" LOG_EFFECT_SIZE="0.2449140536850498" ORDER="444" O_E="0.0" SE="0.659707670924236" STUDY_ID="STD-Ritola-1981" TOTAL_1="33" TOTAL_2="29" VAR="0.43521421107628006" WEIGHT="70.31613377765491"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.680254257798718" CI_START="0.701918329442452" DF="0" EFFECT_SIZE="1.8125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="0.6702694470398327" LOG_CI_START="-0.15371341655377013" LOG_EFFECT_SIZE="0.2582780152430313" NO="2" P_CHI2="1.0" P_Z="0.21918274934900428" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="100.0" Z="1.2287042127723167">
<NAME>Carbamazepine vs. Barbital</NAME>
<DICH_DATA CI_END="4.680254257798718" CI_START="0.701918329442452" EFFECT_SIZE="1.8125" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.6702694470398327" LOG_CI_START="-0.15371341655377013" LOG_EFFECT_SIZE="0.2582780152430313" ORDER="445" O_E="0.0" SE="0.4840116128558388" STUDY_ID="STD-Flygering-1984" TOTAL_1="32" TOTAL_2="29" VAR="0.23426724137931038" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-04-28 11:37:13 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Carbamazepine vs Oxcarbazepine</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-28 11:36:54 +0200" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.0" STUDY_ID="STD-Schik-2005" TOTAL_1="14" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="63.19673887573602" CI_START="0.12405703426273017" DF="0" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="1.8006946680796287" LOG_CI_START="-0.9063786053951907" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2009-09-23 11:28:33 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5173090368065669" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.6474990133559342">
<NAME>Chlormethiazole vs. Pentobarbital</NAME>
<DICH_DATA CI_END="63.19673887573602" CI_START="0.12405703426273017" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8006946680796287" LOG_CI_START="-0.9063786053951907" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2009-09-23 10:58:43 +0200" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="1.5901482410679288" STUDY_ID="STD-Mariani-2006" TOTAL_1="14" TOTAL_2="13" VAR="2.528571428571428" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9153965905932524" CI_END="1.846342265249329" CI_START="0.43964476136004726" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9009632093457037" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2663122113870033" LOG_CI_START="-0.35689809736310785" LOG_EFFECT_SIZE="-0.04529294298805226" METHOD="MH" MODIFIED="2009-09-23 11:28:52 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5616601143155898" P_Q="0.0" P_Z="0.775730029362236" Q="0.0" RANDOM="YES" SCALE="1000000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="175" TOTAL_2="158" WEIGHT="500.0" Z="0.2848878966345969">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Anticonvulsant 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Anticonvulsant 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.017769049574946" CI_END="3.1081272817189562" CI_START="0.08302162456788276" DF="1" EFFECT_SIZE="0.5079781258007723" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" I2="50.440314256447955" ID="CMP-003.02.01" LOG_CI_END="0.49249879539796537" LOG_CI_START="-1.0808087725960938" LOG_EFFECT_SIZE="-0.2941549885990641" NO="1" P_CHI2="0.15546779845387027" P_Z="0.4636235962668822" STUDIES="2" TAU2="0.8823592170481619" TOTAL_1="61" TOTAL_2="60" WEIGHT="100.0" Z="0.7328931675603977">
<NAME>Carbamazepine vs. Chlormethiazole</NAME>
<DICH_DATA CI_END="5.0445652801099365" CI_START="0.24298730179099517" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7028237464730195" LOG_CI_START="-0.6144164214889124" LOG_EFFECT_SIZE="0.044203662492053486" ORDER="446" O_E="0.0" SE="0.7737533951048305" STUDY_ID="STD-Lucht-2003" TOTAL_1="28" TOTAL_2="31" VAR="0.5986943164362519" WEIGHT="57.6675778888028"/>
<DICH_DATA CI_END="1.4185313055135176" CI_START="0.02177655531190222" EFFECT_SIZE="0.17575757575757575" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.15183892466606214" LOG_CI_START="-1.6620108172959625" LOG_EFFECT_SIZE="-0.7550859463149502" ORDER="447" O_E="0.0" SE="1.0654643171295226" STUDY_ID="STD-Ritola-1981" TOTAL_1="33" TOTAL_2="29" VAR="1.13521421107628" WEIGHT="42.3324221111972"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.5735568656562133" CI_START="0.34004691503781764" DF="0" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.41053376892108373" LOG_CI_START="-0.468461160791717" LOG_EFFECT_SIZE="-0.02896369593531662" NO="2" P_CHI2="1.0" P_Z="0.8972268905890683" STUDIES="1" TAU2="0.0" TOTAL_1="31" TOTAL_2="29" WEIGHT="100.0" Z="0.1291652522067171">
<NAME>Carbamazepine vs. Barbital</NAME>
<DICH_DATA CI_END="2.5735568656562133" CI_START="0.34004691503781764" EFFECT_SIZE="0.9354838709677419" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.41053376892108373" LOG_CI_START="-0.468461160791717" LOG_EFFECT_SIZE="-0.02896369593531662" ORDER="448" O_E="0.0" SE="0.5163259728083748" STUDY_ID="STD-Flygering-1984" TOTAL_1="31" TOTAL_2="29" VAR="0.2665925101965146" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="72.6230071114122" CI_START="0.14100214804229522" DF="0" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2009-04-28 11:38:36 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.4652770182299425" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="100.0" Z="0.7301851594185668">
<NAME>Carbamazepine vs Oxcarbazepine</NAME>
<DICH_DATA CI_END="72.6230071114122" CI_START="0.14100214804229522" EFFECT_SIZE="3.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8610742278439367" LOG_CI_START="-0.8507742712041246" LOG_EFFECT_SIZE="0.505149978319906" MODIFIED="2009-04-28 11:38:36 +0200" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="1.592953232207399" STUDY_ID="STD-Schik-2005" TOTAL_1="14" TOTAL_2="15" VAR="2.5374999999999996" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.9718748285209" CI_START="0.03497734088625491" DF="0" EFFECT_SIZE="0.37272727272727274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.5989955534841596" LOG_CI_START="-1.4562132103611385" LOG_EFFECT_SIZE="-0.4286088284384895" MODIFIED="2009-04-28 11:38:07 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.41364760161712033" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="41" WEIGHT="100.0" Z="0.8174915190840245">
<NAME>Pentobarbital vs. Paraldehyde</NAME>
<DICH_DATA CI_END="3.9718748285209" CI_START="0.03497734088625491" EFFECT_SIZE="0.37272727272727274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.5989955534841596" LOG_CI_START="-1.4562132103611385" LOG_EFFECT_SIZE="-0.4286088284384895" ORDER="449" O_E="0.0" SE="1.2072398013301844" STUDY_ID="STD-Kaim-1972" TOTAL_1="55" TOTAL_2="41" VAR="1.4574279379157429" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.053290790329684" CI_START="0.27505615152972895" DF="0" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-003.02.05" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" MODIFIED="2009-09-23 11:28:52 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.6888871952820483" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="100.0" Z="0.400365685600474">
<NAME>Chlormethiazole vs. Pentobarbital</NAME>
<DICH_DATA CI_END="7.053290790329684" CI_START="0.27505615152972895" EFFECT_SIZE="1.3928571428571428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8483917891377037" LOG_CI_START="-0.5605786377691437" LOG_EFFECT_SIZE="0.14390657568427995" MODIFIED="2009-09-23 11:00:36 +0200" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.8276362032811789" STUDY_ID="STD-Mariani-2006" TOTAL_1="14" TOTAL_2="13" VAR="0.684981684981685" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-01-06 11:09:28 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>(Anticonvulsant + Other) versus Other</NAME>
<DICH_OUTCOME CHI2="4.139174267820102" CI_END="3.5216780563476497" CI_START="0.17669183268537142" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7888293541089372" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="23" I2="51.681183961039146" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.5467496512500998" LOG_CI_START="-0.7527835246395389" LOG_EFFECT_SIZE="-0.10301693669471952" METHOD="MH" MODIFIED="2009-12-14 12:57:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1262381937071343" P_Q="0.0" P_Z="0.7559970973891255" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.905764121579008" TOTALS="YES" TOTAL_1="140" TOTAL_2="171" WEIGHT="100.00000000000001" Z="0.3107415639174724">
<NAME>Alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>Anticonvulsant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.151584735618438" CI_START="0.025480036524685883" EFFECT_SIZE="0.1712962962962963" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="18" LOG_CI_END="0.06129589962336167" LOG_CI_START="-1.5937999537912333" LOG_EFFECT_SIZE="-0.7662520270839359" ORDER="461" O_E="0.0" SE="0.9722114971523403" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="0.9451951951951951" WEIGHT="31.481330085015415"/>
<DICH_DATA CI_END="25.408151475090577" CI_START="0.23212862177146804" EFFECT_SIZE="2.4285714285714284" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.404973069876406" LOG_CI_START="-0.6342713071483719" LOG_EFFECT_SIZE="0.3853508813640171" ORDER="462" O_E="0.0" SE="1.1978622414868214" STUDY_ID="STD-Lucht-2003" TOTAL_1="28" TOTAL_2="34" VAR="1.434873949579832" WEIGHT="24.89520355295842"/>
<DICH_DATA CI_END="4.519393869396579" CI_START="0.3457322032896022" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6550801921502974" LOG_CI_START="-0.46126016613418463" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="463" O_E="0.0" SE="0.6557438524302001" STUDY_ID="STD-Rothstein-1973" TOTAL_1="100" TOTAL_2="100" VAR="0.43" WEIGHT="43.62346636202618"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.8903003552775431" CI_START="0.02018592881154148" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.13405797101449274" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-0.05046345331705551" LOG_CI_START="-1.6949512626793901" LOG_EFFECT_SIZE="-0.8727073579982227" METHOD="MH" MODIFIED="2009-12-21 10:59:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.037502373266545166" Q="0.0" RANDOM="YES" SCALE="100000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="12" TOTAL_2="37" WEIGHT="100.0" Z="2.0802525637242306">
<NAME>Severe, life-threatening adverse events</NAME>
<GROUP_LABEL_1>Paraldehyde+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8903003552775431" CI_START="0.02018592881154148" EFFECT_SIZE="0.13405797101449277" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="23" LOG_CI_END="-0.05046345331705551" LOG_CI_START="-1.6949512626793901" LOG_EFFECT_SIZE="-0.8727073579982227" MODIFIED="2009-09-08 12:12:23 +0200" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.9659802795653775" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="0.9331179005092047" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7988436324145276" CI_END="1.7150871919092745" CI_START="0.18347169737800553" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5609545064003602" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.23428620368054115" LOG_CI_START="-0.7364309211697821" LOG_EFFECT_SIZE="-0.25107235874462047" METHOD="MH" MODIFIED="2010-01-06 11:09:28 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4068048419682436" P_Q="0.0" P_Z="0.31064254543969383" Q="0.0" RANDOM="YES" SCALE="10000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="177" WEIGHT="100.0" Z="1.0138747283949543">
<NAME>Dropout</NAME>
<GROUP_LABEL_1>Anticonvulsant+other</GROUP_LABEL_1>
<GROUP_LABEL_2>Other</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.483824090129374" CI_START="0.015748766803938528" EFFECT_SIZE="0.26573426573426573" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.6516485659691651" LOG_CI_START="-1.8027534476656684" LOG_EFFECT_SIZE="-0.5755524408482517" MODIFIED="2010-01-06 11:09:28 +0100" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="1.441727892295013" STUDY_ID="STD-Golbert-1967" TOTAL_1="12" TOTAL_2="37" VAR="2.0785793154214205" WEIGHT="15.642061367742182"/>
<DICH_DATA CI_END="5.0445652801099365" CI_START="0.24298730179099517" EFFECT_SIZE="1.1071428571428572" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7028237464730195" LOG_CI_START="-0.6144164214889124" LOG_EFFECT_SIZE="0.044203662492053486" MODIFIED="2009-09-08 12:14:11 +0200" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.7737533951048305" STUDY_ID="STD-Lucht-2003" TOTAL_1="28" TOTAL_2="31" VAR="0.5986943164362519" WEIGHT="54.3069548464694"/>
<DICH_DATA CI_END="1.860378908666544" CI_START="0.03153744899221923" EFFECT_SIZE="0.24222222222222223" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="0.2696014072200105" LOG_CI_START="-1.5011734388894507" LOG_EFFECT_SIZE="-0.61578601583472" MODIFIED="2009-09-08 12:14:11 +0200" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="1.0401619100815536" STUDY_ID="STD-Spies-1996" TOTAL_1="50" TOTAL_2="109" VAR="1.0819367991845057" WEIGHT="30.050983785788414"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-01-05 17:31:52 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Anticonvulsant1 + other vs anticonvulsant 2</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-05 17:31:13 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>alcohol withdrawal seizures</NAME>
<GROUP_LABEL_1>AC1 + other</GROUP_LABEL_1>
<GROUP_LABEL_2>AC2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-01-05 17:28:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Oxcarbaxepine+tiapride vs chlometiazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 17:28:48 +0100" MODIFIED_BY="[Empty name]" ORDER="730" O_E="0.0" SE="0.0" STUDY_ID="STD-Croissant-2009" TOTAL_1="27" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-05 17:31:22 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>alcohol withdrawal delirium</NAME>
<GROUP_LABEL_1>AC1 + other</GROUP_LABEL_1>
<GROUP_LABEL_2>AC2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-01-05 17:29:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Oxcarbaxepine+tiapride vs chlometiazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 17:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="731" O_E="0.0" SE="0.0" STUDY_ID="STD-Croissant-2009" TOTAL_1="27" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.037610051168972" CI_START="0.45024096559523147" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6835016835016835" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.01603417004024768" LOG_CI_START="-0.34655499284824653" LOG_EFFECT_SIZE="-0.16526041140399944" METHOD="MH" MODIFIED="2010-01-05 17:31:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.07399899001594198" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="1.7866196101493559">
<NAME>adverse events</NAME>
<GROUP_LABEL_1>AC1 + other</GROUP_LABEL_1>
<GROUP_LABEL_2>AC2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.037610051168972" CI_START="0.45024096559523147" DF="0" EFFECT_SIZE="0.6835016835016835" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.01603417004024768" LOG_CI_START="-0.34655499284824653" LOG_EFFECT_SIZE="-0.16526041140399944" MODIFIED="2010-01-05 17:26:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.07399899001594198" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="1.7866196101493559">
<NAME>Oxcarbaxepine+tiapride vs chlometiazole</NAME>
<DICH_DATA CI_END="1.037610051168972" CI_START="0.45024096559523147" EFFECT_SIZE="0.6835016835016835" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.01603417004024768" LOG_CI_START="-0.34655499284824653" LOG_EFFECT_SIZE="-0.16526041140399944" MODIFIED="2010-01-05 17:26:53 +0100" MODIFIED_BY="[Empty name]" ORDER="729" O_E="0.0" SE="0.21298666912600467" STUDY_ID="STD-Croissant-2009" TOTAL_1="27" TOTAL_2="29" VAR="0.04536332122539019" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2010-01-05 17:31:52 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="YES" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>severe, life threatening adverse events</NAME>
<GROUP_LABEL_1>AC1 + other</GROUP_LABEL_1>
<GROUP_LABEL_2>AC2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-01-05 17:30:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Oxcarbaxepine+tiapride vs chlometiazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-05 17:30:53 +0100" MODIFIED_BY="[Empty name]" ORDER="732" O_E="0.0" SE="0.0" STUDY_ID="STD-Croissant-2009" TOTAL_1="27" TOTAL_2="29" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="106.78285035218646" CI_START="0.26876019414337615" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="2.0285015092893035" LOG_CI_START="-0.5706350538623797" LOG_EFFECT_SIZE="0.728933227713462" METHOD="MH" MODIFIED="2010-01-05 17:31:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="0.0" P_Z="0.2716146151784681" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="1.0993519107133911">
<NAME>drop out</NAME>
<GROUP_LABEL_1>AC1 + other</GROUP_LABEL_1>
<GROUP_LABEL_2>AC2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="106.78285035218646" CI_START="0.26876019414337615" DF="0" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="2.0285015092893035" LOG_CI_START="-0.5706350538623797" LOG_EFFECT_SIZE="0.728933227713462" MODIFIED="2010-01-05 17:21:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2716146151784681" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="1.0993519107133911">
<NAME>Oxcarbaxepine+tiapride vs chlometiazole</NAME>
<DICH_DATA CI_END="106.78285035218646" CI_START="0.26876019414337615" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0285015092893035" LOG_CI_START="-0.5706350538623797" LOG_EFFECT_SIZE="0.728933227713462" MODIFIED="2010-01-05 17:16:33 +0100" MODIFIED_BY="[Empty name]" ORDER="728" O_E="0.0" SE="1.5267456831287853" STUDY_ID="STD-Croissant-2009" TOTAL_1="27" TOTAL_2="29" VAR="2.330952380952381" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-01-08 13:08:28 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="flow chart.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-01-08 09:30:32 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Flow chart showing identification of studies</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-01-08 12:13:37 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADOCAMAAAAdQhu+AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-01-08 12:13:37 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATIAAAeYCAIAAAAt88wgAABgC0lEQVR42u3dv25Ux//G8ZVoKFy4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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-01-03 15:00:11 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Anticonvulsant versus Placebo, outcome: 1.1 Alcohol Withdrawal Seizures post treatment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA6kAAAHgCAMAAABwydsMAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-01-08 13:06:01 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Anticonvulsant versus Placebo, outcome: 1.4 Adverse events (N. of patients with at least one adverse event).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3oAAADwCAMAAABhTuZpAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-01-04 20:42:27 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Anticonvulsant versus Placebo, outcome: 1.5 Dropout.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3oAAAGwCAMAAADIYeexAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-01-08 13:08:28 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.04" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Anticonvulsant versus Placebo, outcome: 1.6 Dropout due to adverse events</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3oAAAEACAMAAADSq/TEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-01-03 15:03:19 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-002.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.1 Alcohol Withdrawal Seizures </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA34AAAHwCAMAAADO0k2nAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-01-03 15:04:13 +0100" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-002.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.2 Alcohol Withdrawal Delirium </P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2gAAAGQCAMAAADslrNSAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-01-06 10:16:15 +0100" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-002.06" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.14 Adverse events (number of patient with at least one adverse event)</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3wAAAJACAMAAADhBZRyAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-01-06 10:16:48 +0100" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-002.07" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.15 Severe, life-treating adverse events</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuYAAAIQCAMAAAD6jFtlAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2010-01-06 10:17:52 +0100" MODIFIED_BY="[Empty name]" NO="12" REF_ID="CMP-002.08" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.18 Dropout.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3wAAAKgCAMAAAD3QY/wAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2010-01-06 10:19:35 +0100" MODIFIED_BY="[Empty name]" NO="13" REF_ID="CMP-002.09" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Anticonvulsant versus Other, outcome: 2.19 Dropout due to adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2IAAAHwCAMAAADzQCzBAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2009-12-21 11:05:09 +0100" MODIFIED_BY="[Empty name]" NO="14" REF_ID="CMP-003.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Anticonvulsant 1 versus Anticonvulsant 2, outcome: 3.1 Adverse events (number of patients with at least one adverse event).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAAIgCAMAAADdrQ0dAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2009-12-21 11:05:09 +0100" MODIFIED_BY="[Empty name]" NO="15" REF_ID="CMP-003.02" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Anticonvulsant 1 versus Anticonvulsant 2, outcome: 3.2 Dropout.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvQAAAKQCAMAAADHZx5oAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAA1rklEQVR42u19PawlR3ZevcdH1tCWxFk+zpAj/poLUwoWThQ6kBNn
tTJgZQYMOLBzZwqcODMUGAYMCBDgzIESaw0DqsChMwkGKHgBwZJJkxLJIbU7M49Lc39mjjji+N7u
6q7/6qru29Xdt7+PnHe767+rvzp1qu65py44A4B94RJdAID0AADSA8B54Wo1LRGMSeNOHgJkTq5I
IiGHUsxU46HUnGJO0V9NTbo95hWzWpH7bDtp7tU6x+Jk5gjvolKNx7clRBWCHSo51CQTcad6tjNr
7tV6aC5FO8Kb/w+jvaGP6pBOSLT/GwFGJ9mJlOAVtWuUC3ScQRNHQjYR7rMt/Z4Xb+76dPojDyXr
yCWPz64+1LwX6MYmkTQSyb67ZPUaFyGSaqZLoqaFzrOtQb4t29z1qTcycd+IUiGUZDU7i7G+g2Sq
tPlrZNXUZ0MSKrXBVpMlWwXH19fcM9i9afTBilwbqrFaO3r9uGuPoc5JWbctm2ru5XrEgGAjB7ps
1OvSDpurxpo860SjlP7yT47ok50093JFgiD8xEIEus5cpIqxfTVLjUvwTLdnVfrMapu7UvVG9YZs
O0gGaCb7nXgzkSdUFqhRCCHq9pMMDsOmvUJ4z7b4a128uRcwOAP2BpghACA9AID0AADSAwBIDwAg
PQCsGabtjdodZcKxfIvvlXY5hlNmw7WttuLkmCLEQAMr1ihkZ8XfR/j25VadXWqmjVWMrLGGD70z
2b06YX79YFuSjnhxG2mpSXqhrJpFwXNadtAngkxTK6cAszfEGmtM1C3KMpd2v7b3lx2Z/KjTY1Ut
vQq8vt6cWRoDtn2r+gszaT5O/9a7pMooURpD0rBNzx1OuhBtsV5gZK2tszNy1amxEyki0DWsq995
m8NiyGwzs23+VaBIWIIKc86Z9juajbTU0unVl8CWwiKcBqiXJY0c1vQtdKYmrW0TLcrMAyyzdmXM
m21k3SZtc8ncXBVq1Lbk+kr0vTPidVp2/V1p1oOEur2iscTaWnppT7R+8TJhAOflkEP6Qs77PNqu
uFVKh1nFk2uy3+rXGO4XGYuSEQII2wYo2P2xn3O1TBMnJNVmWnrlqzZlr7YwR6mW6xk8jjNAdaes
pWss1/1NZTIwaWSXJYW5+9BsW5Qs486ipVehmbeU9jMiZIxXPsxKWDtnjbKVd8p6UGaXpXdHAiXK
sjEp2XyvbCMtvXQ0ek8OpTaHjBzCkl0i0R+l+yF2s+Yzjq1fo1FTzhaTlLFXlTeFtJmEsJUvIe1p
+wQ0W31LL201VCle3ZaodEScY+Js5JCdKiCtTNry3EiQodMH61MNyyWhrjtHp69bo1WT3cve3CmT
tWszdDMgbo2u9vqsaBF8u2PkxjZammdPX1SDkGwFv6TbEOIdlswyqp5FHm5tLb3KonyZKrYO30Lb
QXmHgfOTgF9OAQAA1MZvV67vCpIeWByVSQjTYmB3AOmB3cG1p/d9rFtG0Y7937iv53MTWl6WhnKJ
obTYLwV8SW+Z/UnmeBs8lRNZmc35oupEeQ0AJH3MwtAUlL5JvXD9tNshzLKpFyGX764pu1Od8Ysi
XZhXVWf3pn8H4NUfnqyAvev0YW9rrhphmtQLz0+7GdIaYQR8vQvLB3xatgt3+ukrNkrpBmSXNlj/
ahy0AysivUEJETPxds0nzCDphVijSEZGUm/KHjRcj57XwuJpw/UDQGr3pswtrx9kryljtld2uBxp
OSdEtJH+b88g54GI7c2JOJ8W1izgFniM2YUsaD/kPhCypxciKKDDNsxD1tLSLFvEpLRlwauDsuVy
dCYJ/TQbsh6S3qC10OaUgW0OFS3toSC8oD6tKkf25TrG9GZ9/r0b6we4zZJD9ceKAHaGelaWWFMC
MWpUZgbMEAAsZGcD5DywvoUsAID0AADSA8A5AL+RBZbE0yWWl5D0ANQbADh3mHMKBVQdFdZ9tL/h
DX7UQnl1U9s5usZgj7bRh/jjX5VMXVHzp7QuHn5XTWm66f2VUT6xPtCIJcZ3RPqs/j32SuijGueL
q5vaztE1tmQOgXd/iBlXTSOpfHzZV2TUopveX5HXDjeWE9sf6fUr41pgNF3Coy+wHniFHCeqkSL0
8WQzGy82dB3qKlIpT7ZjCbTWUf/NDZDLkF53SS8jOWGT54Sjxdd+iI8kIneveO4gCeltVFHKD/5G
byH1JiDdg3p/XWk/orpjq/n4tUd5jekcEX3p0MLD/7P1pl8lX1rab0Gnj77Dql3Ha6nmE2pM5uCp
CJq1N62i+br0nXq4nCottoCVtvoE2k1xbUQsocGkY8+c9N5GQFK5qcuU6pynU+eg5UYY51wLeK8d
Vuxe1Jt2v7hVLRsN0+kzapc+Sju2P6opN8XV2a2uUeNADjua7F7mo3T6yLhWNTWb72alagT0sZXf
ocu/2j8ige3N2SIxwaXnvuraIH45BSyoCS6mfS2n3gDnBD4qiu1Aq4ekB3YHkB7YHaDeALXxdGnu
QdIDu5b0vZ2r9VU4uTZJKqlpol51k4vKDWEm29MXfzUwUCPZ0X36clMJsg2ETdP4kD293STigRbt
zJ6+IzBPE8AzUa+6yUVjBsk0u39+6hrJSGWlL7anN+ogN4AHqzDlWbBFu7Snby1MKfKzGwonryjn
aRxl+fga5xkkfPSgGt8xPJmD15FVz7lBP6i8TxpZTHAK/uxmBT8jWWDqPfl39Al+jlcUJ/26Zn65
xf2FbB9U+xvZgO1NXn92Pyzbgv5n/AZs5PuiMRrOsC6mrSuVFdN0e/rBd7IyE4Q16PQJHdTuWU6s
9s9jJ0gZ9WvHUY3lE/gXFKCBVrRNO4U9PU0Yonvcven0mnBHLq1kbAoJZZB1PwIPcW1+NSMq1SIt
Okfk7tPTtB2UZZWbaW0ebcEfy9iZrRvKTeXRONiieQWtwmokfS/q260rHp6nlzGln6blVrSnz7Pg
V6lMc/Zye3ptEx9qrWcxr+sMjQNitItJHPb0Z65ibWExC3t64MR6XaVsG17IAmeDDdjTv/XTi588
A+mB/eDiOx8e/t776Te1K34OrAcWwfu3f/jg+Pmzv7n3cWWNylzIqlOL+zvprjJEKFIdOdtmbs5p
7ZO1UYe0YtFT1rrDY+sd6in6Lgkfr270mbR6yuy9vHqMAtqzp7tnZdIr326ReSN0D9U5avfin/6B
vrn+O5/eWmghe3hiKVniTHAR6vRjLtXlhwurv3QUW/KYbqFaISrXaDy+04cqRiformTp2DJqaLrf
qE/65VvpzRsRknpz6vLfedJw/rq9vfnF9+89WVCnl91wV1JDaGkuTMGuk9ui35gPmqD2Wi5IetGL
wNo1RqKGBsy4KmWpcJFeq2r10Pv/+MMj269v2M3hX/P5xzd3f/XjatLe2rJ0jrsX7VzbiYz2UlrC
wsosBoiwGO1FNRE22BdyRQ8pekklZ26cRfmXf/Ov2c1Rvlv/Hv7laxcLkF66tJfBlxZ7n+1gEIP0
rw9ZS1F1aizn/ITey3lIafDcbGVNzrPf+oc34Yhn95aQ9DJHC3BXg2oUSNkplocZAYeDjx0rY3tP
ZmUS8dFYD5//0XdfvVb6vPHvzjs//mIR9Saj7/wdECnBcaAE97/6ldcOGs210myOn6+8+eCv623g
XAY1+oItFyFspUcvxFp1R+Al5/TglGXsoYBUN3txbYAKXuQFffGT7/4O67Scw+ebTx7U3LM0vpz6
4L0DDlQ9fMr3Dn+Pey7N3Qcf9BHt5THygybHB00u2WZuJoFD0HttbBd2vHtvudmgbxlTzapVo67Y
xLERdoJDSKj38isyC+ge0qhGRxsvhNk3Rq463fT1n7zzws/V9b2/e/NtVUpMs7LM/bpHQM2vPX2k
ejw9n1R7WW/87OlByt/7y5e2ZWUpT54QOB3tx3K+pm7/6q0vX6reNbCnB5Yfn7CnBwCQHgBAegAA
6QEApAcAkB4Aehj29Oo3W/7h1UMuIWq7jKheHzy6nS3pN+KYsrqLiq147ASmqDdEpLxdNVdOMNMR
hzTBlACwEUlvSzbunlth3vRHkPBQyrkFL4YXcGrSWwqPF2QdEMMHUp8FOHT6PZHeVp8poVfXI0Z9
7Ro6/a5Ib/ul5ympXlG9AQWB0y9ko7K+2bwjPjALzKxscA5lAzi1pO9UlcZDvV41mhoMd48jPWe9
Fzr9eZOeO39597+h0vBQkqqsqM1AMH5n6g0AgPQAANIDAEgPACA9AID0ALAkzC1L4vqvfZUJ94h3
x0JfBzoF643w7isC+2sAZp7s2xqclZXQfbnMvfb2V+S31C6mPxDZeshYa9pDW1VTYMewXtJPBvfv
KWiw4HNPDzjPZtOxfeHlJUTGMFlRoROzjWLICDBt7gKt0Schq6ZYRnrAStUb16LeNJknao3qDYt6
M5lO75anbfEzGaB5pr4YplgJPD38gm0qE76+aSnp0vmEgoGVSHrfol5fHv9njkW9loi8s3bnEYHZ
G4xRmK0x5nJDe8ovQWtdndGQkYlHWBos1zhKnrdlJZ7Hs1vAMFgv6SlPcTF/xeG/Te5P5iGz+yAN
lJlLxNqFp0rwlRceajJPzit8cBi5y5ZgayzdqjVgIhgzrJT03VLN1HbTusfwcMmJdqeERSzY+clS
BYa8P1aAtS1k+fBL5gVcoMBijwqYFlYQrBLSgr6o2sKWZeTCLxw3snuT2LmksCqs7Y55VNZToWDt
iiOeHnZDnKeCasdJZA4Nftuktyzqe6W117ebK0vtNu763XS7PJUnKPJU7uPi0NLpVRkZ9uzU7593
Wc0N9Vi99rhiyZb5AXFquyuTtlkYCavBKP/0xKdEn6qaE5ZQWhN+NntS1PZPX/zlFGVp8BtD4ZdH
4PuZ6vTjNd6TMYLXK4GXFwvibxYwOANAegAA6QEApAeAs1nIBq3ftWVtoU2ia8Tl7lSbBmgsbh/f
mblbhu2Dtu+9YRq+/QeSpE/tPU+kTsr0JG3HblpV6q+9Bmzf26ESsH0HAJbwT28a1Xum9Szird73
U98V4ljkt6b3eUOK+Pj9QRAeSEp6R2SagtIxrWcJb/U2hS3LfNP+3rRIT+k5vhXNsO17b+DV274D
QJr0A4LSNqpxvNVn8ivI44HveZ1fzY6yfQeACOmV+Mz3W0rBS/+eJqwXOKMMg2erQBAeyCY9H17Y
xgS3ZzlfcFZJTFUZkQfmMUC5epOrGXDyfsRBSUnuuhkx7fAzhHfWQhUmkEAp6R1zcLLt6Zl/Zxvd
W6brVibDIr9dbbb7kYFd95gdOxtp+w4ABi42R4kxtu/AqlHbnn57ZgiFvzcF54Htk36M7TsAbJv0
AADSAwBIDwAgPQCA9ABIDwAgPQCA9AAA0gMASA8AID0AgPQAANIDAEgPACA9AID0AADSAwBIDwAD
ML0hiMM/Gb0yL/sM5b/ozcwjmr/B6o4f+qfEY9oAQNJr+siWbKEr83IKpMxOGKnuJM0AIOltsRq6
aiSq7AV+J/ab4C5IivbDTNSn1dHqyi1D+lNJsLp2NEoWTA4AZTq9yNAVRCeBG5HdcK8POt6ZIVJK
c4oQvYhuEzkyOziVBKpj7fATEiIfmKzTs5azjqrsDASbaNIKkl6IlTk0gTR3h1obQS9M3adld6C6
YEMAYOruTZTzwZWjH2SsOdsZJFyLsIeTFaAEeXzywRIWOIGkPzXnw4I9Gt4qRrnMBueBE+zeiO5D
C2jNrFbsisAyM6H/67EjwolFv9aV3YpCiFSBAHDS3Zsj3bw9+f5KRUuLlM02jPR42occs/TlSls4
m/UF7pVO71enVgFSYAgAo1DPazHUESBGDXgtBoAlFrJzAHIe2J16AwAWni4mgaHeALsDSA+A9AAA
0gMASA8A24a5YFYHusbP4wvHqPOQ1amz3dFms53qR8WHp3U5xjZpdI1+xnBf6YDyc2+9QvoSjqXF
Y728ber+mN+9kH7wYXmk11VXqmPG1ZnIc3G+mBddDqpdo58x3FdGAPFSzruFGM/Jk7H2g/HuD5We
WXou6g21/6g9zZuovW/uiDV3Xdwy57SOOlRzUkNPc4zngmfa8mSYbtgujt29SgoRMgVlPzuq/1Mv
mGYUFyOnX169xjFNmE66dNdHYqdqgBsmfffovJtlzR7izovzeo9U4Mz9Rrz41Uwk7YgatV5dMiYa
1WJCY6m4EwztZkdHq2fo9JT/wkx1dR26DRtanM84R/BS/ZizCb1nvIF4J0Rid2aLcnWqd87dgUJ7
tuohPo5LU9RCntP1dizx1Sw6Fl/IMu7MzjQ4Adh3nPP1SA9aivO0xGNGuj4Y23Oc2K5wNThfBtV0
b+ZWqebX6ctrmNqm8vzUro5iGe2+IiNhe83LG0fh2mKx3aAkpfVUWIqtCRc8uYmQmu8IVskbULFG
vLpKL3Y50+Kr+GNTQiul/a1+zor1K1MH1yHpAaCWpP819n8qS3qQHlgWdx7fvPJTSHpgR7j72eHP
mw8WI71yvNTfKcc3hiuaUKRyjNNmFsx0Hq/dFS/5q/Dec081JyRGl4TdwXkJet/MssgfRsA9Ue9Q
kclEtJ+5dRrdvcK6nGfs9uOajHD80wfcBgcvdYj2Ndz4KJb2+9XO7RfkfOc0uXKNYS/MwQTdlRz5
aKGHlOlou3nHdydbJ9NV5ZPi/PVXd2vW6q4dZOcDXjnZFlqai4BX+NCBIJbjY8kMKbIIZHTIzl1j
RDQPEFlWapFz9ACrOhd2+vwvjoy/YTfXn9WU9a5/eqf/hdQiw/cKL+zMgk152zNKXsGqi7ARA+Ik
jyqTfRCLFsu4SLx7/+bwt/1XU9Zf2u9DiEH5EOufzrP2Yl0YJ9oY1WGyhjOG8/P1XvAAi76VvfJT
VzAs9VvVS7tjhkWy2zFqFKjjFA7zgJBwZqY0u1L6ju89VdeAbiTC5+TJpd7Xj24ftZv2X80NnCu3
74pFmIQH7Ugn1ewZVdcA863onKMHZsbjtz856PMHnb7upuVlUKMv2HIRwlZ6dJeHPdovodEvw3mR
eRKc2cBRy9jjOQLKsbm7gWZG9/trQtitXPAdHWX9Uaevu1F/aU+Roj3mqd9zkeaBCf2lqaGqc6qk
eUqbMOZcWWUBNzTzy9oDTQjzBK9wk3TLQr1X9GjBuiLl261cqIe0rGds0S+nTrdeG5sOmHslnTGf
VH5ZL37FapshTFtAy5MnBE5H+7Gcry3r3/zNylXC9gZYfnziJBIAAOkBAKQHAJAeAEB6AADpAaCH
YXvjeGTN92Rb1xdIfRctBM8PZ0v6bTjxpOrNJA4fP+ev3jQO6Vtv9EReMNMRrbN6P+XcqM9AcP5M
Jb0t2bh7lIZ5Y/isD6ScXduoTUEC6fezkA286qMDdR5OUIvzvPb5MPVrBGpLeuatbf0b8sdCLdJD
twHmJL19PBlP8QCLPeA81BsW8ELfH39HLCH5AWBTkr5TVRpVVmuzpgbjaDOt0ltH0Nd3pc6xT3/W
pOfOX979b6g0PJSkIiug0wMzqzcAANIDAEgPACA9AID0AADSA8BaSE/GX/sqExQ+UjmrRPJjaWQz
AKCepOchKk/JDgDVSO9a1Jsm80StUb1hUW8m0+kbHpNXopu3K0LZ6hvFsT6mrrk+cOYIGpz5FvX6
8vg/cyzqtTn9IQ+FpLYu0cvbfXTp/Frx4yVgPtJTnuZhWpf7TDzynpt30cJ4sAjuJQCA+UjPeyVj
eBxQpu4eYv2gqkKT1gYAUK7eMD68uOTj16C2mX5WAsh8YO6FbFrYU1rYO7I9+FM7MnJQqHTyYiDs
gTklvWVR36ve7aWysbeNzI07xXhyIvsSWV9E86k/urTcSwCTduCkGOWffmAjJXOfxR8ewD5R2z/9
VTHhBzVssBjY4kI2AX6CFFY6DBFgLQtZAADpAQCkBwCQHgC2tpCl4MKy21gsWnCaNmRddqcEbWMW
rNX1k28FUHABbHxXoL4UOH5gLwlIkD5lyTiROpQgHw8Ub1hVkhfAh/JYFpwcrAcy1BsyjNqV8bxj
Ws8i3up9w/euEMcivzW9zxhSxFlQrAPAKSS9IzJNQemY1rOEt3qbwpZlvml/fwzyVRoWMjROzTk0
PCQg6oFh0qco54Q5tvPZEpmXS3NrSdB/LRxVx/BmgSLSK/GZb+RFcbZlGErmSWIePQwiINsZTlEA
ykjPhxe2McHtWcIXnFWSoapk5oE+A4xQbyhzr48Td8U1JSW5XhF40an6Yo3h46cOAKS3tANl1G5t
DUYt6JltdG9pFlYmwyK/KZfazfTArrtKSdwvJ7ou1XnsB8AQABxcbI4SpSQG6VeP2vb02zNDKFyj
gvPA9klfuEwF54EzID0AgPQAANIDAEgPACA9ANIDAEgPACA9AID0AADSAwBIDwAgPQCA9AAA0gMA
SA8AID0AgPQAANIDwABMbwji8E9Gr8zLPkP5L3rz8vh1FRczpnHA3iT9gSWyYVvwyrycApnH+el1
SXAeGJT0MnnVCE7ZC+FOFDfBXZAU7YeZqE+ro9WVW4bsxXtblxB9eSomUXVWRQDg6fQioBK4YUIq
IdxIUnG87oOOd2aIlNIU26KX3m0iR5zHxbuKiVddVhEASW/KeiGkoxEbYUzLU2sm6IOkF2KNmNAE
0ty1Mr2hMHNjusQyXXVWRQCQ2L1JrAJDs4EXJAw9pZktwkUJe8j5CaXF23jVRRUBkPTzcX5I3rpy
vdFX3F0cHTJcdWZFACS9LQ6FMOSmFpGNIuFJTDG0CWOWLWIiWK1WTZWKqQWs3jxKVZ1bEQA4uzda
ge73O0ylur2UFn2a3RHpayWiV7UPtO3KkLZcNutjwbqcmFTVJRUBO0c9r8XVvizCt1JbA7wWA8Ai
C9k5IM+uIgDqDQCMwtPaohjqDbA7gPQASA8AID0AgPQAsG1Y6+TjuX36EGTefVgHI/PQR9XjzMrP
C/RPeC7LXv586oxor2f6cG6V2wcUnHsbyK0CjsUYbY6cb81jRdDZH0535b4Rt8/d477VINAftQ/w
o9E5aPwgKxwuFOg8He72nxFAPJvzgdxdM62bwNMrfkeK4MR2RHrj3XDmCJ44uysf1ErF74Sqv0VV
o9czp2wJD4ql7Kc/to27BfJlBNdzQ4KNz016T5gPMpuqyno+Okc98vNIz/Cc8TJXW6yn98dj1fna
ruvpCV7yaNJzrYM6cp144qVwHMsdf7clPXPo/8P/2fQjxicPFUPf14rOvhayPPLUdFrRuwzqv04+
JoO1cTCQuuCRBpLuS2hd5nBbr222LAiIGJ3nyMzJZT19dDtrH1P2ZdEWSfE0sCZdg/PV7zONKzyH
qcGn3ynngzo999XKdieN2qUZpy6Z8XHGmvnYB4xltDuOuE7YXvOCwo/akPVW3NgEq1VG3QBitAtN
B6bF54eEvM4S5bXlPUyLgaX1qrP/bgqSHlgcraT/9WfPHrx68Rc1JP1zV+h0YFlc/tYnr7/4wl99
++njhw9ffunl//n7c6sfkPTAwnj+le/9ySPj/vqFF26+qUZ65Xipv1Me6g3PxaFIw6Nw43hY6mTa
i/CyP9a2ff9Vq9HuTzdG+scA2L2XLt85QMDw+Gw4dg4+fOspSDpHD0irEdXw1r/4j09v/OC7L3w1
I+8d//S+d18RvNQh2glZ4zpY2u9XO7dflPO129BVJaUMxXRemL1jAGT+mJKRopjtGC7w8NLx8dx4
otZl1GP8k4u7v/zhv/nxgfPXnZDvPh/c/9lLd954MlPFrkove396rPMZ30lzYQp2ndwW/cZ8ILT7
VSmW53z1GkP8GW5LlqDPd8ssohORdKeNurPxkz/99xfssyPLr2/YzfWN9/ng+v4r37n1aA6B7/qn
d/pfSC052ktzNhB2ZrEq5rkUqaliyWiXnKoRIlckZz28qOzq8+17L3//N/7gcHGT/Hfzo7/i//re
/5uT9NKlvQz2Yax/pHK7Wr8Ls8Vi7Rp9bVEOy+W83rNEjyx8+H5F1nvM1cpSlQ569tW3f5yX8uaj
Z/9gVkkvZYZIdvtFjQKlvB7mASFX6WOs/lq6/NCrUb2XQ1Qhs3JWU+g/ffwV/b17140On/p37/Z7
f/SjT+ZVbzLek98vciMnmgnBzvEMnszTGs2Hj21mVfV8+80XXz767q07B1l+rbQZ5/PizXefffn4
kznqvgxq9AVbLkLYSo8WKmGP9ospObL2Wi330c10mfORd5TAQMHq4UXAp78Qi3D+iFv3H3399//z
3W7H0vy888a7Dx98fmv+3Rup+NseAcW0B3ip/cNLy0d8sy0vurMAmbMTbIXt0Ktq3C2+6W9feklF
WdGtcmnVlemQ3zuEYIFTGD/9V+yXrn/+yAp79cVHXx+GxHyVTvtGNlc4wGX8OtSdzC++ar8s8Yd/
+v2/ORL/+uaV52/9+Utz1zfRDCF3Ogbn65E+cV6YnFjAnJsMr3/zhL3we//kVoX6YHsDLD9QcRIJ
AID0AADSAwBIDwAgPQCA9ADQw/hGVv0K3vfZOuQSorrf4sp9RHtze7cj0m/EEWt1DxUED7U7UG+I
SHm7aq6cYKYjiIVTnpWcB85Z0tuSjduHW9gCr7tu0ngpZwU4D8y6kA0Q7OhAPXIIBugIbFbSx/Rn
SijWHIs94DxIT9ykN09JdSz2gPNQbzyRTp3T7tQsAACbk/SdqtIcrqiP5zI1GEebaY9hPFdBD9Xt
vEnPnb/cPGnR/HCTrPt8wa1VCCyr3gAASA8AID0AgPQAANIDAEgPAGshPRl/7atMUODLrNwSyY+l
kc0AgHqSnoeoPCU7AFQjvWtRb5rME7VG9YZFvZlMp294TF6Jbt6uCGWrbxTH+ph65vrADhA0OPMt
6vVlcy67Y1GvzekPeSgktXWJXt7uo0vn14ofLwHzkZ7yNA9OKZXkyHtu3kUL48EiuJcAAOYjPe+V
jOFxQJm6e4j1g6oKTVobAEC5esP48OKSj1+D2mb6WQkg84G5F7JpYU9pYe/Idk6x0sNbkuQlgLAH
5pf0lkV9r3q3l8rG3jYyN+4U48mJ7EtkfRHNp/7o0nIvAUzagZNilH/6gY2UzH0Wf3gA+0Rt//RX
xYQf1LDBYmCLC9kE+AlSWOkwRIC1LGQBAKQHAJAeAEB6ANjaQpaCC8tuY7FowWnakHXZnRK0jVmw
1i6EVCSZjvMpuAA29/L773Q59pKABOlTlowTqeMNAmZV60Vqq0restkwsyQ+lEcPlWawgfXAsHpD
hlG7Mp53TOtZxFu9b/jeFeJY5Lem93lDivjofU0QHkhLekdkmibwjmk9S3irt5lmWeab9vfHIF+l
CWotPHEbztMZ9fdtB4A06R3VIxXm2M5nS+Qgjwe+57WcZzLLvSAATCW9Ep/5Rl4UvPTvaYIOwqOH
QUCpAaaTng8vbGOC27OELzirJKaqjMiDHxgC5epNaruF2fqNy01KCl69IvCi+QjhzSOB4DtQRHpt
OG9tDUYt6JltdG/9aMTKZFjkt6vNdlMxsOuuUhL3y4muS708UHaAMC42R4lSEoP0q0dte/rtmSFw
AueBnZG+cJsSnAfOgPQAANIDAEgPACA9AID0AEgPACA9AID0AADSAwBIDwAgPQCA9AAA0gMASA8A
ID0AgPQAANIDAEgPAAMwvSGIwz/pXB2vZRekA3Ueyex0VmSXVabT6epZONIoKFJItFQASEj6A29k
yzx91VGxoaMOdIg6gEC+WMLclABwEkkvA1cRgXzkpmz+P4rwfl5oxG0X34YJ1g0kac4fKqUUwdnD
KMGcfaQ1CbUt0J/2/AQAeTq98JUEzyVJPwuIVmeRdsjhj7qT0qK61DGhycWqUpeg86gRYlfWlyJi
hQFAmvTSItKQLhIOkcehE0xkxjTDQ8lp6RVjpRPhGqVZCgQ8MHIhG1gXmoJeaywsrf5IkRsjhTW6
VA1mOj+PSGteADCO9OY2Sc98maPxJ6YIEZwchDGwpJcukEeWTD4AkN69Ed1HtzAUzX5KYKUpcgWt
iPNTtLqLjJcXK8zWkmQ4CgAySC+NhawQMfpIa7lrcbfZRXF0etFr+k5MoLCkTq+2+kM5ElEA4ONi
274ewfJzQG2vxVfbpjw4D+yM9GA8sEP1Btgini4se2FlCewOID0A0gMASA8AID0AbBvmstk52Dhw
Lp9K0R7Yerzk3V1FFJ8XSH1Dx7V0zBP6h0R7HWiU2weUn/vsFqJP5T2WFqjCPN89mJfO/nC6qzil
eJA9/Qn0qgurn0dP5Vl47IGy+Vt8eG24qVYH6nJ1APFSzruFcF1vuApbqgXycmI7Iz1pcdC+g0Zc
cBVHfuLaUoGK3wnxcRNEfPCPbSrNySeeMxXyoQebU371D/9cPIovQPqW89xkCimJ4TdokXOJ+ajO
5qyqHtaym49o+wn6dEoRs77SvuynpxMsJyC9R24ebhAtT/6yzlZzEvEVckG3s1EtxqvUWTmtRMbN
2es0MdJ3GiVlvJvtgFcXJmPHiJpmx2fPyGkl6ufwPWjyEdIfljKdakPDLCK+DUG/zH7RuF45gdY/
quLdvMoGl74YH5L1tALNfsT6ierRiHNef9uPihNRWd4zlfQt6/nAZMedvV5i697YVe3lNHqb/sRP
aDfouFXYVdBe8/KyzEJSsTpgMO8ZA6bFe1TK0nPX7HM3TIuBRRWek2WDpAeAIUn/a88evHrxF0tI
epAeWAJvPXn87Iaxa/7i/fo/DId6A9TH6y9/+dmjA+fZzRcfvfTikyXVm8bDjOdH3hiGIhTZ++Jj
jZsb0xe9dnC85E+41WPZTzd7nY5DfTvG6DNp9ZTlyT/v0ZwCWO97UfoHDgj7BQczz+5i4vnb1z+0
Q1755Y9vLSTpxZAHehHqdO0r2POGZrgRXtbxmGydxEopa46zuMs31TH+gQCyeGjZBUjjEaUfLRwX
vcHMM/fR+9f/6P4Pr9WN+nz09Z27b1fkg7uCkJ1LeeVc3vBAL1wn86F5wZgPBOsHgVyQ9HGhW4n6
A0FuilHNTHr/DKSKkHvuTnr+7k+/d9wdurk+6vM3xudn7Hf+y0e1xL3rn97pf9MDve9kXtiZRRkB
6pGvbZmo5uiyI64c4N1pHzKnbCtVbS+Ib93hHz88MJ4F//3ux3f+01vVSe+5UpVBYRF1cilbbacm
u3K1m/6Mh7r1FnN+Qu91Z1Wkq7D6IHRGxpz98e1A/KP/voCklxne572OUaNA6ZKHeUDIdXke61tW
b2aRo5u6SO/JSs6e7z98dPtOo8eH/v2z95/94NMldHpZzHm9cwPYAlsuU7McxfqcWeIEuMUef/cX
Rx2etXp9/3nn1k9+8INFdm+Eo4FncVkIW1YIa/tgBQ7jtdv9qptFsrSB4yeJ44kCIqd8qyuM4whq
nlB3/0u63dZ8o0JursW7Dx58U5ESjn965WG+33ORpgd6z8l85xVeOs7hhTFtypkXcHmTt1yV93qv
SaHeyy+HpRz9y1gf2LEVe+abx//h3df07d3bn/PPq27TTzRDyKUR3MivSs8RcvGX9fbP6dFxt/JX
b310a2NmCPLkCYFTLizGcb4GPnn05J1X7/7thzeVhfwJJD0AnGJ8wuAMAEB6AADpAQCkBwCQHgBA
egDoYdje9A6e1a12cziwrUkr908/ucJdOYXZF+n5Nty6VfdQQXw3/u52rN4QkfLr1Vw5wUxHHNIE
U56VnIeUP2dJb0s2Hj+3Ql83abyUoCCw3YVsgGBHB+o8nOCM6Qjt5twlfUx/poRizbHYA86D9Laj
ep6S6me92IOg35F644l0Yqw//o5YQvKD88CmJH2nqjiO6k0NxtFmmpRnq94QNurPmvTc+cu7/w2V
hoeS1CRFbf6B73tTbwAApAcAkB4AQHoAAOkBAKQHgLWQ3j03ufgbJwp8mZVbIvmxk089BoDZJT0P
UXlKdgCoRnrXot40mSdqjeoNi3ozmU7f8Ji8Et28XRHKVt8ojvUx9cz1gR0gaHDmW9Try+P/zLGo
1+b0hzwUktq6RC9v99Gl82vFj5eA+UhPeZoHp5RKcuQ9N++ihfFgEdxLAADzkZ73SsbwOKBM3T3E
+kFVhSatDQCgXL1hfHhxycevQW0z/awEkPnA3AvZtLCntLB3ZDunWOnhLUnyEkDYA/NLesuivle9
20tlY28b0Bt3ivHkRPYlsr6I5lN/dGm5lwC/RgROilH+6Qc2UjL3WfzhAewTtf3TXxUTflDDBouB
LS5kE+AnSGGlwxAB1rKQBQCQHgBAegAA6QFgawtZCi4su43FogWnaUPWZXdK0DZmwVr1vr/a4Dcd
51NwAWzu5cNODcgifYohE6njDQJmVetFarba1phdSDqP9a0uB+uBDPWGDKN2ZTzvmNaziLd63/C9
K8SxyG9N7/OH1AxfoQGQ9J7INE3gHdN6lvBWb5PNssw37e+PQb5Kk0FvV20K5WkVoN58AuQHhkg/
IGAt58W27Xy2ROYhHgfzaqsbaywxy70gAEwlPTl0G1Ykgpf+PZWrIeG1KOwggBOTng8vbGMc9Czh
C84qSas34aZE1BsQHyhXb1LbLbb2wV1OUpKuekXgRfMR0ptHAsF5oIj02nDe2hqMWtAz2+je+tGI
lcmwyG9Xm+0GfGDXXaU8LnbVVb8LH12X6jxQdoAkLjZHiVISg/SrR217+u2ZIXAC54Gdkb5wmxKc
B86A9AAA0gMASA8AID0AgPQASA8AID0AgPQAANIDAEgPACA9AID0AADSAwBIDwAgPQCA9AAA0gMA
SA8AAzC9IYjDPxm4sgJFe6c+EhBDaYeKaKr20+hfEQcKMGpMpgNA+p4boqGKvjJYZwUOQ+jL0ZQ7
ZPRqFLkZ8W6BYdLLwJWwON+LfFv0H/6K5v82RgUwPX66VN284U8pKqMUQdneTTGiK7dPpiu0ihL9
VMMg5YGkTi9CCoMQIb2lZZeilVShTUwbrEZIn1Y2aaWUZkbjqh9Z0pPRfaDoyrVCurKNdrRUlzoG
AGKkNyjS09+njYxpFIEY2X+qsRPRr9VoUQyPKy2hkL5sL5EdAwD+QjawyBylG4hwgSLEeTutFFYK
rbEM1CdFaQwA0hdurAwuI7MLlAGJL/15YoDzxTEA1JtOo1cf3cafMNSDRsvJ1RaEyGeh6Fe3sltU
+NkjBYq8aQYAIqSXxkJWiJ6LWtNx1rkyuPDtgu2lgNbphUFur4hgkXagNTqkqklYGpK00gGAgwv4
egSWBrwWAwBIDwBQb4BzwVMv5AqSHgBAegAA6QEApAcAkB4AEqtl/2Dj+LGs3SGzoY95MaIS/4Tn
OjX6Ga1wHd0H8AlHhrqlHksLVMHsY67d19kd87sX0vuH3AfeNtcpefhjZs6XV0LOZ60a/YwU6Dwr
gHgx551mGpWGq7CPaHdaylnxmaVno94QEWuP6Sbzjvpeir6Z2YUEH0XaRWrkp25J8uH4mIcYmNbn
FV9EwcD5x5wl6flR0JAe+JaQ6ARFWuyscGbsp/9qIoyPHz6lvOMnGjKjFblJvfS0vtD0SO/WzAN3
qdeTMSxOotRXH1ljn6qsqUdtmiY8HmkFPfYQPE1rvo8T1q/SimKZLswrSYhRL2aJt1nYVD5NcDQ5
25Ezbn2yF5OUq2jXpJa3bIsSgcZv31R71hOoYDz/IWinhleXzgTLM2X9Yv01mhScc1aX87REx9CE
h6CdkP4qrlyG77ruaZRDpSLaHzNrDFR7Gqax67tYU+3uIq4TKvVk1LgMvQRdhf3CrBEQyXvGgGnx
2SIh29Niv94sDtNiYB2a4PkrOc9dgRznqrlelSm1GflOjW/bj19/8s6dRxWFMEgPLIfLI/73f/2/
9OjhS881d9DpgR3g9a9bIX/nl75YYiFr+KJnhm9iw81eKFL53mszC2Z6htfuhpf1NJbtU/+0NUZc
MOsY13uz3Xslj+aVKILeoc0WGe7//VdYDe//2z/sr1/9lU8rTTBW/wV9BocudYh2NNy4JJb2C+nK
E8tyvnYbgi6ZvRjfe7Mc+Wh+iZZz51D08XVJ9z0dg2rKpyfX32s4f93c/fjDO8/XJr3qisYrWOsZ
rPHw17rzsy91clfiGPNB69FeMrawj3ixUI1SjmlLkaAXxmtLIRItXBlVt5uevPZ9ahl/c91+3n/z
tSe1Se84wXP8wfsu34WdWayKee7IrKli9c4RAz4K56goXFf5YK3qBfGN1z6RN4dP89+ff/Lbb1Ql
vec6VQZ7OdYx7WAQ1fuugBi1a8z17W+JhpLek273p5V/x1WoN0zqHmHx7/42FPrRt3UlvczwBe/1
lBoFagI9zANCrtJBttiA1+7JvSfT/qJFktaycg/984dvvqL0+f6fuP2/KuzhXLmdVsj57RxqJjbC
/KlzjMh7bSvw3n+LvcU/P+jzN612c/h84X98c6vy7o1wNPAsLgthSxhhOdVej69sb29p/lE2wpn/
qFGpzxEQoV1SIdwVqwjeLPCqPn30Z3cbxh9x8+q7X35Te/dGKufx/VZx5/3ddDlvTaBS5ZKOE3lh
TLZyKcV6BVJXxE/YslXsUO+Nqcs+9NQ7cGDwRIH6wv83fvzOK+3V9ds/+rxSpdO+kc3tJJyDU1+Z
k2PXN7Vf1vO37x80m9fv36pW4zRjB3nyhMAp1zDjOF8Z3zy8+y/v/dmjepyH7Q2wgvGJk0gAAKQH
AJAeAEB6AADpAQCkB4Aehu2N+hW89nfKvKswKju7re6bhfbj8G53pN+G906q3kzi+3WAtx/1pnER
3rjEspyFq2CmI1qX9X7KOVGffeD7GUt6W7Jx99wK88ZyWc9rHUICAPMvZAMsPjpQ5+EEtThPtBn/
9MBWJD3z1rb+DfljoRrpOTgIzEd62zM9T0n1s1ZvMMh2pN6wgJ/63oU9sYTkn5GA4DxweknfqSrH
Jarhmd7UYBxtpklZ6/Cd7finBzZBeu785d3/hkrDQ0nqHkpXF+D73tQbAADpAQCkBwCQHgBAegAA
6QFgLaQn4699lQkKH7qcVSL5sTSyGQBQT9LzEJWnZAeAaqR3LepNk3mi1qjesKg3k+n0DY/JK9HN
2xWhbPWN4lgfU89cH9gBggZnvkW9vmyOXHcs6rU5/SEPhaS2LtHL23106fxa8eMlYD7SU57mwSml
khx5z827aGE8WAT3EgDAfKTnvZIxPA4oU3cPsX5QVaFJawMAKFdvGB9eXPLxa1DbTD8rAWQ+MPdC
Ni3sKS3sHdnOKVZ6eEuSvAQQ9sD8kt6yqO9V7/ZS2djbZu3GnWI8OZF9iawvovnUH11a7iVYwoge
OGOM8k8/sJGSuc/iDw9gn6jtn/6qmPCDGjZYDGxxIZsAP0EKKx2GCLCWhSwAgPQAANIDAEgPAFtb
yFJwYdltLBYtOMl1vUfWbrxRbletW6sR0qQk03E+BRfAxncF6ksBuAAEBkifsmScSB1KkI8Hirc8
JDsBxIfyWBacHKwHMtQbMozalfG8Y1rPIt7qfcP3rhDHIr81vT/RkIoNJQAYkvSOyDQFpWNazxLe
6m0KW5b5pv39MchXaQJsJcd2x1WbIppO2rgZAOmL5KXlvNi2nc8WsDzE4wJu9l8L87Q2BSM1IJP0
SnzmG3lR8NK/p/L1QjiS54wpy/0sACRJz4cXtjEOepbwBWeVRNSbZCsoVS7UGqBEvaHMvT5O3JXI
lBTWekXgRcdkeqoh5ZMEAMT901sm8CxhQc9so3tLpbAyGRb57Qq13UwP7LqrlMT9cqLrUp3HfgBw
H3BwsTlKlJIYpF89atvTb88MoXBxCs4D2yd94foUnAfOgPQAANIDAEgPACA9AID0AEgPACA9AID0
AADSAwBIDwAgPQCA9AAA0gMASA8AID0AgPQAANIDAEgPAAO4wM/pgJNi+EfJxAcCRhQBSQ8AID0A
gPQAdHoAiCjP5/MoHKQHsJAFAOj0AADSAwAWsgCwTVyhC4DJa9fgCb6hFap5GnBkWdqfFsYjy1e7
DhrhoxekByZzPnyCb+AAMuM0YHsouDcUOk3DioocZwmdHlh8MGREBeR8aXEgPbASZJ4VxkfkAekB
AKQHAJAeAEB6YM/AliUwecEaOcE3kTCzyETUQFVJ4BtZAOoNAID0AADSAwBIDwCbAnZvgDjE8Y/M
Ty5zA0NxhZUNNyBaM0gPJCDPsjKoN0CGBBWilcRCXfc3OqS9MQNUrua/JrQP7EJa6T6qslh5TiJI
emC81tDpCuZ1e9uHSHVlffSBTJqJm0sZUkAyK1M3fnlWIkh6YJyIV3qHFAEmSVczCV01l3JQlSmu
TLJ0tZD0wHg1O6ksHPjpME0kcolTVzYCID2Qp94kyWpLZZnIJU9dGRaywFy873R2X2YnBLpghcK+
rDIx8mEg6YFhJUc0aoWpXxhBhsbREtVJYrHXUU8CQju3smNgpLwhHQhWlsDuAPUGAOkBAKQHAJAe
AEB6AADpAQCkBwCQHgBAegAA6QFgLvx/rWx56GJ9GKsAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-16" MODIFIED="2010-01-05 14:58:27 +0100" MODIFIED_BY="[Empty name]" NO="16" REF_ID="CMP-004.01" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 (Anticonvulsant + Other) versus Other, outcome: 4.1 Alcohol Withdrawal Delirium post treatment.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAACwCAMAAABev6oNAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-17" MODIFIED="2010-01-06 11:09:29 +0100" MODIFIED_BY="[Empty name]" NO="17" REF_ID="CMP-004.03" SETTINGS="SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 4 (Anticonvulsant + Other) versus Other, outcome: 4.3 Dropout.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvAAAACwCAMAAABev6oNAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-12-14 11:23:02 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2009-12-08 15:28:20 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-03-21 10:41:48 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-08 15:28:20 +0100" MODIFIED_BY="[Empty name]">
<P>Free text: (((alcohol*) AND (withdraw* or detox* or abstinen* or abstain*)) AND (anticonvulsant*)))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-12-08 15:29:24 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-12-08 15:28:45 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-08 15:29:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol-related disorders [mesh]</LI>
<LI>((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)) [tiab]</LI>
<LI>Alcohol-Induced Disorders, Nervous System<B> </B>[mesh]</LI>
<LI>1 or 2 or 3</LI>
<LI>ANTICONVULSANTS [Mesh]</LI>
<LI>anticonvulsant* [tiab]</LI>
<LI>(ACTH or carbamazepine or clorazepate or clobazam or clonazepam or chlordiazepoxide or divalproex or ethosuximide or ethosuccimide or ethotoin or felbamate or fosphenytoin or gabapentin or lignocaine or lamotrigine or Levetiracetam or lidocaine or hydantoins or levetiracetam or mephobarbital or  methsuximide or oxcarbazepine or paraldehyde or phenacemide or phenytoin or pregabalin or primidone or succinimide or tiagabine or topiramate or valproate or vigabatrin or zonisamide) [tw]</LI>
<LI>5 or 6 or 7</LI>
<LI>randomized controlled trial[pt]</LI>
<LI>controlled clinical trial[pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo[tiab]</LI>
<LI>drug therapy[mesh]</LI>
<LI>trial[tiab]</LI>
<LI>groups[tiab]</LI>
<LI>9 or 10 or 11 or 12 or 13 or 14 or 15</LI>
<LI>animals [mesh]</LI>
<LI>humans [mesh]</LI>
<LI>animals NOT (17 and 18)</LI>
<LI>16 NOT 19</LI>
<LI>4 AND 8 AND 20</LI>
<LI>Anticonvulsants/adverse effects [mesh] or Anticonvulsants/poisoning [mesh] or anticonvulsants/toxicity [mesh] or Anticonvulsants/contraindications [mesh]</LI>
<LI>adverse effects [subheadings]</LI>
<LI>Drug toxicity [mesh]</LI>
<LI>&#8220;adverse effect*&#8221;[tiab]</LI>
<LI>&#8220;side effect* [tiab]</LI>
<LI>serious or safety or surveillance or adverse or toxicity or complication or tolerability [tiab]</LI>
<LI>22 or 23 or 24 or 25 or 26 or 27</LI>
<LI>4 AND 8 AND 28</LI>
<LI>29 NOT 19</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-12-08 15:33:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-03-21 10:47:00 +0100" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-08 15:33:55 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>exp alcohol withdrawal</LI>
<LI>exp withdrawal syndrome</LI>
<LI>((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy)).ti,ab</LI>
<LI>1 or 2 or 3</LI>
<LI>exp anticonvulsive agent/</LI>
<LI>(ACTH or carbamazepine or clorazepate or clobazam or clonazepam or chlordiazepoxide or divalproex or ethosuximide or ethosuccimide or ethotoin or felbamate or fosphenytoin or gabapentin or lignocaine or lamotrigine or Levetiracetam or lidocaine or hydantoins or levetiracetam or methsuximide or oxcarbazepine or paraldehyde or phenacemide or phenytoin or pregabalin or primidone or succinimide or tiagabine or topiramate or valproate or vigabatrin or zonisamide)</LI>
<LI>5 or 6</LI>
<LI>random*.ti,ab</LI>
<LI>placebo. Ti,ab</LI>
<LI>(singl* or doubl* or trebl* or tripl*) and (blind* or mask*)).ti,ab</LI>
<LI>crossover*.ti,ab</LI>
<LI>exp randomized controlled trial/</LI>
<LI>exp double blind procedure/</LI>
<LI>exp single blind procedure/</LI>
<LI>exp triple blind procedure/</LI>
<LI>exp crossover procedure/</LI>
<LI>exp Latin square design/</LI>
<LI>exp placebos/</LI>
<LI>exp multicenter study/</LI>
<LI>8/19</LI>
<LI>4 AND 7 AND 20<B> </B>
</LI>
<LI>limit 21 to human</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-12-14 11:23:02 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2009-12-08 15:34:38 +0100" MODIFIED_BY="[Empty name]">CINAHL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-14 11:23:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>MESH alcohol related disorders</LI>
<LI>MESH alcohol withdrawal delirium</LI>
<LI>TX ((alcohol*) and (disorder* or withdr* or abstinen* or abstain* or detox* or neuropathy))</LI>
<LI>1 or 2 or 3</LI>
<LI>MH ANTICONVULSANTS</LI>
<LI>MH Dipotassium</LI>
<LI>Valproic acid:ME</LI>
<LI>TX Acetazolamide or carbamazepine or Chlormethiazole or Clorazepate or Clorazepate or  divalproex or or Ethosuximide or felbamate or fosphenytoin or gabapentin or lamotrigine or Levetiracetam or Metaclazepam or lidocaine or mephobarbital or lignocaine or methsuximide or oxcarbazepine or paraldehyde or pentobarbital or phenytoin or primidone or tiagabine or topiramate or valproate or vigabatrin or zonisamide</LI>
<LI>5 or 6 or 7 or 8</LI>
<LI>MH Random Assignment/</LI>
<LI>MH Clinical Trials/</LI>
<LI>TW random*</LI>
<LI>TW placebo*</LI>
<LI>TW group*</LI>
<LI>TW (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)</LI>
<LI>MH crossover design</LI>
<LI>TW crossover*</LI>
<LI>TW allocate*</LI>
<LI>TW assign*</LI>
<LI>10/19 OR</LI>
<LI>4 and 9 and 20</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-12-14 11:15:31 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-12-08 15:23:11 +0100" MODIFIED_BY="[Empty name]">Criteria for risk of bias in RCTs and CCTs</TITLE>
<APPENDIX_BODY MODIFIED="2009-12-14 11:15:31 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="13">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Item</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Judgment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B>Description</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was the method of randomization adequate?</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as: random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimization</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process such as: odd or even date of birth; date (or day) of admission; hospital or clinic record number; alternation; judgement of the clinician; results of a laboratory test or a series of tests;  availability of the intervention</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was the treatment allocation concealed?</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled, randomization); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Investigators enrolling participants could possibly foresee assignments because one of the following method was used: open random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate safeguards (e.g. if envelopes were unsealed or non ­opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3/4</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Was knowledge of the allocated interventions adequately prevented during the study? (blinding of patients, provider, outcome assessor)</B>
</I>
</P>
<P>
<I>
<B>Objective outcomes</B>
</I>
</P>
<P>
<I>
<B>Subjective outcomes</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Blinding of participants, providers and outcome assessor and unlikely that the blinding could have been broken;</P>
<P>Either participants or providers were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</P>
<P>No blinding, but the objective  outcome measurement are not likely to be influenced by lack of blinding</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding;</P>
<P>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;</P>
<P>Either participants or outcome assessor were not blinded, and the non-blinding of others likely to introduce bias</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>
<I>
<B>Were incomplete outcome data adequately addressed? </B>
</I>
</P>
<P>
<I>
<B>For all outcomes except retention in treatment or drop out</B>
</I>
</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>No missing outcome data;</P>
<P>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</P>
<P>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</P>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</P>
<P>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</P>
<P>Missing data have been imputed using appropriate methods</P>
<P>All randomized patients are reported/analyzed in the group they were allocated to by randomization irrespective of non-compliance and co-interventions (intention to treat)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</P>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</P>
<P>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</P>
<P>&#8216;As-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomization;</P>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient reporting of attrition/exclusions to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217; (e.g. number randomized not stated, no reasons for missing data provided; number of drop out not reported for each group);</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>